var title_f33_12_33984="Humerus fracture";
var content_f33_12_33984=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F71015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F71015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Humerus fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiograph of a comminuted humerus fracture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_12_33984=[""].join("\n");
var outline_f33_12_33984=null;
var title_f33_12_33985="RANK ligand and osteo form";
var content_f33_12_33985=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F66130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F66130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    RANKL and osteoclast formation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 468px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    RANKL (Receptor Activator of Nuclear Factor &kappa;B Ligand)&nbsp;is a potent inducer of osteoclast formation. Osteotropic factors, 1,25-(OH)2 vitamin D, parathyroid hormone (PTH), prostaglandin E-2 (PGE2) and interleukin-11 (IL-11), induce osteoclast formation by upregulating expression of RANKL on the surface of marrow stromal cells and immature osteoblasts. RANKL then binds its receptor RANK on the surface of osteoclast precursors and signals through the NF&kappa;B and JNK (Jun N-terminal kinase)&nbsp;pathways to induce osteoclastogenesis and promote osteoclast survival. In addition to RANK, a decoy receptor, osteoprotegerin (OPG/OCIF), inhibits RANKL binding to RANK. RANKL can also occur in a soluble form produced by T-cells in inflammatory states. The ratio of RANKL to OP cG determines the level of osteoclastogenesis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from&nbsp;Roodman GD. Mechanisms of bone metastases. N Engl J Med 2004; 350:1655.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_12_33985=[""].join("\n");
var outline_f33_12_33985=null;
var title_f33_12_33986="CHD mortality related to BP and age";
var content_f33_12_33986=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75106%7ENEPH%2F66793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75106%7ENEPH%2F66793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    CHD mortality related to blood pressure and age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 398px; background-image: url(data:image/gif;base64,R0lGODlhIAKOAdUAAP///4CAgAAAAMDAwEBAQPDw8BAQENDQ0DAwMODg4KCgoGBgYLCwsCAgIHBwcFBQUP8AAJCQkP+AgP/AwP9AQP8QEP/Q0P9wcP8wMP9QUP8gIP9gYP+wsP+QkP+goP/w8P/g4AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAgAo4BAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJFqIB0SHSBZFxQAFhQeSh4UFkSho1GakpEWE6wfQ6hYnZ8UF0qyRLdRuam8dR4QGhQVEE4Qm0gUxCASE0oSEM1Dz9FQyb2OyRDatQAeEk7TSBMQ3xKfSePfQ+lS7NfvcNquAN+VQpacGxQZHr8aEpg4ZKDQQYi1Zc0+dKBAkMizDhkyjApnQd+FeRVpzeOwTwMxhx4WqjNn4dsHCfs4CFlICxPLCyAmAAQgM6YECx6aTRh4EZ6V/2QTPmwg102dJgobRn04CjDZhk8Ze7IzJ2SCvqTrIFzQp9LdwgwqASxFakroPqJDvE1A6sobJUyhGubbB1UfP4QA8JI0iRKsz0geNTx1NdSCBQgbQEDAIGFDhgsQKojiAOGxVgDW2CW7cKGCQ2MSKnieBqICY9N5TYfGAIAyY49FIl/IAKFgZG0AMFSQgAFCRa28rQLHIBMaPWjPhkmgbDnDXypA80bG/PFfZw0ANOy+oMGCRwwwVaNmZ4zmYpTqzP/rvYoo5NkQVOrmXQFT761oDSKG7DzZsAnv0XbJeY4pxphj7JA3DDHzsfecI51os9gH43Dm22EaXNCBK+UBQP+bK7pRZ95NiAmBiTTGQVbcBB3EBwBkFrSoEoy0YWINEeV9UN5iQhxGQWPk0JYBMx5WRmQ40zwTFm0SSADbg1FEBwBuNwIoDDGibTBTODK+6Bt5m9RoYlbfUMYMUajpKNFllHVw2AYjEnFjb9TNU8E/z4gCjIYfYMhngkTxyAloQ6UHZSKufMCBR81opwFrrV3JWoc3WpMZOe4UgSRynDaTpHHTVPrREB3ueMw4PzYZ1Aa9xSdUqxxsuqJ+TTZ5aDXGKYadNcxxQKcFGXhUn6zHsRLoJjcWAeiZ35RKwbLLyvmRpaMCU+snHA3DWraLRdshqrVSc+shFVwwAQeiufL/TG00bcDBBKJNqcEElJDDnIjsiMaBr591gO5o0ByWwQTaDTpwwc8s9ySpxA1l2zEAiJZTBx5s0AGAtVmMcQctvtbpSpWdC+e4TSTjb28qWZPwosR4spZvCU8gMMGegQlAixvIlN44ObPHDm2xsnvnTr59MDRkhgLVYn+jMjmBWu7CW4FV74p22G7JNAuxxCyeQ7IhG3hUmSmKQeAKCK1iMJE2o3RWmSuXfgOsNhAfN0x3xXbznSke7C1WMhosLERkw3DTISe0ARPrMOXSw3gtHySDAW2z3iO2c18vkc1iYVnzQW+BE5O4Bp+A4JFzfS82is30CBuWeYx/ws4HtDXO/wno53gwTNbSekQB3KMKxThAaVuAtjZqeynYsUPMrXjmjlA2ciGHQ2+9Gclerz0UlB9S/fbgd5F9+OSXb/756Kev/vrst+/++/DHL//89Ndv//3456///vz37///AAygAAdIwAIa8IAITKACF8jABjrwgRCMoAQnSMEKWvCCGMygBjfIwQ568IMgDKEIR0jCEprwhChMoQpXyMIWuvCFMIyhDGdIwxqGrwADGAAaHECAIyiAAAeYIQ51eAYe+hCINtyDAwQgAAZoIQACICISFBCAI0BRijBcYhOfGEUlUNGKXUxiHhrAxAUMgQEEWEAAqgiAATyAAA4oABESsAACwP+xAAkggAAWoAAiUDEBEUjAFwEQATs6IAFXJGQAcBiABLCQjHs8YxrXKAQ33nGOdbxjHvfYxyH8MZCDLCQcEdnFCCxyAI0UYxwYIIAIGEAAcmQlAgJARgCw8gFLfAARBkCAACxgjwcgIwIcQAQ9vpKXAgDALx0QAASgMopQ7GMiVchKV8LSlgKYZS1vmctd9vKXCwhmNok5BGNGUY/KFAAznXnFaAJgmj5B5RoDgEUC/pKOAuijHh2JzgcIYI219GMdBdBDeApBj3IEQD8F8AB6vvOfkWxjKq8gz3nW84D3/KU+BcDPZPoToMkUqB4LGsZyXlOhHmWoQ6EIRTNK1JH/f6loLw9YACYSQJgoPWgy9ThPNgphiQ4YAEEfWk906hQABVgAApjIACiSsYdcqGgAZqrAmhIUp0ZFJ0/nSQSgCpWkRQ1pTpO61CY6daiZo6QBI7DHNb7yAEsMAANqydYHDIABLtUpAxQwVJZi0ag5XUAEBrBEUzbRnxEgahfUmkC2qjEAb43rXJNZ17vmFaV77es//ypWdAqWsK2EIgMQq9hDMZaAS00oUAugxwYElJZM1OUQDvDKkQIgAWSU7VGPClkBGICYVyzAWw2ahdMeMLU/VSdrBeDakMKWoUSgLUGHilvomvS6vf0tUYUrgAMQ9y/GVaAgB6AAAyDgEeFt/+B4y3veBKYXgdJlaBAd8d4FxvcB80VgfVUphv3y93r+/a8XAizgrxG4wE/0KYLBd+AFX6HBDn4OhCM8hQlT+B0WPiAiAymEApgSpkXwcADmW4A/wiHD4g0Ah5H64SOImMQmVh+KCTgABOy1AXIkQATmmtAhFKABCmCAMwGAgB03IL9smPEBa3zjHBu5xx0GspB1WOS5Itl8ShZgAMhJgAH8WAgLcOIu27vGA7RXAZddQ5YLuOWDerkBYBbzEGoshDKfOc2QAKSKE3qAHOawx02dqBHWDEDchrmHvKyzgg9KADQmwMyVhCoapEpVDRoajW2Eanjt6GhIZ7oXemRie/9DzUQdFmCpCBjynOdZ6Qoe4AF4JQAONV1FHgKxALB2AAKC+ICG2lENlF70BV8d61krGgC2PgCuGaBrXvta0pJgQAF+3EU9DtbL6UysEWQqbAnC+qcROICmtT2ECJBztELoswLI2QZCD/DbyA73uItgbiGgGwDqZncvyNhRBBCgk7XNJoiL4G4o5dCPcu6CGoXwgD4aQI67LsIPhRCBvP544GrudgUXDoCGA+DhRL7yxAlp8QZgXBJsJSczHfBKJ5YanEgo+IPUqgDXJpwLuPY3ORWQan0PQdcEeIAcRXnzjHMw53AUAs+HeQSgC52QnC7Eo+d45SIsEc8s/Xgyvxr/c42bD5V2pCWQzyfzCw8Y2lNNgj8bsEYdNsABLO/iL335z667D4pMZKLXAbx3s78B73lH6xECX3d/MreTuGaiz4lQdnj8MvB9h17j/c5FwkM7DJPnRc0JX3eyR57yakb75cGQ+UjU/N+A1zv6Sg/6Kkx9CK8fA+sPcXBPNqDLdSb85w28+9afgZdiRuNFvzB7Q9D89liUqkPHwAAi3hXfb3QiHYMexPFWEY2NPnHvr1H7PTS/kk58dfanj9/bKgCVtow6IRZgACIYAM/E334quv9OB0QA+auEaqMTgIAEsHYAUxdMbWQADRVMeNRJblB8gaCAWIBpCsUA/Od/XRaA/3A2AAQ4YjgmSIXwa+U0evGXVj6FTAQ1fGxgcrgFdWs0U2iGTol2WwYwWHHAgH8gg1dggnBWSClYRSu4dVCVAC9Ign5AACCHVAbggQMmf5AAdr3UVK+Ud0gYBhVnf++0AH6WAA6wAI7Eg7DXTEaIBjTYB19YBVGYWL5UhVeYhZ8mBIjkb4XAV2wHW+TWX09IX5ZneKonBz+GY22kh/g2flp4W45UU9qXOUroUEGWB3koRwPAh+ImfX+YAIEoVoPweDZlBmF4B6kHXJBHBwvAbjxHADYWTHD0iP6GAAjYbnOIXoF3Uw1QdJzoiaXIAKK4RGnIf6B4ioPgXXJ1Bpf4Bv/0l3hO+FDBOAcmdwi9iImBN3Z7UIwBdIxswEu9JFeQ1YSqJ1VAqAZohgjOWAepl4pnkI1a5o2DkHojaI39s41rQH+VhADm1UvXmETomAaZyGbiOI4KxksGsEjxeD4HAFP9WAb7aAbAeIcDFJBmAI1r9EP5mFAGST5UlXZk0JBhUADTuIkEJJGyF3gLuUvvaF9CeHtC2IVcgJFZUHsU+X4JYI4XWY8LaJEcJFQa6YpH+AgIyXJY2EAkCQabNIwe5AC4GJEsaQfd+EA52QX4BEkE2UEilpAAGZR0sJNJuUBFqQUniYUIuXweRGqCJ4eMcJQuyUBTeQVVCWLq6EHZ5Gf/VfeBiYBPWDiUDhSWVHCSSNQIKVmFLCZoPuZnAxBEJYaXgzBL8uiU6QiA4ARTV9mRBSmYcYBKcaeYc8BtCvVkRYBIa1RHRGZkafkHDvCGAfCTWwCZgwB2T4VxZXkIdZlDgdhiIaaXfBljaRBsjUCJnScJJvdlyiSTyqQAngaOhKCVIklRrOaYlviVkQCZOsZjkzlPllllRwZsPdVqh1Bz1DibkOBLafhei4hv7dWChNBnaNmUgoBPxFkHDICbVFCbcHabScBHuwl/Xiic2NgA7DSejCBcjtSClJRs5dRJvTZVv8kHTYVImblY8PmZUsSWslmgVyBurTiSZoSfGped/57GnUmmoF2gfDpUc8roltXpUuJWZ3E4Z+mZbuS1eICgRW7kngS6B5TElo7EoW6gfOy3SDhnAPdJa8hmR/n1bwz3bH9noSNpea51ijDaCPY5BCAXcUbAo0RwcYbwfuz0n8UFpFWghIW5amGHmBFpeSeHBdbZhyB6BNk5WyX6ozNIeMq4Sz2lpeN4WUtnomNKcepXCOc0AJYJlHlQpJXEpltKn2Jpo0gKcWnJpD7GjKh4pn4aQ6DYAKSFp21QmrellVT6YLo3YG7ac2I6olCXfWbqB1rEkzYUXwgAZZg3qXY3mexXVlFZBwXwqaBqPXApgokKQ6eJbY5aobs0o4yUpf954EoPIJvUCaumSgV5lI+uGqw0hAC69GMqOpLDWgRXWUgbOQToWJqLOGQYymDPCgV0tJHZKkZhBJGyt63UqpE0Cq18eqEp6I6w9wAvyD4YiU/nGmHv2nG6xZVJNqvtVqkUqVztE4+156Lh831tFH7Rd1t1VH7Wl36cWgi/lGr5BJ7pqKrIGoO6V14E0KWrR65qGnZX6gfluQYOuH/9938UOIAFmIGeCQhJ5VsmqpaTJoQUy7FLQI7Mla5cQLDPJ37Sl7DVd37XN6eHSlE4W655l7F/kEcNugY2iIJTpYMDVYs/iAgHMKCkJ3+Q2gT4eEphh5V0QI7NWgYjC4ElO4H/QSSAFpiyBziID5aKekoHJslSpIoGYziFZniTf3hbXHgIHMiL8tdgtbe1PVaU5EizQ9C0OPi0ALCDUguDbFulvAoFJ6mvMdq1t2e1ZZCIe8hnfliLkXgIQhaYUdBgbSeE83psi9lTDvVL0ei1bFC3ZYiaZwgAebuGUjqulLqqSSCXdlixcpB6YXsGnehJsTiLpHiLfLuKEvsEDcZy04quv0t4b7S0c6C5i8i5jui5SCWJuGoFgLd7roR7hVi0w/mqbWCoz2FrhrS8TkBgyPR0fECO+YgHw6t0xXt7tNiCtmiKj0sF38sEp1dPWbuYSOm7acCbADRh/sVLDZBJrouM/5R7vho7g+KIkNdYc6qWtO4qqfa1VIsYolc7ul7HwNJkvkJZqXeAwISwZgM8V2k6g7/VryaMWgZgAIR1u20rwmJ6Uwj4v3pgZiicP6xXYj4pCNfqfF1LvvfTRF0mrviqtf6JRRqKiz58B0n1W6qrxFgGn27EUFq8BgngriE6wAT0go3WwOxbs8M4xTvMrnfgqxMsxFysAHNbBxjqSgtQx0QZeF/cvr33vWycBAYpVWRkuFAicyGLqIGXwRZUSPB2q0yQei98qtEbxM0YlLhmAOZ5woEXvA+EQ5jrrE9QY4fnx1/LeYY8cyzJAASox3lqyRbEV6LmykkQaCCWkgMKYf9o1HtkjAblhcormQWJHAjHmspQ4F2Ip5pGoGcd5pqEYABsd3WSi2qqdmpbKVE5qMOBUGOMCsz+A5vP0bKwrAcBYFdEdJx8SARolMjMGcp6YMM/hcPZZnWVqKbZDAVTqXxiLIwRTAfI3GHKPJmm1Mx+eZDPaczYSIBUtKZ+cIKFGmdGYKjtaXxBZad25c5ap0f910YQ1YUKjNCCLL0JpXwPHFUXNcyja84HJZlFsM5i1s6d+g4M2sdu4Mg8CqFFEEx1tEgTKs92oJX1zAQvt0c/FlTXzHh/C9IxN85+O0fuuslI4NBRBtFFINF3FtONQNLMNr/GmMenlkM4mmw15kj/C9effTsIC91TK2sEr8TRXWZ5lGzKelDM6eifDuVKcUQFNt1HOB1dDdxLBdDTWM0INstQcUzBivah7zTGUNWC+fYgczd3Q8RWSjpoWEvTwJnFCOvN8hh4D4AADaDFvjRtzoTTYr3RZe2jCajUQUp4L5uL6Zl9SVp1gNpmUXbYkQCM+sZ1ca3IecdM70fXalC4XspGZTZv3hRpJLpug70INsvaV/CJO4epRmBmQTd0Qut548h5BBVE39rZMxwFAviAHyeobP2i7Oakq12dnO17lr3dhOfJXtjPAKxz9st01e1vT0d0/bsI/NfeIZSSd4nbCQbf9F0G5fVGbgyCRgpF/xSrux4ERenkWxidw4Lw3HKgtDrUyxIG3VYwVxlL0pgtlck0ThGFu4EwWUw93DFMPnDZBMUK1SN0RVvEhpDMB8Wqum3ni6lW4abl4VHQr3n9QoBHZT7tv0BuBK36T7S8Bq3K1Vv8ByQNUJVNnjIuBTprsOPns+aHfth35SlsR/+WAK2UxngAx3YA4gTO4H5Q2BD+Bk8O5lAwthFosmdbgRdogBooY0BeUYVsB5ks51eQ5dC35dTX5UHbsEMLhtz95r+HRdbd5FaAuNGoglGrv1NrCCIWbk0NweE9aUSEx5Kes/pHthIIgHeOshi4ts39yo1uuONLSGUuBrBLhbKLt/9pqLc2novTKd/FbcW9a8DvOdNMC4k3WOlQy4I9mOmtjgduLux9qnig6ONx6VqKyIidq7+f2wcHQMdEwH7ArUdrLcp1UF7TCe1kAHZLBb9qUOt3i4bcabv9rQfBfuAD5tqjngX1u7j3O4q1WIrjDre+da5JV1Pidq+lCreg/Uz2fu+fPgbWi+3Zq+3bO+93sIiN7ujRrk5ogL6SAHZstEQ3BU1HXmEIHcb1StxtMJDoLgb7/omhiL/Hy7/NXr3sZ1ivnoANXwUq7Ai2quRlVVCvTe5uUJU99t1qwMrTabgef+FJTkjvJ0fPbrgPu+DyI4ThhAR7KbrPSF6XewdK21T/O68FPe/0eFBjGTzlO+7k087h6sNzTNQAEZDvT6wGLEe9cnBweK2Idj3iqhyjOi5XN+99Lb4/FvjwN36Qv5SPJV3XdrRUi+b2Lm64bv4Aa84Gcc4/cM9cC3B7NY95547QKj8HPZWaBb24FoVUzty9+cp5Qx8Hkd4/ehRms/X5XgDiwY7Qwj0HUfRnkYmcRaBjqHmZVmb7GQngdcBWIJw/P18E3F3yUjB56sigJTz2OFfvrC2Jtkn7wS9FE73e+4r8eDjtAERVDnCvdtSOWG/mU+pjupp71k/2BLj7ckBQdnWdwgaKPCrY4A8EAOGQWDQekciAgNkUBJJR6ZTKMDgK/1Ttltv1fsHCRKBBCAQQBKNhIHQswtxzPBkwBxyGR4I4sN/b6Lj8zs4IGtr8CAAFqxi0+AYaEgbUAOYcFg8A+BIQHh8e/hrj5uIICwOnChycnKBIwwZUWQ0eY3FzdWVdn4wE4AoeLHdRzbRmt5aYEFSLknellpsesoago4lqb7cIBg4sAyLqYA8GFByyk1DtYMOmmdyjFAwIFnp91aUUzb7TrPUFFBirwAAEC2ZtMtKqibxcxhySU9ZwoBxXEaNhA3AgDR8qCfgUMJBlJAAECvsIIcCtwKSK1wq1owMvXxJwDR6xS/XSCDwEAsbxFDo0VoRFQQOamqI0CqtXRKPQxP+4S2mEmh/TIFAgRAECBOmMPPAK1uhKqEOYfpGapMCSAADPKnFyMm5dqAQOZFpEAGwRcwkFppUohZ49RnaHWLk4cI6wBigRvxTcZe0RBmU8Ru75VDORmCEjBMhMRMHOAqVHdxZQyQmxIQyZuM42+dkfZ88QILo09WyCB/UWBw4wQA/czsJnBi9SYEHf4545P189KwuBCJeNA7A+iw+C64+fbxFgoNDWpLzRUjTi2wBS2lAjXCkYc3hART+dhz9PR+ftAQ8EeOC25ziK7jgBtGlAiAW4GcKbITjiCo7nZqkQsCIaQI8qDS9Rb4i2BMCijwGhuolExgzUT5/3SDknu+f/rHIgphPtEoAAAQGoRAjBCEhjqwhzlC0yfITMpELIZuNwGnkKS80uVFp5IC7YrlJRHRbDYKBBKwEooEckVYxkEh13A0CvTTr5BIBQRnmOvjPMI4KA1pDbxzYhKsEpvMqGYk45LpPMRRhbABXCChELlfObcJDqqZxz8jvur2+MKK28OpeCIoEFyFORT54OaOABBv6oDwwGAhngkQOGeWTTG9FUwA8AGFhky6Gw7MKKagrdJlExQiqpJLqeUYkll/SjUkhcOdxRRgMWeDEyxVJE0b1mo6jVWE8S8HKABDYJNUc9Agi1gATihCpXLrRMlCMCpB2o3S486dG8rr46Qqx8/wEo69bOgCMjUnqaWFaXdc20EUzNEjhkzmr18ZLYHbGNYpIEFDTKECgUWGDOIMVoj0bJKv61tjdbaRRXQk2uaDUB2pISwwZshBZTKRhI1035Pg3oUOM0AiOC5sYJACHu3uADQTI5QcNgklv2giZmFi5mQGEmjjogAWoVS0iuEXzjZq038kqh/nAJ+sM8/iWlpQaykMQacFxd2hKQukQwLoTJ7rCXkmdyqN54+8ZFRgaY0BmA1RAIYJixAdWJU8BLwehdJ3NpboiuemQgVL7sFiMrxYXim+ypq7xSHuIiLVyfAxY+aJnWD6a8rqltfyei+HLvAtnTe08U9eApcyc+0v9d38UB80JLIgKVAzUZd6g/fEC3gDp23XSthxeInwAYWAC85CM26OjHbyce17+pH5dX8iGHX4gCfmI/KVfgJQVVPFdtlROPHxCrWdXKLOEZQC8mtDf18cQT9vPeIoYTAAMgT361q2ARrEAzB17JCTLTnyVWwi1vgWsjCiKOKMyFLv2MoQxniADhKrK9vQmgfhCLhk+qdsFcyLBXbNPJGUYWC3gskAgXy9gdjtGxj5EpASLjkoyaQoQc4oKHQ5EEXqaHIiZ4UIcrImJn3gXD+3mIFENzQNGO9q2kLQ5kYnCaldCHhAB2yWPx60wtgvLDIFKRjF2MnvysAj2h0C8N/RD/VAPglqNEbsQsCQgdJ0KiN/0oABEXIgKAyBAgO55FJ3rAnFBCVQ9T+VF18pPYFAdyAJtVcQqa40pWPFeGVrSxXlqx0sNiYwRhxIMxXxSiK2inj6AtITS+JOVgkvezuihAAOZRGyl+p0NLwWlEsxgGpfbTmZ718kNfKtMxvWiyH56BU23jSR72KIjsgRMJRNqkuv4UQ1hYIVoUY2cpf4U6XsZFYp+8Jy52eYUivCkAFKSiMekAonjap1TlHBF/0ulHVhJFn6kDVQPq+U99zKlHqVOAAoSRQC6YA4Nn+OREH1KGe9hwNnPxp+406ijp4WOfRKGHIGOaC665QUgNGBoT/3CKBHQZQJL0o2EzlIDQLwxqHGiTDEsrl1PPKJWDNKUqFdApVX10ShhcFALj+PK0I0xjCPcQJESWWRzEDHFDMWXHMfJJU4sGBGuo1KogqHQr8jzBDl5gwhCIOicEjAatL9HJISL6kAFJAqow1ehbr3pDuUYWCRx5313VYZRRHYEh5vOrJJkwgHuIdKo8ocllTesQCcoIgomVA2WthFKeWGWyPLECbDG7iuu0xa6/kCRRc2SjpJp2od4rVRs8QSzZIlOqyxWIxABkVcmwLLeZJWouY0GJ0PLhHkabq3Mn0ljJNuRQD70hbvUDXnX8bJxAHEhdq7u1eizCOavBpXDDy//LXYaIuT7TYB+1yAQDsKF9zUVvGHwFFWgMLr4ByRAS8KIX+r4TF+y571xXNBcx7rB3BVBIAULz0kCcRjTpU1EYFTiuYA7ywyGOwohRYyVJXMovvT2oQOITLacSF8DZ9AL9QPgdad1DCN65jI3/SJT2DiCQceFHHgzKEyCrRMhIILJJvoPkodQQv3ISa1vVYSLNIM5Go5QnEuYlx0x0SUEAYNARIjBLIK1TXQeWCz4MkDWKivclD1hzSxb0rzgjaM6kVY2ALJkYBKSWg3auArT2J5RKGNIz1DXCAmSlBjIJJnuEXnQb6zxDfKAWnj1Wx0etnOk2choOnsbTl6dkaDn/0cnHjYDGFbUsELadZUnd1DNp4KCjTUPhTODIgt7YtIgU81q6dmFrRZhJuuwJOxzE1oSx2bgmUShbP/ct0l74QuFBQJBTQSUKRwYr6nyEKqMQXgQCrgCOHanMaRwVgjnQsexSbxAqzOQzKehRtb3A2wHyvgS9C4lffK+4LhIOt4lJ8ezI8M7ZFGGmuZ9hiWHlUJJsfqm4M4wPRx+h3McdSMCnQKaNJ6HjLfl4g0sb8X8/13quVcekwccpLZMJXyvWm78gvu/iVoSQ1nhmNFCeckv0PAo/txXMlUFECc5cmKLasDwZHFP1foFKVM+FKmUdGAPkGuq1BgO6o1tTBecB/+O4IoBADdwim9eCoGZ+SbSJovOyNyUTrDLnjRGcByiww+YPQUOACh+Q3/z9mLL9XkRRHJmsDmUBv84tdeQY2gV49byywMxxqETVozdlTiPXjGwlHoUmR6afeUfA1e8ZKgGTDije6KvZn0GiQUW5Tys1tSC2x24o3hX1UP2oNyPDbthn7vVQFwkN376aX9SqEpwH83CLEB9S2+Vzoe/8Fi7+Ta0W39SUZAKiEHNTK4q2+VBn5ocxeukB04z3jWARUxp2vc40OfWAX4XexY9dUqV/GgmABAgKCIjxQE4aquUyGkAB0gwxJq90aGj5DGUAN8J/XmWO0GWAnm5PXOP2tP8BQOAO92KuQ97iOLxkfB7v+6QguQCCh7RFOxhAhLyBhMTlhMoFblRI396hAetvkMSC7NzGKyzQUECoBgdrhMLFhMglhYIQVzKkELhNijziAF7O/ngD5yLAbBADG+gJaBIv6qagvE7Qd0DiiDYGAJTokZooAsaQwwSB8FSEHf6BKOinU8DAiPoFiTjGY9zQidKrF4QErkQQn8aqCdrj9GBh10pHQyRIcarIjNCoQhJgjR6padIg6HQhAivO6whCdnqHEi8hjS5xAZQG1MZgEw3oTdIFHAygDN4O1rSwDn5P0krFK7Lw+nRpCI9g9KTgbeJmkeiGE9wwkjiRIBZPm4b/LmIOIgC7QBgVaW4a6RjzhmwOyAksLckG6hZ5zBsR0S+sbhdciQ1hqfvccHSSsRF25QjHCBx1gSMmZKLKkXM+AR1pSR1bkT4UZ3kYDQlwLg4PphlNUP2iIZqiZutoRQGHooFAkQ7ADi2CByHhZ2qEZFKwKZz6q+EIUiOJgFMEkjDCLp++CNUMKBY78uv00J7AgM4uiBAQiZqKwNveCRgpMCWTDAb3TqYaAe9gZIJ2LCBUSWcUsoKqsFIKASgWsC4axjtKxe4UC5lYZyfxJCbgSp2i8CWYY3zObYJ4kiq1gxbtIRsKy0rMMEdCUgvewxQiESxzxCpNryKyrisVJyD3/84ijeAvrIAWwaAsw4M5tpGblMAMfNEtByouBSIiz8Inu1HtGgwvZ/IhpQYxqSDyHtEWbcQdMaso7YIxbaqZ7gzDDHOasjKqwmP1KIo3GIIyuYc1owEArWYKki4RHTO+8m1zGE4wv5AKlZLXpsL3XLNlOBMqii4cj2A2f7G17nIKDcE13MkEhU40ISe5MgEqDRMaC0cxjbMIkBP77pIQvQzcHs4jPxEejZM44GA4Gy84+5I+WqE0wWAtx44K1LNvyMAq+ZI846JAJFOI5OF4WPI6v1I4eyE3I+4355M+2fM4bpMrWkezGLIWOzPPcBKfHAMl6lOiFlRq+I0bF8TyvP9TQBfCCSI0cOpiUPygQgPFsuAiQ7vIRcerP4vn0tpPLTe0ZXxBGPLTNBVsHINS0uhrJSVSRAd0plTURD+yRm2USI9gp8xkRx2LohbRTQSMRGD0gq5UF9LOPPlDOd1MSZeUSYsAQDqq7SS0IpKhKYlQi6YiS+XHTd1mS7m0FBqiOCdTTJeDBA30TBkKgtTqJGszQMUUTgXBskiFPtKSPpvAAYwwPm9Ua7BQN98xUBEjPvTiRAg1eTI1S4T0JplgJBUUT+WEQZhgTWc0wCiVn6xnE9byUQtlU9UiMHmiEn4CVKnAJg2Taw7hGaGTHI80lRDgfVpVVLHzLwtzhmyVWLv/YDWg5RA9dBe8pENn1RnoQR6GVVRhdQvm8iwsS1lxITeAoo56NRbQs+tYUykmUFAPk1iz9VZLcD8HzFVzijgGa0r1Uxeg7C1nJMUIyUmuFU/bVQoAlPvII2C9NUp1Ibl28RHR80X+dVDllY64El63AlcPVgsK5F23sy+ptVO16Sco6D0sdicNdj3ukGDh82KlgGY6CrecyxRQVEUuNCoi1j6DUydyLPm8UmVxwUnjaGO9AOfIYPum1SbgDRJrFnjKswlSFulAk2cNxzwcZymjwgmS1Y5uC0tGFmKXVjrv7mmhthGe817VQkb9k7NswS7DNlRv51ezoTvXNgzEc8Ig//JbaLYRvC8ZW6/X4lYagnObhgJu+xYxVEk0UcopzPZApQharIFvBzdEocJc08pUH5c7r6vLwKB+IsIvveBdDtW9nEw5rSJdHLdy13VKCnYneC1BTZcOEKlmrrYOriB1OJcLrMJVp+ENJjZIKM10IessWk/JbgM2WzcOwMZMYvcIDoBr3OJuf2xV96Q1HDZp5ed3zw2jNFNxywpEi3dZDcJxoBQ6WEqGTih739H61LV7i1UgDNI3t9d81bfIFmB2woASRAsY/Gkyji5f6zBeaaRktc700jXUvhR+45cInsf+DBcjBENhrSRakfaAh1QrjzXFKs+AJfgyi5Qe9pRbof9l+Daye50LV1n0C98NTDMYUCZDKWLWSsIPSwBYoxzP5JCgWk9vTlN4rTa3tUKFaDUDMBVCaxMVW9Wn/7gCkUo0wKg3h09XfGmoNzVDI+ZyayWY/BzTAZtWHYwqVZl4ChzOOnBvGrjXfQ1FY7s4U4AvRXLmOehnGHr3jLngwsDWBdODi8lYgpIYjq3Ya7nvGWOYSZHKzdrEQ9X2OM7glOD4VE+Bhj1RZ+dxiamyN6szfBX5DKP4D8YxkV9L7uZnGSVlJalYk1XCRmp1zTb2j3ckcVN469qRQHZWlMMAHLboNIY4hEM5hlQ5g1k5jytiKGFZOCFZdHK5ionIJMPDl3//OQ4IBrvINjzoiYaT2W97co47wzOj2QsCi26b2ZBZBpWJdLmMmUGp+Zq7wIy3mfWQb33J2ZIvSHDXWQvEpsAIJJPT953ZWX7c2Z6ngCbHdZmg+BpqWZeD2QvyWZ+lwOE6mEefRBVA0qA3WYckiHIdWp5TTCcnOkwriHgveinQJSay+KF1eCo3GqPhp/Ik+p3ti9bOuXTg7aPt2ZvD4IJHehA8zEJOmm2fZE5EIaB/Gaa7YBZkeqa7wB/7xWXRCxhlD4cn2qflIM8w2J4L4iCsiZLvdJPogcsGGmCz+hcPzwF4+pqz0WqpVqE/kg2MWKiLNCGHeZ1Z6A5eiCypEL0a/7hRhfaru9h6yWaL7Rit83JhF3kNx0ak65mv9RWwtSYP1/qdWWUvEhphydJL2/KeCbuJW4Z+5jex15nLqLqSWyoe4IuyJ3ustvrenrEFQ3sKmglB5nes45Ma6Nm8Tlu0o0Y71Tm2iWA1EMGUV1rmlNq2mVp5O/W34zZDVgp95dA+5kRWbRuNfwWZYXu5K+sAuuqppZmudBG6q7pQnBu7PQW2TsiuR1q47+2VuXsLAqqxHVsXBra8QdqFx5m9pYCjfsKos2Fm4bu9J+m975vlbkG3gbZQg5W6T/u3C3q/1wAKuoq1qcCGDRy/GZR1G9yLSVTBD5rAIpwMJwnCL1xgb/+Elx0Voj7kujecpLVJw0c8MlDKFNDzxDE8MpJBo1m8CMb2v5d0vWO8ulHcaMY4xud2PGmcPh0Aem8cp+tCEYjKww0cLyKVoikjM4ecxJmttw1cVx1toujBuJ88rYVutOP3vwrmZrY2DyDIOrNcsgcJq8s8L39DFn08ydaln0o3zUEbD7mMj2NcVv5xsBe3nuJczicYeKUamv2cgPVcCEa3ju38xrPVsv980MlYz7cSMtqBzOUcVhkdoB2dE2nDMgvdz5frluUx02cVlZhiMm5LtkV9ztUCcGg71cNsCb6s1CPCEbU805fLdFSJy6H7YWLdWuUheH8RvLn71itmu13/3T4wF9V5tz7ATsCHHKX4IZ2M/diFKdmr0rCX5NCp/cXgMjn2etq3nSytvbCvchpi8aafHK9b246ZKXnDHSKtohniRSnE2NnLPMW98R5c+t214L7+1x0MAhiE/dmJJ9rnQb/5PTU9A73fndgPft8T3v9qO+JVPbuPE+IpXns7PeM3nsg3B+M5XuMnPuQ/fUCsOeQffeQ5njNPHuUJXeUzvihb3uUVvtFp3syVGeRvHknxZOCfXLx3/sOD3nn1B8mH3oKOHnIRzJOTPuWb3uZP5U+f/uWnHuZxxuirXuSrHuiznuiznuu7XumfHuzDvtaTnuzLHueHHu3TvuNvnu3b/x7uhVruy57uw1vX097uN1rvvx7vZ5rvt97v777tW7PuBf/pazfo1Z3wZWxfER9RGT/yJX/yKb/yLf/yC7vuNH/zOb/zPf/zQT/0RX/0VRec2ov0UT/1VX/1WX/1fV5EJ53zx7z1N3/2aV/zbf/2CSr36+4qG+8Oeh/4df8ph5/4h5/3Wx/5u/2M18VFYfT5mwXwcVzZjxvprV/iqT+Hm5++KdziQxii0YMzxZ+qihKGD197op/7+/lsmRuc7o/84Z+O2f/7D9hib/kL7h//X7/nbxUIBoAhsWg8IpPKJbOZHAiVUCfVOK1ir1iqdsvsIsHeMblsPqPT6jW77X7D4//yOb1uv+Pz+j2/7/8DBgoOEhYaHiImKi4yNjo+QkZKTlJWWl5iZmpucnZ6foKGio6Slpqeoqaqch0QJUQERBQQMcQmRA60EhUoBATQ2q7+FUAVz/IGKMwWIjPs9iof5lrpDtVG3Ao3HgQIEBARCIgjDDkIIBgYZDNyexMdGHg3lJ+nr2vnDYjvCyF4nzPz58/BEH/hyBFq922IQiLm0KnDtyicO2sFCjQQMKCAAAMAIggg2IjiQgAZq3H0CFKkRDzEBigQl4CBgAcAHghwNmilSQEza97MSYgkOHELU34M2VKRvpJEMiZoCkCqI6oHBDTIaFMq1aV5FghYAKDbL7L/hLoRDDfArFlCXadW5FrRq6G3SQnKdbqIqj4EA/wpyEsXTwKZYwWURUyosLd4axW3HfSWrzu7gwO9NScWwFVyNG1WrXj1G9nOAD5ftgN2M09zEQpxU5DxLgDXhSaLBog6taADIP3OwtnAl5CMDHAqcOT73MaeDPwVz4mc9xx9PocUbjAAaqHAOAlm33590HLgnH83Nz6dOiCK4oTsE/frgD8DLBm518i5fvL9He+z50Y498mGVX+EiDMcEQU2cKAg+QkBoX/2BVihhRdimKGGG3LYoYcfghiiiCOSWKKJJ6KYooorstiiiy/CGKOMM9JYo4034pijjjvy2KOPPwIZ/6SQQxJZpJFHIpmkkksyCSQxuhzQ3BgHEOCgGw58Q6WVRihAQDUAdPklFWGy+CRDUnqhpRxYclblEmQu6KUXcDaZBlVqkaHPL2aEo0SfCQQQRRLdCHpYoVQQyuKd+o2h5xl9JvFnoEskSkSlWFxa5xmLCnHAAgQ8kFwyQ4zaJajOOFpEBAQQ4MAre8bC2aehijfpcQS8BoCkUSjwQKvLHBbBAw+0kmgBWC4A5acOLHOAr3iuyKmsoIraX6msPoCqYqqy6iospL7mKbW1CnFrrrsO0euvlgogLLGGAnAsAckytGyzzzKq6aYVqVUYAgEsYFNF7jzgQABQpToEWAb7Bf/WAVct4C/AocZT5WfmpCUAXIk9cLCg3RAQQDrwohMAOgkkYMC/KgOQsgEBQKsipxIHDMDA3xR8sE8JA7CwyQM4DDHNFHujwMVK9eloNx1rx27IIyda8skpr0yOyzDnq28ZnF7VgAOy2LyQO4ASkBEU2w6BU8dC6OOAOQ9j9fUskOI0Czq6auyoAfPEC2yi5jyWi1I0RQCSM2+DJGrWKHIdN9g3twyz2TyrPWnbb3ctN95pC2C3R0krtvcQF7ErBOCEXkUQ4YbXJsByih+qtRfSMkBAPOTcTLUCYJ295+gL+CNUA3sjVPvtmyPfJ+i/zFVEooQS6qiez2tEfewm0m7/O0C5q7y7RjwXALw4zgzfQPHakwOp+hovHzYS1kev2PT6QU//4rJvUUA8DNBkADELMGAAI4uHA8BCAH08YABq4dkCIjAA23SjXVMBoAA/l5PlBAA17cOJAxPIrggwAGr62dsAcAK3BA4PLgmMWYr0l5P+/S+AAwyJARGowO+hrWcOhKA4XgM0GVqQARjUYN4Uw8ESfqxdIfRIokhowqug0CM2ZCH+0hQ8BLQiAVdshQLSYY5vgEVlOPTdWOJBoZaJYxZaHEcrQihBB8TjAXMr4i/CF48GrKMbdyyWfuhjoHRlBIv0EOP1TOTHc2Rxi2DyojvCCB2eiew/2EljyxTp/8bXwLEmc9xYvBZwxzx2BCt87JQ/GgRIRA4SOlV0BE02s0pJtPKVKcJJIWWpCFraMpe63CUve+nLXzrhClG5BzAxE4VhFlND4iBVDpP5h2UehozOZEMvFLiAWfTiFbcwVa7EFapphQpQQhDnWBTAjXjBLFtJABQDPnWA2olkLceRI8z6A822wMxgW9JRNeeFzQBoE0ys6uaskuNNBZCTnMk4ZwHSqZMjsNOd8ByCPIfVUDfZTGPRJFWrRjXNR4XFHDYJh2MwxsGhDU16igmlxqTmujAYpSNZEYDixKiyeNxCPlj7hUhBBqRwLECkeCtpSE56jomlVH4rjUdLX+YPMf9RNKZ7y0hN64OO6+g0HDytiU8/yieN+gNvy9ibL7yROVmclRhKZR5CRgOwZkb1F+1LlDvoGp+V8q15PIJUWMMx1uGALK1pVSlbGeKNt0ozrptTmn7q2ti7Mi+vevHqFtaHPJsBdlTG0w36COs+uISMODCVKx3h5Vj4aNQskPuRZSGFWV9oFn2n6exaP9sU2F7PUXNtLGkey0zmiW2ylK2CWkAyUo0GJVDVpGA6fljBq7xMq58FQDoCEwFz5lC3paVrb1H7WwD4gwExEW6OigsU1+JEuYFirgGcmw7o7nS61R3Ada9CRu1ykrumTa1iwjve4ZIhHBkhwCZ/Z0aAbnGpjag0RwPAAtx34AQrDADJPfDLWPh0N6PfPcCA9bojAXujwJ08sIKxWOJWMNjB03VWgiY8HsXuFsP73XCHyQtgJriWDw9wJRwGEEC0/BS5OubxG3z8GADd2Ak53sMDiOmGmHTkmkH+Q5PnAGUDSDnJWt4yl7vs5S+DOcxiHjOZy2zmM6M5zWpeM5vb7OY3wznOcp4znets5zvjOc963jOf++znPwM60I8IAgA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronary heart disease (CHD) mortality rate, pictured on a log scale with 95 percent confidence intervals, in each decade of age in relation to the estimated usual systolic and diastolic blood pressure at the start of that decade. CHD mortality increases with both higher pressures and older ages. For diastolic pressure, each age-specific regression line ignores the left-hand point (ie, at slightly less than 75 mmHg) for which the risk lies significantly above the fitted regression line (as indicated by the broken line below 75 mmHg).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Prospective Studies Collaboration, Lancet 2002; 360:1903.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Stroke mortality related to blood pressure and age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 390px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stroke mortality rate, pictured on a log scale with 95 percent confidence intervals, in each decade of age in relation to the estimated usual systolic and diastolic blood pressure at the start of that decade. Stroke mortality increases with both higher pressures and older ages. For diastolic pressure, each age-specific regression line ignores the left-hand point (ie, at slightly less than 75 mmHg), for which the risk lies significantly above the fitted regression line (as indicated by the broken line below 75 mmHg).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Prospective Studies Collaboration, Lancet 2002; 360:1903.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_12_33986=[""].join("\n");
var outline_f33_12_33986=null;
var title_f33_12_33987="Hallux valgus measurement";
var content_f33_12_33987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Angles relevant to hallux valgus deformity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 556px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HA: Hallux abductus angle (hallux valgus); IM: Intermetatarsal angle",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_12_33987=[""].join("\n");
var outline_f33_12_33987=null;
var title_f33_12_33988="Vitamin E: Pediatric drug information";
var content_f33_12_33988=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vitamin E: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?19/28/19910?source=see_link\">",
"    see \"Vitamin E: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/45/40659?source=see_link\">",
"    see \"Vitamin E: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F234560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alph-E [OTC];",
"     </li>",
"     <li>",
"      Alph-E-Mixed [OTC];",
"     </li>",
"     <li>",
"      Aqua Gem-E&trade; [OTC];",
"     </li>",
"     <li>",
"      Aquasol E&reg; [OTC];",
"     </li>",
"     <li>",
"      d-Alpha Gems&trade; [OTC];",
"     </li>",
"     <li>",
"      E-Gems&reg; Elite [OTC];",
"     </li>",
"     <li>",
"      E-Gems&reg; Plus [OTC];",
"     </li>",
"     <li>",
"      E-Gems&reg; [OTC];",
"     </li>",
"     <li>",
"      E-Gem&reg; Lip Care [OTC];",
"     </li>",
"     <li>",
"      E-Gem&reg; [OTC];",
"     </li>",
"     <li>",
"      Ester-E&trade; [OTC];",
"     </li>",
"     <li>",
"      Gamma E-Gems&reg; [OTC];",
"     </li>",
"     <li>",
"      Gamma-E PLUS [OTC];",
"     </li>",
"     <li>",
"      High Gamma Vitamin E Complete&trade; [OTC];",
"     </li>",
"     <li>",
"      Key-E&reg; Kaps [OTC];",
"     </li>",
"     <li>",
"      Key-E&reg; Powder [OTC];",
"     </li>",
"     <li>",
"      Key-E&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1062948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nutritional Supplement",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vitamin, Fat Soluble",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vitamin, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11445304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1 unit vitamin E = 1 mg",
"     <i>",
"      dl",
"     </i>",
"     -alpha-tocopherol acetate. Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Estimated Average Requirement (EAR): 4 mg/day (6 units)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Vitamin E deficiency: 25-50 units/day results in normal levels within 1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prevention of vitamin E deficiency:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Low birth weight neonates: 5 units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Full-term neonates: 5 units/L of formula ingested",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prevention of retinopathy of prematurity or BPD secondary to O",
"     <sub>",
"      2",
"     </sub>",
"     therapy: 15-30 units/kg/day to maintain plasma levels between 1.5-2 mcg/mL (may need as high as 100 units/kg/day).",
"     <b>",
"      Note:",
"     </b>",
"     AAP considers this use investigational and routine use is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1062943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/28/19910?source=see_link\">",
"      see \"Vitamin E: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1 unit vitamin E = 1 mg",
"     <i>",
"      dl",
"     </i>",
"     -alpha-tocopherol acetate. All dosages or requirements expressed in units of vitamin E. Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adequate Intake (AI):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 to &lt;6 months: 4 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 to &lt;12 months: 5 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Recommended Daily Allowance (RDA):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: 6 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: 7 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-13 years: 11 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;13 years and Adults: 15 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Vitamin E deficiency:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children (with malabsorption syndrome): 1 unit/kg/day of water miscible vitamin E (to raise plasma tocopherol concentrations to the normal range within 2 months and to maintain normal plasma concentrations)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 60-75 units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prevention of vitamin E deficiency:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 5 units/L of formula ingested",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 30 units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cystic fibrosis, beta-thalassemia, sickle cell anemia may require higher daily maintenance doses: Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cystic fibrosis: 100-400 units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Beta-thalassemia: 750 units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sickle cell: 450 units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: Apply a thin layer over affected area",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F234545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 1000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Key-E&reg; Kaps: 200 units, 400 units [derived from or manufactured using soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, liquid, oral: 400 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral: 100 units, 200 units, 400 units, 600 units, 1000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alph-E: 200 units, 400 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alph-E: 400 units [contains soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alph-E: 1000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alph-E-Mixed: 200 units, 400 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alph-E-Mixed: 1000 units [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aqua Gem-E&trade;: 200 units, 400 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     d-Alpha Gems&trade;: 400 units [derived from or manufactured using soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     E-Gems&reg;: 30 units, 100 units, 200 units, 400 units, 600 units, 800 units, 1000 units, 1200 units [derived from or manufactured using soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     E-Gems&reg; Elite: 400 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     E-Gems&reg; Plus: 200 units, 400 units, 800 units [derived from or manufactured using soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ester-E&trade;: 400 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gamma E-Gems&reg;: 90 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gamma-E PLUS: 200 units [contains soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     High Gamma Vitamin E Complete&trade;: 200 units [contains soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: 1000 units/120 g (120 g); 100 units/g (57 g, 60 g); 30,000 units/57 g (57 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Key-E&reg;: 30 units/g (57 g, 120 g, 600 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lip balm, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     E-Gem&reg; Lip Care: 1000 units/tube [contains aloe, vitamin A]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral/topical: 1150 units/1.25 mL (30 mL, 60 mL, 120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oil, oral/topical: 100 units/0.25 mL (74 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oil, oral/topical [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     E-Gem&reg;: 10 units/drop (15 mL, 60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oil, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alph-E: 28,000 units/30 mL (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Key-E&reg;: 30 units/g (57 g, 113 g, 500 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Key-E&reg; Powder:  (15 g, 75 g, 1000 g) [derived from or manufactured using soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [drops]: 15 units/0.3 mL (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aquasol E&reg;: 15 units/0.3 mL (12 mL, 30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, rectal/vaginal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Key-E&reg;: 30 units (12s, 24s) [contains coconut oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 100 units, 200 units, 400 units, 500 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Key-E&reg;: 200 units, 400 units [derived from or manufactured using soybean oil]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F234531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1062952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May administer with or without food",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1062951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of vitamin E deficiency",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F234584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Aquasol E&reg; may be confused with Anusol&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F234583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Fatigue, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Contact dermatitis with topical preparation, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Creatinuria, gonadal dysfunction, hypercholesterolemia, hypertriglyceridemia, serum thyroxine decreased, serum triiodothyronine decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Diarrhea, intestinal cramps, nausea, necrotizing enterocolitis (infants)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: CPK increased, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Renal: Serum creatinine increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1062955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to vitamin E or any component",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1062942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Necrotizing enterocolitis has been associated with oral administration of large dosages (eg, &gt;200 units/day) of a hyperosmolar vitamin E preparation in low birth weight infants",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F234539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Vitamin E may enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Vitamin E may enhance the anticoagulant effect of Anticoagulants. Vitamin E may also increase the overall risk for bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Vitamin E may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orlistat: May decrease the serum concentration of Vitamins (Fat Soluble). Management: Administer oral fat soluble vitamins at least 2 hours before or after the administration of orlistat.  Similar precautions do not apply to parenterally administered fat soluble vitamins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the adverse/toxic effect of Vitamin E. This interaction only applies to tipranavir oral solution. Management: Patients taking tipranavir oral solution are advised to avoid taking additional vitamin E, beyond the amounts contained in a multivitamin product.  This interaction does not apply to tipranavir capsules.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14192601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vitamin E crosses the placenta. Maternal serum concentrations of &alpha; tocopherol increase with lipid concentrations as pregnancy progresses; however, placental transfer remains constant. Additional supplementation is not needed in pregnant women without deficiency (IOM, 2000).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1062947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Plasma tocopherol concentrations",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1062950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Plasma tocopherol: 6-14 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1062941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antioxidant which prevents oxidation of vitamin A and C; protects polyunsaturated fatty acids in membranes from attack by free radicals and protects red blood cells against hemolysis by oxidizing agents",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1062954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Depends upon the presence of bile; absorption is reduced in conditions of malabsorption, in low birth weight premature infants, and as dosage increases; water miscible preparations are better absorbed than oil preparations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver to glucuronides",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily in bile",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Fetus and Newborn, &ldquo;Vitamin E and the Prevention of Retinopathy of Prematurity,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1985, 76(2):315-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33988/abstract-text/3895151/pubmed\" id=\"3895151\" target=\"_blank\">",
"        3895151",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Office of Dietary Supplements, National Institutes of Health, \"Dietary Supplement Fact Sheet: Vitamin E.\" Available at:",
"      <a href=\"file://ods.od.nih.gov/factsheets/vitamine/\" target=\"_blank\">",
"       file://ods.od.nih.gov/factsheets/vitamine/",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12884 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-23F828356C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_12_33988=[""].join("\n");
var outline_f33_12_33988=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234560\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062948\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11445304\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062943\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234545\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234531\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062952\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062951\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234584\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234583\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062955\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062942\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300224\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234539\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14192601\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062947\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062950\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062941\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062954\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12884\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12884|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/28/19910?source=related_link\">",
"      Vitamin E: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/45/40659?source=related_link\">",
"      Vitamin E: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_12_33989="Dextroamphetamine and amphetamine: Patient drug information";
var content_f33_12_33989=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dextroamphetamine and amphetamine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/41/44695?source=see_link\">",
"     see \"Dextroamphetamine and amphetamine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/53/11096?source=see_link\">",
"     see \"Dextroamphetamine and amphetamine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F158728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adderall XR&reg;;",
"     </li>",
"     <li>",
"      Adderall&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F935382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Adderall XR&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming; avoid long-term use. Use this drug as ordered by your doctor. Tell your doctor if you have a history of drug or alcohol abuse. Misuse of this drug may cause unsafe heart-related side effects. Tell your doctor if you have any heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691738",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat attention deficit problems with hyperactivity.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691979",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat narcolepsy.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701922",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dextroamphetamine, amphetamine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703437",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Both attention deficit/hyperactivity problems and Tourette's syndrome or tics, drug abuse, glaucoma, heart disease, high blood pressure, nervous state, overactive thyroid disease, or structure problems of the heart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697797",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have some heart tests before starting this drug. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699005",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad problems with how you act.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696213",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug early in the day to stop sleep problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695739",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take Adderall XR&trade; in the morning.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695696",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow Adderall XR&trade; whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696308",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may sprinkle contents of capsule on soft food or liquid. Do not chew.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12369 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C9598D4138-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_12_33989=[""].join("\n");
var outline_f33_12_33989=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158728\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F935382\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029472\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029474\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029473\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029478\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029479\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029481\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029476\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029477\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029482\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029483\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?43/41/44695?source=related_link\">",
"      Dextroamphetamine and amphetamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/53/11096?source=related_link\">",
"      Dextroamphetamine and amphetamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_12_33990="Multiple myeloma marrow";
var content_f33_12_33990=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F61145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F61145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Multiple myeloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow aspirate smears from two different patients with multiple myeloma, illustrating a preponderance of mostly mature-appearing plasma cells with eccentrically placed nuclei and prominent Golgi zones (arrow) (Wright Giemsa stain).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Brunning, RD, McKenna, RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_12_33990=[""].join("\n");
var outline_f33_12_33990=null;
var title_f33_12_33991="Pathology of linear IgA bullous dermatosis";
var content_f33_12_33991=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F69124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F69124&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Linear IgA bullous dermatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A subepidermal blister with neutrophils within the blister cavity and an underlying neutrophil-predominant inflammatory cell infiltrate is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_12_33991=[""].join("\n");
var outline_f33_12_33991=null;
var title_f33_12_33992="Herpes simplex keratitis";
var content_f33_12_33992=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Herpes simplex keratitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/12/33992/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/12/33992/contributors\">",
"     Alan Sugar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/12/33992/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/12/33992/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/12/33992/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/12/33992/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/12/33992/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/12/33992/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Keratitis (corneal infection and inflammation) caused by herpes simplex virus (HSV) is a major cause of blindness from corneal scarring and opacity worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HSV keratitis typically presents as an infection of the superficial layer of the cornea, with punctate or diffuse branching (dendritic) lesions of the epithelium that do not usually involve the stroma. Applying topical glucocorticoid drops to the infected eye (without use of concomitant antiviral medication) can exacerbate the infection and potentially lead to involvement of deeper stromal structures with threat to vision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis and treatment of HSV corneal infections will be discussed here. Discussion of the epidemiology and pathogenesis of HSV-1-related infections in general, as well as other clinical manifestations of HSV-1 infection, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38021?source=see_link\">",
"     \"Epidemiology of herpes simplex virus type 1 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/54/29544?source=see_link\">",
"     \"Pathogenesis of herpes simplex virus type 1 infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=see_link\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Herpes simplex virology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two clinically important HSV types exist in the subfamily alpha herpesviridae, HSV-1 and HSV-2. Humans are the only natural host for both types. HSV-1 accounts for most oral, labial, and ocular infections and HSV-2 for most genital infections, although there is considerable and increasing overlap in these distributions.",
"   </p>",
"   <p>",
"    Primary infection with HSV-1 occurs following inoculation of mucosal or skin surfaces by direct contact. Most ocular disease is thought to represent recurrent HSV disease following the establishment of viral latency in the host, rather than a primary ocular infection. Latency develops after the virus enters sensory neurons and travels to sensory ganglia (usually the trigeminal ganglion for ocular disease) by retrograde axoplasmic flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/3\">",
"     3",
"    </a>",
"    ]. The virus remains in ganglia for the lifetime of the host. It has been proposed that HSV-1 latency may also be established in the cornea, although this is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/54/29544?source=see_link\">",
"     \"Pathogenesis of herpes simplex virus type 1 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During latency, the virus does not generally replicate and does not damage neurons. The latent viral genome assumes a circular form that is generally not transcribed. Intermittent shedding of trigeminal ganglion-based virus can be detected in tears and saliva of adult humans without apparent clinical disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Episodically, latency is interrupted, and infectious viral particles travel anterograde to neuronal endings where virus is shed. RNA molecules, known as latency associated transcripts (LAT), become detectable in infected ganglia and play a part in viral reactivation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reactivation of HSV skin and mucosal infection has been attributed to psychological stress, physical trauma, fever, ultraviolet light exposure, and other viral infections. These triggers have not, however, been documented for ocular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/8\">",
"     8",
"    </a>",
"    ]. Documented triggers for keratitis include ultraviolet laser treatment, topical ocular medications (epinephrine, beta-blockers, prostaglandins), and immunosuppression. Immunosuppressive drugs, especially ophthalmic topical glucocorticoids, are thought to allow normally asymptomatic periodic viral shedding to establish active infection, rather than by triggering reactivation from latency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mechanisms of HSV corneal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of HSV corneal disease is complex and involves components of three processes: the active infection itself, inflammation caused by active infection, and immune reaction to past infection. Resulting structural changes in the cornea can lead to additional forms of keratitis.",
"   </p>",
"   <p>",
"    The cornea is the clear thin anterior refracting tissue of the eye. The external, tear-covered, stratified epithelium overlies the collagenous, clear corneal stroma. The stroma comprises the bulk of the cornea and is about 500 microns thick. The single cell layer endothelium, in contact with the aqueous humor of the anterior chamber, maintains corneal clarity through fluid barrier and pump mechanisms.",
"   </p>",
"   <p>",
"    Reactivated virus enters the basal epithelium of the cornea and multiplies within cells, spreading to adjacent cells. In primary infection, an inflammatory response triggers antigen-specific immune responses. IgG and IgA antibodies and CD4+ and CD8+ T cells are involved in modulation of infection and latency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Corneal stromal cells, keratocytes, may support active infection with ensuing necrotizing inflammation. Retained viral antigens may lead to subsequent immune-mediated stromal inflammation without viral replication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSV-1 infection, spread by direct contact with mucous membranes, is endemic in human populations. Most people have been exposed by middle age, with circulating antibodies to HSV-1 detectable in 90 percent or more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/1\">",
"     1",
"    </a>",
"    ]. Latent virus can be detected by PCR at autopsy in the trigeminal ganglion of most older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/1,12\">",
"     1,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary HSV-1 infection has an incubation period from one day to several days and is asymptomatic or not recognized more than 90 percent of the time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/1\">",
"     1",
"    </a>",
"    ]. Most clinical ocular infections are manifestations of recurrent disease; ocular involvement occurs in less than 5 percent of primary infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of ophthalmic HSV cases are unilateral, with recurrences affecting the same eye. Bilateral disease (not necessarily concurrent) occurs in 1 to 12 percent of cases and is more common in patients with atopy or other immune abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of ocular disease is 12 to 31 per 100,000 annually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The prevalence in the US is about 150 per 100,000, with an estimated 20,000 new cases, and 48,000 episodes annually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/19\">",
"     19",
"    </a>",
"    ]. Recurrences after an initial ocular episode have been reported in 9.6 percent at one year, 22.9 percent at two years, 40.0 percent at five years, and 67.0 percent at 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/1,16,20\">",
"     1,16,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpes simplex virus (HSV) epithelial keratitis has an acute onset with variable symptoms of pain, visual blurring, and watery discharge.",
"   </p>",
"   <p>",
"    The diagnosis of HSV keratitis is usually made on the basis of the clinical history and examination findings. The slit lamp findings in epithelial infection are often pathognomonic. Laboratory confirmation is rarely indicated.",
"   </p>",
"   <p>",
"    Physical examination is notable for conjunctival injection near the limbus (ciliary flush), decreased corneal sensation, and characteristic dendritic lesions of the cornea (",
"    <a class=\"graphic graphic_picture graphicRef69708 \" href=\"mobipreview.htm?25/47/26353\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/21\">",
"     21",
"    </a>",
"    ]. When the corneal stroma is involved, symptoms may be similar, but typical findings are corneal edema or infiltrate in the cornea.",
"   </p>",
"   <p>",
"    Laboratory testing is usually not necessary to confirm a clinical diagnosis of HSV keratitis. Testing may be indicated in severe cases where the clinical findings are atypical but suspicion of HSV keratitis is high. However, even in such cases a clinical trial of antiviral therapy is usually initiated.",
"   </p>",
"   <p>",
"    Serologic testing is not helpful because of the high prevalence of prior exposure in the population. When diagnostic testing is performed, ocular samples are taken by scrapings of epithelial lesions. Three types of tests are available: viral culture, detection of viral antigen, and detection of viral DNA.",
"   </p>",
"   <p>",
"    Viral culture results in characteristic cytopathic effects, seen in one to several days. Enzyme immune assays (ELISA) to detect viral antigen are available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/22\">",
"     22",
"    </a>",
"    ] but have been largely superseded by an enzyme linked virus inducible system (ELVIS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/23\">",
"     23",
"    </a>",
"    ]. Polymerase chain reaction (PCR) to detect viral DNA is more sensitive than antigen assays, but PCR will be positive even with inactive virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis, in the absence of obvious dendritic lesions, is that of the red eye. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17607?source=see_link\">",
"     \"Evaluation of the red eye\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TYPES OF OCULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular HSV-1 disease includes eyelid lesions (herpetic blepharitis), conjunctivitis, keratitis, retinitis, and rarely scleritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/25\">",
"     25",
"    </a>",
"    ]. Corneal disease is the most prevalent form.",
"   </p>",
"   <p>",
"    HSV keratitis has been classified in four categories: infectious epithelial keratitis, stromal keratitis, endotheliitis, and neurotrophic keratopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Epithelial keratitis accounts for most first episodes of HSV keratitis, while stromal keratitis is unusual in initial disease but common in recurrent disease. The prognosis for visual loss is significantly worse with stromal than epithelial keratitis. Endothelial disease is uncommon but often leads to corneal edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     HSV epithelial keratitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epithelial keratitis is the most frequent form of ocular HSV infection. With appropriate treatment, healing occurs in two to three weeks, unless infection progresses to stromal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/28\">",
"     28",
"    </a>",
"    ]. In one study, the duration of untreated epithelial keratitis averaged 17.6 days for an initial episode and 28.4 days for a recurrent episode [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epithelial disease is manifested as dendritic lesions or geographic ulcerations of the cornea. These lesions can be observed after staining with dyes such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/21,29\">",
"     21,29",
"    </a>",
"    ]. Although dendritic lesions may be somewhat visible with a hand light without staining, slip lamp magnification and staining are usually necessary to define the details of the lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Dendritic keratitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic form of herpetic keratitis is the dendrite (",
"    <a class=\"graphic graphic_picture graphicRef69708 \" href=\"mobipreview.htm?25/47/26353\">",
"     picture 1",
"    </a>",
"    ). Epithelial infection begins with granular punctuate epithelial lesions that form vesicles, which then rapidly coalesce into a linear branching dendritic lesion.",
"   </p>",
"   <p>",
"    Dendrites may be single or multiple and vary from &lt;1 mm to several millimeters long. Dendrites stain with topically-applied",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    dye in their bed and with Rose Bengal or lissamine green at their edges. Typically, the ends of the branches of the dendrite have bulbous thickenings.",
"   </p>",
"   <p>",
"    Dendritic lesions are caused by actively proliferating virus within epithelial cells. The dendrite is initially elevated but, with lysis of the central epithelial cells, disrupts the corneal epithelial basement membrane and becomes a corneal ulcer. Rapidly healing lesions may not ulcerate. About one-fourth of dendritic lesions will heal rapidly and spontaneously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Geographic ulcer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Geographic ulcers, occurring in up to 22 percent of cases of epithelial HSV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/30\">",
"     30",
"    </a>",
"    ], develop when a dendrite widens and assumes an ameboid shape, often with dendritic extensions at the edges [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/26\">",
"     26",
"    </a>",
"    ]. Like dendrites, geographic ulcers represent destruction and desquamation of epithelial cells from active viral infection.",
"   </p>",
"   <p>",
"    The use of topical glucocorticoids in patients with dendritic lesions has been thought to promote the development of geographic ulcers, but this concept has been disputed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/16\">",
"     16",
"    </a>",
"    ]. Geographic ulcers respond more slowly to treatment and are more likely than dendrites to lead to scarring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Marginal keratitis (limbitis)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active epithelial HSV lesions that occur at the limbus (the junctional zone of the cornea and sclera) are termed marginal keratitis or limbitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/26\">",
"     26",
"    </a>",
"    ]. Marginal lesions often are less dendritic in appearance than central corneal lesions, and thus may not be as easily diagnosed. The proximity to blood vessels at the limbus allows white cell infiltration and neovascularization of the underlying corneal stroma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     HSV stromal keratitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stromal involvement in HSV keratitis is rarely an initial ocular finding, accounting for less than 2 percent of initial presentations, but for 20 to 60 percent of recurrent corneal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/16,27,31\">",
"     16,27,31",
"    </a>",
"    ]. Active stromal lesions do not usually occur at the same time as epithelial disease.",
"   </p>",
"   <p>",
"    Stromal disease may result from active viral infection or immune and inflammatory reaction to infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Immune stromal keratitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune (non-necrotizing) keratitis occurs in 20 to 60 percent of eyes with recurrent HSV keratitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/1,16,32,33\">",
"     1,16,32,33",
"    </a>",
"    ] and accounts for 90 percent of recurrent stromal keratitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/31\">",
"     31",
"    </a>",
"    ]. The immune reaction is felt to represent a delayed hypersensitivity reaction by T lymphocytes reacting to viral antigens in the cornea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several forms of this condition occur:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A \"ghost-like\" superficial stromal opacity beneath the site of a previous dendrite. These dendrite-shaped superficial lesions are clinically insignificant but may be helpful in making the diagnosis of past HSV infection.",
"     </li>",
"     <li>",
"      Localized or diffuse inflammation of the stroma, usually without epithelial disease. The stromal inflammatory deposits are thought to represent complexes of viral antigen with antibodies and complement. These may take the form of a ring infiltrate.",
"     </li>",
"     <li>",
"      The term \"disciform keratitis\" has been used to describe circular areas of stromal edema. Although previously considered a form of stromal keratitis, this is now recognized as edema of the stroma secondary to corneal endothelial inflammation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Endotheliitis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Stromal neovascularization may occur. Blood vessels may grow into the normally avascular corneal stroma, especially when the disease is long standing. These vessels may regress with treatment of the keratitis. Corneal stromal scarring almost always results and may decrease vision significantly depending on location and severity, making prompt treatment of active inflammation mandatory.",
"     </li>",
"     <li>",
"      Stromal thinning, fibrosis and vascularization beneath the epithelium (pannus), and lipid deposits from stromal vessels are common as well.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Necrotizing stromal keratitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;This form of HSV stromal disease, also known as interstitial keratitis, is the result of viral infection of the stroma and is less common than immune stromal keratitis. The typical finding is the presence of cellular infiltrates within the stroma at one or more sites (",
"    <a class=\"graphic graphic_picture graphicRef59223 \" href=\"mobipreview.htm?10/5/10320\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These infiltrates may be true abscesses and are often associated with overlying stromal ulceration. Typically there are white cell deposits on the corneal endothelium, keratic precipitates, and an inflammatory reaction in the anterior chamber. Hypopyon or hyphema may result.",
"   </p>",
"   <p>",
"    Corneal perforation may occur, particularly following glucocorticoid treatment without adequate concurrent antiviral treatment (",
"    <a class=\"graphic graphic_picture graphicRef62435 \" href=\"mobipreview.htm?6/31/6640\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/7\">",
"     7",
"    </a>",
"    ]. The severe corneal destruction and occasionally rapid progression may make necrotizing HSV keratitis difficult to distinguish from bacterial or fungal infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Endotheliitis (disciform keratitis)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corneal stromal edema in a circular pattern with underlying endothelial keratic precipitates occurs as a frequent form of recurrent HSV disease. Formerly known as disciform keratitis, this condition is now termed disciform endotheliitis. This is thought to be a manifestation of immune reaction rather than infection of the endothelial cells, although HSV has been isolated from the aqueous humor in rare cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/35\">",
"     35",
"    </a>",
"    ]. It is not temporally associated with either active epithelial infection or infiltrative stromal disease, and triggers for disciform endotheliitis are unknown. Endotheliitis is often associated with significant visual loss but is usually reversible with topical glucocorticoid therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Neurotrophic keratopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;HSV keratitis is variably associated with corneal hypesthesia or complete anesthesia from damage to corneal nerves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/28\">",
"     28",
"    </a>",
"    ]. Hypesthesia may lead to persistent non-healing corneal epithelial defects. These oval defects do not represent active viral disease and are made worse by antiviral drops. These non-healing lesions can lead to stromal scarring, corneal perforation, or secondary bacterial infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     HSV keratouveitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uveitis, inflammation of the vascularized intraocular tissues of the iris, ciliary body, and uveal tract, may occur with or without corneal involvement by HSV infection. Recurrent HSV should lead the differential diagnosis when iritis and keratitis occur together.",
"   </p>",
"   <p>",
"    Isolated HSV iritis may be difficult to diagnose. One feature that distinguishes uveitis due to HSV is the tendency for involvement of the trabecular meshwork with resulting increase in intraocular pressure. Uveitis tends to recur and is often not diagnosed as herpetic unless typical corneal lesions appear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Postinfectious epithelial disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following resolution of active epithelial infection, the corneal epithelium may be unstable. Punctate epithelial staining with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    or lissamine green dye is common. Recurrent corneal erosions and intermittent sloughing of corneal epithelium without recurrent HSV infection may occur and may be provoked by use of topical ocular medications, such as antivirals and preserved glaucoma drops.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MEDICAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of herpes simplex virus (HSV) keratitis is dependent upon whether the episode of disease is caused by active viral replication or immune response to past infection. The use of topical glucocorticoids when active HSV epithelial disease is present should be strongly discouraged, as they have long been observed to exacerbate epithelial lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Epithelial keratitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the availability of antiviral drugs, dendritic and geographic lesions were treated by debridement and chemical cauterization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/37\">",
"     37",
"    </a>",
"    ]. These methods have been abandoned, although gentle \"wiping\" debridement is somewhat effective and may be used as an adjunct to antivirals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antiviral medications hasten the resolution of epithelial keratitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/38\">",
"     38",
"    </a>",
"    ]. Topical antiviral therapy has been the standard for treatment of dendritic and geographic HSV keratitis in the past, although oral antivirals are equally effective in randomized trials and are now frequently used because of their convenience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. When topical antivirals are used, a randomized trial found that concomitant treatment with oral agents does not improve the outcomes or prevent later iritis or stromal keratitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of 99 trials found that use of any of four topical antiviral agents (vidarabine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17939?source=see_link\">",
"     trifluridine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    ) resulted in improvement in most patients within one week, and no treatment was significantly better than another [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trifluorothymidine 1% (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17939?source=see_link\">",
"       trifluridine",
"      </a>",
"      , Viroptic) is given one drop every two hours (eight or nine doses daily) and leads to healing in 89 percent after one week and 99 percent after two weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/42\">",
"       42",
"      </a>",
"      ]. Full dosing for two weeks may be necessary to prevent early reactivation, but drops are often tapered after the first week. Treatment is limited by epithelial toxicity, especially when used for longer than three weeks.",
"     </li>",
"     <li>",
"      Topical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      0.15% gel (Zirgan) is given as one drop five times daily until epithelial healing occurs and then three times daily for one week. Randomized clinical trials in Africa and Europe comparing 0.15% ganciclovir and 3%",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      gels showed healing rates of 85 percent for both treatments [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. Ganciclovir gel appears to have less corneal toxicity than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17939?source=see_link\">",
"       trifluridine",
"      </a>",
"      and may be better tolerated for long term use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/45,46\">",
"       45,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       Acyclovir",
"      </a>",
"      3% ophthalmic ointment is available in Europe but not in the US.",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      , 400 mg five times daily, is equivalent to topical treatment and avoids corneal epithelial toxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/40\">",
"       40",
"      </a>",
"      ]. Acyclovir resistant HSV has been isolated from 6.4 percent of eyes with herpetic keratitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other oral antiviral drugs, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"       famciclovir",
"      </a>",
"      are thought to be effective for ocular infection, but they have not been studied in comparative trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The addition of topical interferons to antiviral therapy enhances the speed of healing, but these agents are not commercially available for this use. Interferon as monotherapy was not better than other antiviral agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Stromal keratitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A combination of topical corticosteroids and antivirals is the standard of care for necrotizing and non-necrotizing stromal keratitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/31\">",
"     31",
"    </a>",
"    ]. Topical glucocorticoids, although not advised in the treatment of HSV epithelial disease, have been shown to be effective in the immune forms of stromal keratitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/48\">",
"     48",
"    </a>",
"    ]. Topical or oral antiviral medications should always be added to topical glucocorticoid therapy to prevent reactivation of epithelial disease.",
"   </p>",
"   <p>",
"    In the Herpetic Eye Disease Study, patients with stromal keratitis were randomly assigned to treatment with topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17939?source=see_link\">",
"     trifluridine",
"    </a>",
"    1% plus placebo or to trifluridine plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    administered every two hours in a tapering 10-week course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/48\">",
"     48",
"    </a>",
"    ]. The duration of inflammation and risk of progression were significantly reduced in patients receiving prednisolone. The rate of epithelial HSV recurrence was not increased by the topical steroids. The addition of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    to topical glucocorticoids and topical antivirals provided no additional benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of other anti-inflammatory agents in stromal keratitis has not been well studied. Topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    0.05% showed some effectiveness in several small series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/50-53\">",
"     50-53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Endotheliitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endotheliitis with disciform corneal stromal edema responds well to topical glucocorticoids in conjunction with prophylactic antivirals in controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/48\">",
"     48",
"    </a>",
"    ]. Linear endotheliitis appears to be more responsive to oral antiviral agents than to topical glucocorticoids, but this has not been validated in controlled trials because of the infrequency of this variant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Keratouveitis (keratoiritis)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with stromal or epithelial keratitis, even when combined with iritis, should be treated for their keratitis as discussed above. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'HSV epithelial keratitis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H12\">",
"     'HSV stromal keratitis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUPPRESSION OF RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent ocular infections with HSV-1 are treated with the same topical agents used for primary infections. However, the most important issue in HSV ocular disease is to prevent recurrences, which lead to corneal scarring and visual impairment.",
"   </p>",
"   <p>",
"    Randomized trials indicate that recurrent infections can be prevented by daily suppressive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/15,54-56\">",
"     15,54-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a double-blind placebo-controlled trial, 703 patients with a history of herpes simplex virus (HSV) ocular disease within the preceding year were randomly assigned to either oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      (400 mg twice daily) or placebo for 12 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/54\">",
"       54",
"      </a>",
"      ]. Patients assigned to the acyclovir arm had lower rates of recurrence than patients in the placebo arm (19 versus 32 percent). The magnitude of benefit was greatest in those with more frequent previous recurrences [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/15\">",
"       15",
"      </a>",
"      ]. This effect did not persist after the drug was stopped.",
"     </li>",
"     <li>",
"      One small randomized study evaluated the efficacy of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      (one 500 mg tablet daily) compared with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      (one 400 mg tablet twice daily) in 52 immunocompetent patients who had a history of recurrent ocular HSV disease within the past 12 months; both suppressive regimens were found to be equivalent (23 percent of patients with recurrences in both groups) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Long-term",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    therapy is well tolerated but has not been fully studied for ocular HSV. Limiting suppressive treatment to those with more frequent episodes and the threat of vision loss may be a cost-effective approach to management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/57\">",
"     57",
"    </a>",
"    ]. Suppressive acyclovir has been successful and well tolerated in children and may be reasonable to prevent amblyopia from vision threatening keratitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vaccines for HSV have been studied in animal models, but they may increase the severity of immune stromal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SURGICAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corneal transplantation may be indicated when corneal scarring significantly limits vision. The success rate, while moderately high, is lower than for many other conditions because of a high rejection rate, related to corneal vascularization, and because of recurrence of herpes simplex virus (HSV) keratitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/60\">",
"     60",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     Acyclovir",
"    </a>",
"    prophylaxis improves corneal graft survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/61\">",
"     61",
"    </a>",
"    ]. Other oral antivirals may be effective but have not been studied for this indication.",
"   </p>",
"   <p>",
"    The use of artificial corneas, an evolving area in surgical treatment of corneal disease, may be contraindicated in HSV keratitis because of corneal melting in some trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A history of HSV keratitis is considered to be a relative contraindication to laser refractive surgery. The ultraviolet light used in excimer laser corneal refractive surgery has been associated with recurrent keratitis.",
"   </p>",
"   <p>",
"    Surgical treatment of the cornea may be necessary on an urgent basis to treat corneal perforation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33992/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Keratitis (corneal infection and inflammation) caused by herpes simplex virus (HSV) is a major cause of blindness from corneal scarring and opacity worldwide. Most ocular disease is thought to represent recurrent HSV disease rather than a primary ocular infection. Corneal disease results from active infection, inflammation, and immune reaction to past infection. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of HSV keratitis is largely clinical, with symptoms of pain, vision loss, and discharge. Physical examination is notable for chemosis, conjunctivitis, decreased corneal sensation, and characteristic dendritic lesions of the cornea (",
"      <a class=\"graphic graphic_picture graphicRef69708 \" href=\"mobipreview.htm?25/47/26353\">",
"       picture 1",
"      </a>",
"      ). Laboratory confirmation is rarely indicated, and serologic testing is not useful. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HSV keratitis has been classified in four categories: infectious epithelial keratitis, stromal keratitis, endotheliitis, and neurotrophic keratopathy. Epithelial disease is most common, manifested as dendritic lesions or geographic ulcerations of the cornea. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'HSV epithelial keratitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stromal keratitis accounts for 20 to 60 percent of recurrent corneal disease. Immune (non-necrotizing) keratitis usually presents as immune-mediated stromal inflammation without concurrent epithelial disease. Necrotizing stromal keratitis is due to active viral infection and may progress to corneal perforation. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'HSV stromal keratitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of HSV keratitis is dependent upon whether the episode of disease is caused by active viral replication or immune response to past infection. We recommend NOT using topical glucocorticoids when active HSV epithelial disease is present (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Medical treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients with epithelial HSV keratitis receive antiviral agents (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Oral and topical antivirals are equally effective, but oral agents are more convenient to use. Trifluorothymidine 1% (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17939?source=see_link\">",
"       trifluridine",
"      </a>",
"      ) is given one drop every two hours (eight or nine doses daily) for two weeks.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"       Ganciclovir",
"      </a>",
"      0.15% gel is given one drop five times daily until epithelial healing occurs and then three times daily for seven days. Oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      is given 400 mg five times daily. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Epithelial keratitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treatment of stromal keratitis with a combination of an oral antiviral agent and a topical glucocorticoid (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Stromal keratitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with recurrent episodes of significant keratitis receive ongoing suppressive oral antiviral therapy with either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Valacyclovir is given 500 mg once daily and acyclovir 400 mg two times a day. Suppressive therapy may not be cost-effective for patients with mild recurrent disease, and its effect does not persist when the drug is discontinued. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Suppression of recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who have significant vision impairment due to corneal scarring from keratitis may require corneal transplantation. Oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      improves corneal graft survival. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Surgical treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/1\">",
"      Liesegang TJ. Herpes simplex virus epidemiology and ocular importance. Cornea 2001; 20:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/2\">",
"      Benz MS, Glaser JS, Davis JL. Progressive outer retinal necrosis in immunocompetent patients treated initially for optic neuropathy with systemic corticosteroids. Am J Ophthalmol 2003; 135:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/3\">",
"      Cunningham AL, Diefenbach RJ, Miranda-Saksena M, et al. The cycle of human herpes simplex virus infection: virus transport and immune control. J Infect Dis 2006; 194 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/4\">",
"      Kaye SB, Baker K, Bonshek R, et al. Human herpesviruses in the cornea. Br J Ophthalmol 2000; 84:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/5\">",
"      Kennedy DP, Clement C, Arceneaux RL, et al. Ocular herpes simplex virus type 1: is the cornea a reservoir for viral latency or a fast pit stop? Cornea 2011; 30:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/6\">",
"      Kaufman HE, Azcuy AM, Varnell ED, et al. HSV-1 DNA in tears and saliva of normal adults. Invest Ophthalmol Vis Sci 2005; 46:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/7\">",
"      Kaye S, Choudhary A. Herpes simplex keratitis. Prog Retin Eye Res 2006; 25:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/8\">",
"      Predictors of recurrent herpes simplex virus keratitis. Herpetic Eye Disease Study Group. Cornea 2001; 20:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/9\">",
"      Pollara G, Speidel K, Samady L, et al. Herpes simplex virus infection of dendritic cells: balance among activation, inhibition, and immunity. J Infect Dis 2003; 187:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/10\">",
"      Knickelbein JE, Khanna KM, Yee MB, et al. Noncytotoxic lytic granule-mediated CD8+ T cell inhibition of HSV-1 reactivation from neuronal latency. Science 2008; 322:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/11\">",
"      Inoue Y. Immunological aspects of herpetic stromal keratitis. Semin Ophthalmol 2008; 23:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/12\">",
"      Liedtke W, Opalka B, Zimmermann CW, Lignitz E. Age distribution of latent herpes simplex virus 1 and varicella-zoster virus genome in human nervous tissue. J Neurol Sci 1993; 116:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/13\">",
"      Holland EJ, Mahanti RL, Belongia EA, et al. Ocular involvement in an outbreak of herpes gladiatorum. Am J Ophthalmol 1992; 114:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/14\">",
"      Souza PM, Holland EJ, Huang AJ. Bilateral herpetic keratoconjunctivitis. Ophthalmology 2003; 110:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/15\">",
"      Oral acyclovir for herpes simplex virus eye disease: effect on prevention of epithelial keratitis and stromal keratitis. Herpetic Eye Disease Study Group. Arch Ophthalmol 2000; 118:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/16\">",
"      Liesegang TJ. Epidemiology of ocular herpes simplex. Natural history in Rochester, Minn, 1950 through 1982. Arch Ophthalmol 1989; 107:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/17\">",
"      Young RC, Hodge DO, Liesegang TJ, Baratz KH. Incidence, recurrence, and outcomes of herpes simplex virus eye disease in Olmsted County, Minnesota, 1976-2007: the effect of oral antiviral prophylaxis. Arch Ophthalmol 2010; 128:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/18\">",
"      Labetoulle M, Auquier P, Conrad H, et al. Incidence of herpes simplex virus keratitis in France. Ophthalmology 2005; 112:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/19\">",
"      Liesegang TJ, Melton LJ 3rd, Daly PJ, Ilstrup DM. Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982. Arch Ophthalmol 1989; 107:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/20\">",
"      Shuster JJ, Kaufman HE, Nesburn AB. Statistical analysis of the rate of recurrence of herpesvirus ocular epithelial disease. Am J Ophthalmol 1981; 91:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/21\">",
"      Teng CC. Images in clinical medicine. Corneal dendritic ulcer from herpes simplex virus infection. N Engl J Med 2008; 359:e22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/22\">",
"      Kowalski RP, Gordon YJ, Romanowski EG, et al. A comparison of enzyme immunoassay and polymerase chain reaction with the clinical examination for diagnosing ocular herpetic disease. Ophthalmology 1993; 100:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/23\">",
"      Kowalski RP, Karenchak LM, Shah C, Gordon JS. ELVIS: a new 24-hour culture test for detecting herpes simplex virus from ocular samples. Arch Ophthalmol 2002; 120:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/24\">",
"      Satpathy G, Mishra AK, Tandon R, et al. Evaluation of tear samples for Herpes Simplex Virus 1 (HSV) detection in suspected cases of viral keratitis using PCR assay and conventional laboratory diagnostic tools. Br J Ophthalmol 2011; 95:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/25\">",
"      Bhat PV, Jakobiec FA, Kurbanyan K, et al. Chronic herpes simplex scleritis: characterization of 9 cases of an underrecognized clinical entity. Am J Ophthalmol 2009; 148:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/26\">",
"      Liesegang TJ. Classification of herpes simplex virus keratitis and anterior uveitis. Cornea 1999; 18:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/27\">",
"      Holland EJ, Schwartz GS. Classification of herpes simplex virus keratitis. Cornea 1999; 18:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/28\">",
"      Cook SD. Herpes simplex virus in the eye. Br J Ophthalmol 1992; 76:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/29\">",
"      Langston DP, Dunkel EC. A rapid clinical diagnostic test for herpes simplex infectious keratitis. Am J Ophthalmol 1989; 107:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/30\">",
"      Wilhelmus KR, Coster DJ, Donovan HC, et al. Prognosis indicators of herpetic keratitis. Analysis of a five-year observation period after corneal ulceration. Arch Ophthalmol 1981; 99:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/31\">",
"      Knickelbein JE, Hendricks RL, Charukamnoetkanok P. Management of herpes simplex virus stromal keratitis: an evidence-based review. Surv Ophthalmol 2009; 54:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/32\">",
"      Wishart MS, Darougar S, Viswalingam ND. Recurrent herpes simplex virus ocular infection: epidemiological and clinical features. Br J Ophthalmol 1987; 71:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/33\">",
"      Green LK, Pavan-Langston D. Herpes simplex ocular inflammatory disease. Int Ophthalmol Clin 2006; 46:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/34\">",
"      Streilein JW, Dana MR, Ksander BR. Immunity causing blindness: five different paths to herpes stromal keratitis. Immunol Today 1997; 18:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/35\">",
"      Suzuki T, Ohashi Y. Corneal endotheliitis. Semin Ophthalmol 2008; 23:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/36\">",
"      Williams HP, Falcon MG, Jones BR. Corticosteroids in the management of herpetic eye disease. Trans Ophthalmol Soc U K 1977; 97:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/37\">",
"      DAVIDSON SI, EVANS PJ. IDU AND THE TREATMENT OF HERPES SIMPLEX KERATITIS. Br J Ophthalmol 1964; 48:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/38\">",
"      Wilhelmus KR. Therapeutic interventions for herpes simplex virus epithelial keratitis. Cochrane Database Syst Rev 2008; :CD002898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/39\">",
"      A controlled trial of oral acyclovir for iridocyclitis caused by herpes simplex virus. The Herpetic Eye Disease Study Group. Arch Ophthalmol 1996; 114:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/40\">",
"      Collum LM, McGettrick P, Akhtar J, et al. Oral acyclovir (Zovirax) in herpes simplex dendritic corneal ulceration. Br J Ophthalmol 1986; 70:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/41\">",
"      Guess S, Stone DU, Chodosh J. Evidence-based treatment of herpes simplex virus keratitis: a systematic review. Ocul Surf 2007; 5:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/42\">",
"      A controlled trial of oral acyclovir for the prevention of stromal keratitis or iritis in patients with herpes simplex virus epithelial keratitis. The Epithelial Keratitis Trial. The Herpetic Eye Disease Study Group. Arch Ophthalmol 1997; 115:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/43\">",
"      Colin J, Hoh HB, Easty DL, et al. Ganciclovir ophthalmic gel (Virgan; 0.15%) in the treatment of herpes simplex keratitis. Cornea 1997; 16:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/44\">",
"      Kaufman, HE. Ganciclovir: a promising topical antiviral gel for herpetic keratitis. Expert Rev Ophthalmol 2009; 4:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/45\">",
"      Tabbara KF, Al Balushi N. Topical ganciclovir in the treatment of acute herpetic keratitis. Clin Ophthalmol 2010; 4:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/46\">",
"      Croxtall JD. Ganciclovir ophthalmic gel 0.15%: in acute herpetic keratitis (dendritic ulcers). Drugs 2011; 71:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/47\">",
"      Duan R, de Vries RD, Osterhaus AD, et al. Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. J Infect Dis 2008; 198:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/48\">",
"      Wilhelmus KR, Gee L, Hauck WW, et al. Herpetic Eye Disease Study. A controlled trial of topical corticosteroids for herpes simplex stromal keratitis. Ophthalmology 1994; 101:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/49\">",
"      Barron BA, Gee L, Hauck WW, et al. Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis. Ophthalmology 1994; 101:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/50\">",
"      Rao SN. Treatment of herpes simplex virus stromal keratitis unresponsive to topical prednisolone 1% with topical cyclosporine 0.05%. Am J Ophthalmol 2006; 141:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/51\">",
"      G&uuml;nd&uuml;z K, Ozdemir O. Topical cyclosporin as an adjunct to topical acyclovir treatment in herpetic stromal keratitis. Ophthalmic Res 1997; 29:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/52\">",
"      Heiligenhaus A, Steuhl KP. Treatment of HSV-1 stromal keratitis with topical cyclosporin A: a pilot study. Graefes Arch Clin Exp Ophthalmol 1999; 237:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/53\">",
"      Sheppard JD, Wertheimer ML, Scoper SV. Modalities to decrease stromal herpes simplex keratitis reactivation rates. Arch Ophthalmol 2009; 127:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/54\">",
"      Acyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic Eye Disease Study Group. N Engl J Med 1998; 339:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/55\">",
"      Uchoa UB, Rezende RA, Carrasco MA, et al. Long-term acyclovir use to prevent recurrent ocular herpes simplex virus infection. Arch Ophthalmol 2003; 121:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/56\">",
"      Miserocchi E, Modorati G, Galli L, Rama P. Efficacy of valacyclovir vs acyclovir for the prevention of recurrent herpes simplex virus eye disease: a pilot study. Am J Ophthalmol 2007; 144:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/57\">",
"      Lairson DR, Begley CE, Reynolds TF, Wilhelmus KR. Prevention of herpes simplex virus eye disease: a cost-effectiveness analysis. Arch Ophthalmol 2003; 121:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/58\">",
"      Chong EM, Wilhelmus KR, Matoba AY, et al. Herpes simplex virus keratitis in children. Am J Ophthalmol 2004; 138:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/59\">",
"      Toma HS, Murina AT, Areaux RG Jr, et al. Ocular HSV-1 latency, reactivation and recurrent disease. Semin Ophthalmol 2008; 23:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/60\">",
"      Halberstadt M, Machens M, Gahlenbek KA, et al. The outcome of corneal grafting in patients with stromal keratitis of herpetic and non-herpetic origin. Br J Ophthalmol 2002; 86:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/61\">",
"      Garcia DD, Farjo Q, Musch DC, Sugar A. Effect of prophylactic oral acyclovir after penetrating keratoplasty for herpes simplex keratitis. Cornea 2007; 26:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33992/abstract/62\">",
"      Hicks CR, Crawford GJ, Tan DT, et al. Outcomes of implantation of an artificial cornea, AlphaCor: effects of prior ocular herpes simplex infection. Cornea 2002; 21:685.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6896 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-F0948400E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_12_33992=[""].join("\n");
var outline_f33_12_33992=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Herpes simplex virology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mechanisms of HSV corneal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TYPES OF OCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HSV epithelial keratitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Dendritic keratitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Geographic ulcer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Marginal keratitis (limbitis)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      HSV stromal keratitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Immune stromal keratitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Necrotizing stromal keratitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Endotheliitis (disciform keratitis)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Neurotrophic keratopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      HSV keratouveitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Postinfectious epithelial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MEDICAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Epithelial keratitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Stromal keratitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Endotheliitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Keratouveitis (keratoiritis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUPPRESSION OF RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SURGICAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6896\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6896|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/47/26353\" title=\"picture 1\">",
"      Herpes simplex keratitis - Dendritic corneal ulceration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/5/10320\" title=\"picture 2\">",
"      Herpes simplex stromal keratitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/31/6640\" title=\"picture 3\">",
"      Corneal perferation in steroid-treated HSV keratitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/8/38021?source=related_link\">",
"      Epidemiology of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/12/17607?source=related_link\">",
"      Evaluation of the red eye",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/54/29544?source=related_link\">",
"      Pathogenesis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_12_33993="Vincristine (conventional): Pediatric drug information";
var content_f33_12_33993=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vincristine (conventional): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"    see \"Vincristine (conventional): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/7/42100?source=see_link\">",
"    see \"Vincristine (conventional): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F234194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vincasar PFS&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10518612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vincristine Sulfate Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Mitotic Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F16342255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosing and frequency may vary by protocol and/or treatment phase; refer to specific protocol. In pediatric patients, dosing may be based on either BSA (mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) or weight (mg/kg); use extra precaution to verify dosing parameters during calculations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Neuroblastoma (CE-CAdO regimen):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Newborns: 0.035 mg/kg/dose on day 1 every 21 days for 2 cycles (Rubie, 1998) or on days 1 and 5 for 2 cycles (Rubie, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Older neonates: 0.75 or 1.05 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1 and 5 every 21 days for 2 cycles (Rubie, 1998) or 0.05 mg/kg days 1 and 5 for 2 cycles (Rubie, 2001)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"      see \"Vincristine (conventional): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses may be capped at a maximum of 2 mg/dose. Dosing and frequency may vary by protocol and/or treatment phase; refer to specific protocol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents: In pediatric patients, dosing may be based on either BSA (mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) or weight (mg/kg); use extra precaution to verify dosing parameters during calculations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      General dosing:",
"     </b>",
"     Manufacturer&rsquo;s labeling: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &le;10 kg: 0.05 mg/",
"     <b>",
"      kg",
"     </b>",
"     /dose once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &gt;10 kg: 1.5-2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose; frequency may vary based on protocol; maximum dose: 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Acute lymphocytic leukemia (ALL):",
"     </b>",
"     I.V.: Children: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose; maximum dose: 2 mg; reported frequency variable; both regimens studied in children &le;10 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Bostrom, 2003:",
"     </i>",
"     Administer dose on the following days: Induction phase: Days 0, 7, 14, and 21; Consolidation phase: Days 0, 28, and 56; Delayed intensification phase: Days 0, 7, and 14; Maintenance phase: Days 0, 28, and 56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Avramis, 2003:",
"     </i>",
"     Administer dose on the following days: Induction phase: Days 0, 7, 14, and 21; Consolidation phase: Days 0, 28, and 56; Interim maintenance phases: Days 0 and 28; Delayed intensification phase: Days 0, 7, and 14; Maintenance phase: Every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Burkitt lymphoma and B-cell ALL:",
"     </b>",
"     I.V.: Children and Adolescents: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose; maximum dose: 2 mg; reported frequency variable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Bowman, 1996:",
"     </i>",
"     Administer dose on days 4 and 11 of initial phase cycle; initial phase is in combination with cyclophosphamide, doxorubicin, and CNS prophylaxis (alternates with secondary phase) for a total of 4 cycles of each phase",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Reiter, 1999:",
"     </i>",
"     Administer dose on day 1 of cycle AA in combination with dexamethasone, ifosfamide, methotrexate, cytarabine, etoposide, and CNS prophylaxis and of cycle BB in combination with dexamethasone, cyclophosphamide, methotrexate, doxorubicin, and CNS prophylaxis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Ewing Sarcoma:",
"     </b>",
"     Limited data available: I.V.: Children and Adolescents: Dose and frequency regimens variable:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Grier, 2003:",
"     </i>",
"     2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose on day 1 of a 21 day cycle, administer either every cycle or during odd-numbered cycles; maximum dose: 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Kolb, 2003:",
"     </i>",
"     0.67 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /",
"     <b>",
"      day",
"     </b>",
"     as a continuous I.V. infusion on days 1, 2, and 3; total dose for cycle: 2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /",
"     <b>",
"      cycle",
"     </b>",
"     (maximum dose/cycle: 2 mg) during cycles 1, 2, 3, and 6",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hodgkin lymphoma (BEACOPP regimen):",
"     </b>",
"     I.V.: Children and Adolescents: 2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose administered on day 7 of a 21 day treatment cycle; maximum dose: 2 mg (Kelly, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Neuroblastoma:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants weighing &lt;10 kg:  0.75 or 1.05 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 5 every 21 days for 2 cycles; some infants may only receive on day 1 (Rubie, 1998) or 0.035 mg/",
"     <b>",
"      kg",
"     </b>",
"     days 1 and 5 for 2 cycles (Rubie, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants weighing &ge;10 kg: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose on days 1 and 5 every 21 days for 2 cycles or 0.05 mg/kg days 1 and 5 for 2 cycles; maximum dose: 2 mg  (CE-CAdO regimen) (Rubie, 1998; Rubie, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     CE-CAdO regimen: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 5 every 21 days for 2 cycles; maximum dose: 2 mg (Rubie, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     CAV-P/VP regimen: 0.033 mg/",
"     <b>",
"      kg/day",
"     </b>",
"     as a continuous infusion days 1, 2, and 3 (total dose: 0.1 mg/",
"     <b>",
"      kg",
"     </b>",
"     ), then 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     bolus day 9 of courses 1, 2, 4, and 6; maximum dose: 2 mg/dose (Kushner, 1994)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Retinoblastoma:",
"     </b>",
"     Limited data available: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants and Children &le;36 months: 0.05 mg/",
"     <b>",
"      kg",
"     </b>",
"     /dose; maximum dose: 2 mg; reported frequency variable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Rodriguez-Galindo, 2003:",
"     </i>",
"     Administer dose on day 1 every 21 days in combination with carboplatin for 8 cycles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Freidman, 2000:",
"     </i>",
"     Administer dose day 0 every 28 days in combination with carboplatin and etoposide for 6 cycles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &gt;36 months: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 0 every 28 days in combination with carboplatin and etoposide for 6 cycles; maximum dose: 2 mg  (Friedman, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Rhabdomyosarcoma:",
"     </b>",
"     Infants, Children, and Adolescents (Crist, 2001):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     VA regimen:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants: Initial: 0.75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose as a single dose during week 1; if tolerated, may increase to dose to 1.13 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose as a single dose for week 2 and further increase to 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose weekly for weeks 3-8, weeks 13-20, and weeks 25-32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children and Adolescents: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose weekly  (maximum dose: 2 mg/dose) for weeks 1-8, weeks 13-20, and weeks 25-32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     VAC regimen:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants: 0.75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose weekly for weeks 0-12, week 16, and weeks 20-25; continuation therapy: Weeks 29-34 and weeks 38-43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children and Adolescents: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose  weekly (maximum dose: 2 mg/dose) for weeks 0-12, week 16, and weeks 20-25; continuation therapy: weeks 29-34 and weeks 38-43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Wilm's tumor:",
"     </b>",
"     Dose and frequency regimens variable; regimens studies in infants, children, and adolescents",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Pritchard, 1995:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants: 0.75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose weekly for 10-11 weeks then every 3 weeks for 15 additional weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children and Adolescents: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose weekly for 10-11 weeks then every 3 weeks for 15 additional weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Green, 2007:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Infants and Children &le;30 kg: 0.05 mg/",
"     <b>",
"      kg",
"     </b>",
"     /dose (maximum dose: 2 mg) weeks 1, 2, 4, 5, 6, 7, 8, 10, and 11, followed by 0.067 mg/",
"     <b>",
"      kg",
"     </b>",
"     /dose (maximum dose: 2 mg) weeks 12, 13, 18, and 24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children and Adolescents &gt;30 kg: 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (maximum dose: 2 mg) weeks 1, 2, 4, 5, 6, 7, 8, 10, and 11, followed by 2 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (maximum dose: 2 mg) weeks 12, 13, 18, and 24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      General dosing:",
"     </b>",
"     Manufacturer's labeling: 1.4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose; frequency may vary based on protocol; maximum dose: 2 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      ALL:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hyper-CVAD regimen: 2 mg/dose days 4 and 11 during odd-numbered cycles (cycles 1, 3, 5, 7) of an 8-cycle phase, followed by maintenance treatment (if needed) of 2 mg monthly for 2 years (Kantarjian, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Larson (CALBG 8811) regimen: Induction phase: 2 mg/dose days 1, 8, 15, and 22 (4-week treatment cycle); Early intensification phase: 2 mg/dose days 15 and 22 (4-week treatment cycle, repeat once); Late intensification phase: 2 mg/dose days 1, 8, 15 (8-week treatment cycle); Maintenance phase: 2 mg/dose day 1 every 4 weeks until 24 months from diagnosis (Larson, 1995)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Central nervous system tumors:",
"     </b>",
"     I.V.: PCV regimen: 1.4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (maximum dose: 2 mg) on days 8 and 29 of a 6-week treatment cycle for a total of 6 cycles (van de Bent, 2006)",
"     <b>",
"      or",
"     </b>",
"     1.4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (no maximum dose) on days 8 and 29 of a 6-week treatment cycle for up to 4 cycles (Cairncross, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hodgkin lymphoma:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     BEACOPP regimen: 1.4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (maximum dose: 2 mg) on day 8 of a 21-day treatment cycle (Diehl, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Stanford V regimen: 1.4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (maximum dose: 2 mg) in weeks 2, 4, 6, 8, 10, and 12 (Horning, 2000; Horning, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Non-Hodgkin lymphoma:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Burkitt lymphoma:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     CODOX-M/IVAC: Cycles 1 and 3 (CODOX-M): 1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (no maximum dose) days 1 and 8 of cycle 1 and days 1, 8, and 15 of cycle 3 (Magrath, 1996)",
"     <b>",
"      or",
"     </b>",
"     1.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (maximum dose: 2 mg) days 1 and 8 of cycles 1 and 3 (Mead, 2002; Mead, 2008); CODOX-M is in combination with cyclophosphamide, doxorubicin, methotrexate, and CNS prophylaxis and alternates with IVAC (etoposide, ifosfamide, and cytarabine) for a total of 4 cycles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Hyper-CVAD: 2 mg (flat dose) days 4 and 11 of courses 1, 3, 5, and 7 (in combination with cyclophosphamide, doxorubicin, and dexamethasone) and alternates with even courses 2, 4, 6, and 8 (methotrexate and cytarabine) (Thomas, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Follicular lymphoma:",
"     </i>",
"     CVP regimen: 1.4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (maximum dose: 2 mg) on day 1 of a 21-day treatment cycle for 8 cycles (Marcus, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Large B-cell lymphoma:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     CHOP regimen: 1.4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (maximum dose: 2 mg) on day 1 of a 21-day treatment cycle for 8 cycles (Coiffier, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     EPOCH regimen: 0.4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day continuous infusion for 4 days (over 96 hours) (total 1.6 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /cycle; dose not usually capped) of a 21-day treatment cycle (Wilson, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment for renal impairment:",
"     </b>",
"     Adults: No dosage adjustment necessary (Kintzel, 1995)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment for hepatic impairment:",
"     </b>",
"     All patients: The manufacturer's labeling recommends the following adjustment: Serum bilirubin &gt;3 mg/dL: Administer 50% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     The following adjustments have also been recommended:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Floyd, 2006:",
"     </i>",
"     Serum bilirubin 1.5-3 mg/dL or transaminases 2-3 times ULN or alkaline phosphatase increased: Administer 50% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Superfin, 2007:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Serum bilirubin 1.5-3 mg/dL: Administer 50% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Serum bilirubin &gt;3 mg/dL: Avoid use.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F234173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate [preservative free]: 1 mg/mL (1 mL, 2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vincasar PFS&reg;: 1 mg/mL (1 mL, 2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F234158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"     <b>",
"      Note: For I.V. administration only; fatal if given intrathecally;",
"     </b>",
"     vincristine should",
"     <b>",
"      <span style=\"text-decoration: underline\">",
"       NOT",
"      </span>",
"     </b>",
"     be delivered to the patient with any medications intended for central nervous system administration.",
"     <b>",
"      Note:",
"     </b>",
"     In order to prevent inadvertent intrathecal administration, the World Health Organization (WHO) and the Institute for Safe Medical Practices (ISMP) recommend dispensing vincristine in a minibag (rather than a syringe). Vincristine should",
"     <b>",
"      <span style=\"text-decoration: underline\">",
"       NOT",
"      </span>",
"     </b>",
"     be prepared during the preparation of any intrathecal medication. After preparation, keep vincristine in a location away from the separate storage location recommended for intrathecal medications. If dispensing vincristine in a syringe, affix an auxiliary label stating",
"     <b>",
"      \"For intravenous use only - fatal if given by other routes\"",
"     </b>",
"     to the syringe and the syringe must be packaged in the manufacturer-provided overwrap which bears the statement",
"     <b>",
"      \"Do not remove covering until the moment of injection. For intravenous use only. Fatal if given intrathecally.\"",
"     </b>",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Parenteral: For I.V. use only; avoid extravasation; may further dilute in NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W and administer as a short 5-10 minute infusion (preferred); may also be administered undiluted (1 mg/mL) slow I.V. push (over 1 minute) or as a 24-hour continuous I.V. infusion (depending on protocol)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Vincristine is a vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do",
"     <b>",
"      NOT",
"     </b>",
"     flush the line); initiate hyaluronidase antidote; apply dry warm compresses for 20 minutes 4 times a day for 1-2 days; elevate extremity. Hyaluronidase: If needle/cannula still in place, administer 1-6 mL hyaluronidase (150 units/mL) into the existing I.V. line; the usual dose is 1 mL hyaluronidase for each 1 mL of extravasated drug (Perez Fidalgo, 2012; Schulmeister, 2011). If needle/cannula has been removed, inject 1-6 mL (150 units/mL) subcutaneously in a clockwise manner using 1 mL for 1 mL of drug extravasated (Schulmeister, 2011)",
"     <b>",
"      or",
"     </b>",
"     administer 1 mL  (150 units/mL) as 5 separate 0.2 mL injections (25-gauge needle) subcutaneously into the extravasation site (Polovich, 2009). Remaining portion of the vincristine dose should be infused through a separate vein.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Do not administer to patients while they are receiving radiation therapy through ports that include the liver. If used in combination with L-asparaginase, administer vincristine 12-24 hours before L-asparaginase to minimize toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F234250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, amphotericin B cholesteryl sulfate complex, anidulafungin, aztreonam, bleomycin, caspofungin, cisplatin, cladribine, cyclophosphamide, doxorubicin HCl, doxorubicin liposome, droperidol, etoposide phosphate, filgrastim, fludarabine, fluorouracil, gemcitabine, granisetron, heparin, leucovorin calcium, linezolid, melphalan, methotrexate, metoclopramide, mitomycin, ondansetron, oxaliplatin, paclitaxel, pemetrexed, piperacillin/tazobactam, sargramostim, teniposide, thiotepa, topotecan, vinblastine, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Cefepime, furosemide, idarubicin, sodium bicarbonate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Bleomycin, cisplatin, cyclophosphamide, doxapram, doxorubicin, droperidol, fluorouracil, heparin, leucovorin calcium, methotrexate, metoclopramide, mitomycin, vincristine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Furosemide.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1050605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal (NIOSH, 2012).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); protect from light; store vials upright. Solution further diluted in 25-50 mL of NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W (minibag) are stable for 7 days under refrigeration or 2 days at room temperature; in ambulatory infusion devices, solution is stable for 7 days at room temperature.",
"     <b>",
"      Note:",
"     </b>",
"     In order to prevent inadvertent intrathecal administration, the World Health Organization (WHO) and the Institute for Safe Medical Practices (ISMP) recommend dispensing vincristine in a minibag (rather than a syringe). Vincristine should",
"     <b>",
"      NOT",
"     </b>",
"     be prepared during the preparation of any intrathecal medication. After preparation, keep vincristine in a location away from the separate storage location recommended for intrathecal medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     If dispensing vincristine in a syringe, affix an auxiliary label stating \"For intravenous use only - fatal if given by other routes\" to the syringe and the syringe must be packaged in the manufacturer-provided overwrap which bears the statement",
"     <b>",
"      \"Do not remove covering until the moment of injection. For intravenous use only. Fatal if given intrathecally.\"",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, neuroblastoma, non-Hodgkin lymphomas, Wilms' tumor, and rhabdomyosarcoma [FDA approved in pediatrics (age not specified) and adults]; has also been used in the treatment of central nervous system tumors, chronic lymphocytic leukemia (CLL), Ewing's sarcoma, gestational trophoblastic tumors (high-risk), multiple myeloma, retinoblastoma, and small cell lung cancer",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F234253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       VinCRIStine may be confused with vinBLAStine, vinorelbine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       VinCRIStine conventional may be confused with vinCRIStine liposomal",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Oncovin may be confused with Ancobon&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       For I.V. use only. Fatal if administered by other routes. To prevent fatal inadvertent intrathecal injection, it is recommended that vincristine doses be dispensed in a small minibag. Vincristine should",
"       <b>",
"        NOT",
"       </b>",
"       be prepared during the preparation of any intrathecal medications. After preparation, keep vincristine in a location",
"       <b>",
"        away",
"       </b>",
"       from the separate storage location recommended for intrathecal medications. Vincristine should",
"       <b>",
"        NOT",
"       </b>",
"       be delivered to the patient at the same time with any medications intended for central nervous system administration.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F234249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema, hyper-/hypotension, MI, myocardial ischemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, coma, cranial nerve dysfunction (auditory damage, extraocular muscle impairment, laryngeal muscle impairment, paralysis, paresis, vestibular damage, vocal cord paralysis), dizziness, fever, headache, neurotoxicity (dose-related), neuropathic pain (common), seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic toxicity: Alopecia (common), rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperuricemia, parotid pain, SIADH (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, abdominal pain, anorexia, constipation (common), diarrhea, intestinal necrosis, intestinal perforation, nausea, oral ulcers, paralytic ileus, vomiting, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Bladder atony, dysuria, polyuria, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia (mild), leukopenia (mild), thrombocytopenia (mild), thrombotic thrombocytopenic purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatic sinusoidal obstruction syndrome (SOS; veno-occlusive liver disease)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Phlebitis, tissue irritation/necrosis (if infiltrated)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, bone pain, deep tendon reflex loss, difficulty walking, foot drop, gait changes, jaw pain, limb pain, motor difficulties, muscle wasting, myalgia, paralysis, paresthesia, peripheral neuropathy (common), sensorimotor dysfunction, sensory loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Cortical blindness (transient), nystagmus, optic atrophy with blindness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Deafness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute uric acid nephropathy, hemolytic uremic syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, dyspnea, pharyngeal pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions (rare), anaphylaxis (rare), hypersensitivity (rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to vincristine or any component; patients with demyelinating form of Charcot-Marie-Tooth syndrome",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1050601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should only be prescribed and administered by individuals experienced in the use of chemotherapeutic agents",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Use with caution in patients with impaired hepatic function or hepatobiliary dysfunction; may be associated with hepatic sinusoidal obstruction syndrome (SOS; formerly called veno-occlusive disease [VOD]), increased risk in children &lt;3 years of age; monitor for signs or symptoms of hepatic SOS, including bilirubin &gt;1.4 mg/dL, unexplained weight gain, ascites, hepatomegaly, or unexplained right upper quadrant pain (Arndt, 2004).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with pre-existing neuromuscular disease and/or with concomitant neurotoxic agents; may cause neurotoxicity; typically follows a sequence with initial paresthesia and sensory impairment reported followed by neuritic pain and finally motor impairment; alterations in mental status such as depression, confusion, or insomnia may also occur; neurologic effects are dose-dependent and dose-limiting; effects may be additive with spinal cord irradiation; dosage adjustment may be required. Acute uric acid nephropathy has been reported after vincristine administration; monitor serum uric acid during induction. Acute shortness of breath and bronchospasm have been reported following administration of a vinca alkaloids usually in combination with mitomycin-C; onset may be several minutes to hours after vincristine administration and up to 2 weeks after mitomycin-C; progressive dyspnea requiring treatment may develop; permanently discontinue vincristine if pulmonary dysfunction occurs.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause constipation, paralytic ileus, intestinal necrosis, and/or perforation; constipation may present as upper colon impaction with an empty rectum (may require flat film of abdomen for diagnosis); generally responds to high enemas and laxatives; patients should be on a prophylactic bowel management regimen. May cause SIADH (rarely); reported more frequently in Asian patients although the exact mechanism has not been determined (Moore, 2009).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1050600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     ; avoid eye contamination.",
"     <b>",
"      For I.V. administration only; intrathecal administration usually results in death [U.S. Boxed Warning]",
"     </b>",
"     . To prevent administration errors, the World Health Organization recommends dispensing vincristine diluted in a minibag (WHO, 2007);",
"     <b>",
"      if not dispensed in a minibag, affix an auxiliary label stating \"For intravenous use only - fatal if given by other routes\" and also place in an overwrap labeled \"Do not remove covering until moment of injection.\"",
"     </b>",
"     Vincristine should",
"     <b>",
"      NOT",
"     </b>",
"     be prepared during the preparation of any intrathecal medications. After preparation, keep vincristine in a location",
"     <b>",
"      away",
"     </b>",
"     from the separate storage location recommended for intrathecal medications. Vincristine should",
"     <b>",
"      NOT",
"     </b>",
"     be delivered to the patient at the same time with any medications intended for central nervous system administration.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Vincristine is a vesicant; avoid extravasation. Ensure proper catheter or needle position prior to (and during) infusion, individuals administering should be experienced in vincristine administration; discontinue administration immediately if extravasation occurs and initiate appropriate extravasation management, including local injection of hyaluronidase and moderate heat application to the affected area. Use a separate vein to complete administration",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F234239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F234167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of VinCRIStine. VinCRIStine may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May enhance the adverse/toxic effect of VinCRIStine. Itraconazole may increase the serum concentration of VinCRIStine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May increase the serum concentration of VinCRIStine. Management: Monitor closely for signs and symptoms of vincristine toxicity; consider temporary interruption of lopinavir/ritonavir antiviral therapy if patients develop significant toxicity with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Macrolides may also increase the distribution of Vinca Alkaloids into certain cells and/or tissues. Management: Consider an alternative to using a macrolide antibiotic when possible in order to avoid the potential for increased vinca alkaloid toxicity.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MitoMYcin (Systemic): Antineoplastic Agents (Vinca Alkaloids) may enhance the adverse/toxic effect of MitoMYcin (Systemic). Specifically, the risk of pulmonary toxicity may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NIFEdipine: May increase the serum concentration of VinCRIStine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of VinCRIStine. VinCRIStine may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Posaconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Management: Consider vinca alkaloid dose adjustment.  Specific dose adjustment guidelines are not currently available.  Monitor response to vinca alkaloid therapy, including development of vinca alkaloid toxicities (e.g., gastrointestinal toxicity, neurotoxicity).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase the serum concentration of VinCRIStine. Management: Monitor closely for signs and symptoms of vincristine toxicity; consider temporary interruption of ritonavir antiviral therapy if patients develop significant toxicity with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teniposide: May enhance the neurotoxic effect of VinCRIStine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Voriconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F234169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10517724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have demonstrated teratogenicity and fetal loss. May cause fetal harm if administered during pregnancy. Women of childbearing potential should avoid becoming pregnant during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1050609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum electrolytes (sodium), hepatic function tests, neurologic examination, CBC with differential, serum uric acid, monitor infusion site, monitor for constipation/ileus and for signs/symptoms of peripheral neuropathy",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to tubulin and inhibits microtubule formation, therefore, arresting the cell at metaphase by disrupting the formation of the mitotic spindle; it is specific for the M and S phases. Vincristine may also interfere with nucleic acid and protein synthesis by blocking glutamic acid utilization.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1050616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     In pediatric patients, significant intrapatient and interpatient variability has been reported (Gidding, 1999).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Rapidly removed from bloodstream and tightly bound to tissues; poor penetration into the CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive in the liver via CYP3A",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, terminal: 85 hours (range: 19-155 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily in feces (~80%); urine (10% to 20%; &lt;1% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: In pediatric patients, correlation with diagnosis has been reported; clearance in patients with ALL and non-Hodgkin lymphoma  higher than Wilms&rsquo; tumor (Gidding, 1999):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants: Vincristine clearance is lower compared to children; more closely related to body weight than to body surface area (Crom, 1994)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children and Adolescents 2-18 years: Reported means: 357-482 mL/minute/m",
"     <sup>",
"      2",
"     </sup>",
"     ; some suggest faster clearance in children &lt;10 years of age than in adolescents (Crom, 1994); however, more recent data does not support this finding nor a dosage reduction in adolescent patients (Frost, 2003; Gidding, 1999)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1050607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/7/42100?source=see_link\">",
"      see \"Vincristine (conventional): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     This medication can only be administered by infusion; report immediately any redness, swelling, burning, or pain at infusion site. Maintain adequate nutrition and hydration, unless instructed to restrict fluid intake. Susceptibility to infection is increased. May cause postural hypotension, hair loss (will grow back after therapy), nausea or vomiting (request antiemetic if persistent), photosensitivity, feelings of extreme weakness or lethargy, or mouth sores. Report persistent gastrointestinal changes (eg, constipation, abdominal cramps, bloating); numbness, tingling, or pain in legs, fingers, or toes; signs of infection (eg, fever, chills, sore throat, burning urination, fatigue); unusual bleeding (eg, tarry stools, easy bruising, blood in stool, urine, or mouth); unresolved mouth sores; skin rash or itching; or respiratory difficulty.  Stool softener and laxatives should be used for constipation prophylaxis. Women of childbearing potential should avoid becoming pregnant.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F2998179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Ten times the usual recommended dose of vincristine in children &lt;13 years of age has been lethal; doses of 3-4 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     can be expected to produce severe toxic manifestations. Treatment is supportive and symptomatic, including anticonvulsants, fluid restriction, and diuretics to prevent adverse effects from SIADH and enemas or cathartics to prevent ileus. Use of leucovorin calcium may be helpful in treating vincristine overdose. Leucovorin calcium 100 mg I.V. every 3 hours for 24 hours, then every 6 hours for at least 48 hours has been administered in case reports.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Arndt C, Hawkins D, Anderson JR, et al, \"Age Is a Risk Factor for Chemotherapy-Induced Hepatopathy With Vincristine, Dactinomycin, and Cyclophosphamide,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(10):1894-901.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/15143082/pubmed\" id=\"15143082\" target=\"_blank\">",
"        15143082",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians, 2007, 120, 174.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Avramis VI, Sencer S, Periclou AP, et, al, \"A Randomized Comparison of Native Escherichia Coli Asparaginase and Polyethylene Glycol Conjugated Asparaginase for Treatment of Children With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia: A Children's Cancer Group Study,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2002, 99(6):1986-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/11877270/pubmed\" id=\"11877270\" target=\"_blank\">",
"        11877270",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bostrom BC, Sensel MR, Sather HN, et al, \"Dexamethasone Versus Prednisone and Daily Oral Versus Weekly Intravenous Mercaptopurine for Patients With Standard-Risk Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2003, 101(10):3809-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/12531809/pubmed\" id=\"12531809\" target=\"_blank\">",
"        12531809",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bowman WP, Shuster JJ, Cook B, et al, &ldquo;Improved Survival for Children With B-Cell Acute Lymphoblastic Leukemia and Stage IV Small Noncleaved-Cell Lymphoma: A Pediatric Oncology Group Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14(4):1252-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/8648381/pubmed\" id=\"8648381\" target=\"_blank\">",
"        8648381",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cairncross G, Berkey B, Shaw E, et al, \"Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(18):2707-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/16782910/pubmed\" id=\"16782910\" target=\"_blank\">",
"        16782910",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Crist WM, Anderson JR, Meza JL, et al, \"Intergroup Rhabdomyosarcoma Study-IV: Results for Patients With Nonmetastatic Disease,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(12):3091-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/11408506/pubmed\" id=\"11408506\" target=\"_blank\">",
"        11408506",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Crom WR, deGraaf SS, Synold T, et al, &ldquo;Pharmacokinetics of Vincristine in Children and Adolescents With Acute Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1994, 125(4):642-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/7931891/pubmed\" id=\"7931891\" target=\"_blank\">",
"        7931891",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Diehl V, Franklin J, Pfreundschuh M, et al, \"Standard and Increased-Dose BEACOPP Chemotherapy Compared With COPP-ABVD for Advanced Hodgkin's Disease,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(24):2386-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/12802024/pubmed\" id=\"12802024\" target=\"_blank\">",
"        12802024",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd JD, Nguyen DT, Lobins RL, et al, \"Cardiotoxicity of Cancer Therapy,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      . 2005, 23(30):7685-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/16234530/pubmed\" id=\"16234530\" target=\"_blank\">",
"        16234530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd J, Mirza I, Sachs B, et al, \"Hepatotoxicity of Chemotherapy,\"",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2006, 33(1):50-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/16473644/pubmed\" id=\"16473644\" target=\"_blank\">",
"        16473644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Friedman DL, Himelstein B, Shields CL, et al, \"Chemoreduction and Local Ophthalmic Therapy for Intraocular Retinoblastoma,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2000, 18(1):12-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/10623688/pubmed\" id=\"10623688\" target=\"_blank\">",
"        10623688",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frost BM, L&ouml;nnerholm G, Koopmans P, et al, \"Vincristine in Childhood Leukaemia: No Pharmacokinetic Rationale for Dose Reduction in Adolescents,\"",
"      <i>",
"       Acta Paediatr",
"      </i>",
"      , 2003, 92(5):551-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/12839283/pubmed\" id=\"12839283\" target=\"_blank\">",
"        12839283",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Granowetter L, Womer R, Devidas M, et al, \"Dose-Intensified Compared With Standard Chemotherapy for Nonmetastatic Ewing Sarcoma Family of Tumors: A Children's Oncology Group Study,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(15):2536-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/19349548/pubmed\" id=\"19349548\" target=\"_blank\">",
"        19349548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Green DM, Cotton CA, Malogolowkin M, et al, \"Treatment of Wilms Tumor Relapsing After Initial Treatment With Vincristine and Actinomycin D: A Report From the National Wilms Tumor Study Group,\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2007, 48(5):493-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/16547940/pubmed\" id=\"16547940\" target=\"_blank\">",
"        16547940",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grier HE, Krailo MD, Tarbell NJ, et al, \"Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of Bone,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(8):694-701.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/12594313/pubmed\" id=\"12594313\" target=\"_blank\">",
"        12594313",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Horning SJ, Hoppe RT, Breslin S, et al, \"Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkin's Disease: Mature Results of a Prospective Clinical Trial,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(3):630-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/11821442/pubmed\" id=\"11821442\" target=\"_blank\">",
"        11821442",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Horning SJ, Williams J, Bartlett NL, et al, \"Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkin's Disease: Eastern Cooperative Oncology Group Pilot Study E1492,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2000, 18(5):972-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/10694546/pubmed\" id=\"10694546\" target=\"_blank\">",
"        10694546",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobson JO, Polovich M, McNiff KK, et al, \"American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(32):5469-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/19786650/pubmed\" id=\"19786650\" target=\"_blank\">",
"        19786650",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kantarjian H, Thomas D, O'Brien S, et al, \"Long-Term Follow-Up Results of Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone (Hyper-CVAD), A Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia,\"",
"      <i>",
"       Cancer",
"      </i>",
"      , 2004, 101(12):2788-801.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/15481055/pubmed\" id=\"15481055\" target=\"_blank\">",
"        15481055",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kelly KM, Hutchinson RJ, Sposto R, et al, \"Feasibility of Upfront Dose-Intensive Chemotherapy in Children With Advanced-Stage Hodgkin's Lymphoma: Preliminary Results From the Children's Cancer Group Study CCG-59704,\"",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2002, 13(Suppl 1):107-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/12078889/pubmed\" id=\"12078889\" target=\"_blank\">",
"        12078889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kintzel PE and Dorr RT, &ldquo;Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,&rdquo;",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 1995, 21(1):33-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/7859226/pubmed\" id=\"7859226\" target=\"_blank\">",
"        7859226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kolb EA, Kushner BH, Gorlick R, et al, \"Long-Term Event-Free Survival After Intensive Chemotherapy for Ewing's Family of Tumors in Children and Young Adults,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(18):3423-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/12972518/pubmed\" id=\"12972518\" target=\"_blank\">",
"        12972518",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kushner BH, LaQuaglia MP, Bonilla MA, et al, &ldquo;Highly Effective Induction Therapy for Stage 4 Neuroblastoma in Children Over 1 Year of Age,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1994, 12(12):2607-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/7527454 /pubmed\" id=\"7527454 \" target=\"_blank\">",
"        7527454",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larson RA, Dodge RK, Burns CP, et al, \"A Five-Drug Remission Induction Regimen With Intensive Consolidation for Adults With Acute Lymphoblastic Leukemia: Cancer and Leukemia Group B Study 8811,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 1995, 85(8):2025-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/7718875/pubmed\" id=\"7718875\" target=\"_blank\">",
"        7718875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Legha SS, \"Vincristine Neurotoxicity. Pathophysiology and Management,\"",
"      <i>",
"       Med Toxicol",
"      </i>",
"      , 1986, 1(6):421-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/3540519/pubmed\" id=\"3540519\" target=\"_blank\">",
"        3540519",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Magrath I, Adde M, Shad A, et al, &ldquo;Adults and Children With Small Non-Cleaved-Cell Lymphoma Have a Similar Excellent Outcome When Treated With the Same Chemotherapy Regimen,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14(3):925-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/8622041 /pubmed\" id=\"8622041 \" target=\"_blank\">",
"        8622041",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCune JS and Lindley C, \"Appropriateness of Maximum-Dose Guidelines for Vincristine,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1997, 54(15):1755-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/9262750/pubmed\" id=\"9262750\" target=\"_blank\">",
"        9262750",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mead GM, Barrans SL, Qian W, et al, \"A Prospective Clinicopathologic Study of Dose-Modified CODOX-M/IVAC in Patients With Sporadic Burkitt Lymphoma Defined Using Cytogenetic and Immunophenotypic Criteria (MRC/NCRI LY10 Trial),\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 112(6):2248-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/18612102/pubmed\" id=\"18612102\" target=\"_blank\">",
"        18612102",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mead GM, Sydes MR, Walewski J, et al, \"An International Evaluation of CODOX-M and CODOX-M Alternating With IVAC in Adult Burkitt's Lymphoma: Results of United Kingdom Lymphoma Group LY06 Study,\"",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2002, 13(8):1264-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/12181251/pubmed\" id=\"12181251\" target=\"_blank\">",
"        12181251",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moore A and Pinkerton R, \"Vincristine: Can Its Therapeutic Index Be Enhanced?\"",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2009, 53(7):1180-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/19588521/pubmed\" id=\"19588521\" target=\"_blank\">",
"        19588521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan C, Tillett T, Braybrooke J, et al, \"Management of Uncommon Chemotherapy-Induced Emergencies,\"",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2011, 12(8):806-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/21276754/pubmed\" id=\"21276754\" target=\"_blank\">",
"        21276754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, et al, &ldquo;Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2012, 23(Suppl 7):167-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/22997449/pubmed\" id=\"22997449\" target=\"_blank\">",
"        22997449",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Polovich M, Whitford JN, and Olsen M,",
"      <i>",
"       Chemotherapy and Biotherapy Guidelines and Recommendations for Practice",
"      </i>",
"      , 3rd ed, Pittsburgh, PA: Oncology Nursing Society, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pritchard J, Imeson J, Barnes J, et al, \"Results of the United Kingdom Children's Cancer Study Group First Wilms' Tumor Study,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1995, 13(1):124-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/7799012/pubmed\" id=\"7799012\" target=\"_blank\">",
"        7799012",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reiter A, Schrappe M, Tiemann M, et al, &ldquo;Improved Treatment Results in Childhood B-Cell Neoplasms With Tailored Intensification of Therapy: A Report of the Berlin-Frankfurt-M&uuml;nster Group Trial NHL-BFM 90,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1999, 94(10):3294-306.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/10552938/pubmed\" id=\"10552938\" target=\"_blank\">",
"        10552938",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodriguez-Galindo C, Wilson MW, Haik BG, et al, \"Treatment of Intraocular Retinoblastoma With Vincristine and Carboplatin,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(10):2019-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/12743157/pubmed\" id=\"12743157\" target=\"_blank\">",
"        12743157",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubie H, Michon J, Plantaz D, et al, &ldquo;Unresectable Localized Neuroblastoma: Improved Survival After Primary Chemotherapy Including Carboplatin-Etoposide. Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique (SFOP),&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 1998, 77(12):2310-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/9649151 /pubmed\" id=\"9649151 \" target=\"_blank\">",
"        9649151",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubie H, Plantaz D, Coze C, et al, \"Localised and Unresectable Neuroblastoma in Infants: Excellent Outcome With Primary Chemotherapy. Neuroblastoma Study Group, Soci&eacute;t&eacute; Fran&ccedil;aise d'Oncologie P&eacute;diatrique,\"",
"      <i>",
"       Med Pediatr Oncol",
"      </i>",
"      , 2001, 36(1):247-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/11464897/pubmed\" id=\"11464897\" target=\"_blank\">",
"        11464897",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schulmeister L, \"Extravasation Management: Clinical Update,\"",
"      <i>",
"       Semin Oncol Nurs",
"      </i>",
"      , 2011, 27(1):82-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/21255716/pubmed\" id=\"21255716\" target=\"_blank\">",
"        21255716",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shields CL, Honavar SG, Meadows AT, et al, \"Chemoreduction for Unilateral Retinoblastoma,\"",
"      <i>",
"       Arch Ophthalmol",
"      </i>",
"      , 2002, 120(12):1653-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/12470138/pubmed\" id=\"12470138\" target=\"_blank\">",
"        12470138",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stefanou A and Dooley M, \"Simple Method to Eliminate the Risk of Inadvertent Intrathecal Vincristine Administration,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(10):2044.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/12743160/pubmed\" id=\"12743160\" target=\"_blank\">",
"        12743160",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Superfin D, Iannucci AA, and Davies AM, \"Commentary: Oncologic Drugs in Patients With Organ Dysfunction: A Summary,\"",
"      <i>",
"       Oncologist",
"      </i>",
"      , 2007, 12(9):1070-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/17914077/pubmed\" id=\"17914077\" target=\"_blank\">",
"        17914077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thomas DA, Faderi S, O&rsquo;Brien S, et al, &ldquo;Chemoimmunotherapy With Hyper-CVAD Plus Rituximab for the Treatment of Adult Burkitt and Burkitt-Type Lymphoma or Acute Lymphoblastic Leukemia,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2006, 106(7):1569-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/16502413/pubmed\" id=\"16502413\" target=\"_blank\">",
"        16502413",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson WH, Grossbard ML, Pittaluga S, et al, &ldquo;Dose-Adjusted EPOCH Chemotherapy for Untreated Large B-Cell Lymphomas: A Pharmacodynamic Approach With High Efficacy,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2002, 99(8):2685-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/11929754/pubmed\" id=\"11929754\" target=\"_blank\">",
"        11929754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Woods WG, O'Leary M, and Nesbit ME, &ldquo;Life-Threatening Neuropathy and Hepatotoxicity in Infants During Induction Therapy for Acute Lymphoblastic Leukemia,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1981, 98(4):642-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/12/33993/abstract-text/6937637/pubmed\" id=\"6937637\" target=\"_blank\">",
"        6937637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      World Health Organization, \"Vincristine (and Other Vinca Alkaloids) Should Only Be Given Intravenously Via a Minibag,\" July, 2007, Alert 115. Available at file://www.who.int/medicines/publications/drugalerts/Alert_115_vincristine.pdf",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12882 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4D6C774D8A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_12_33993=[""].join("\n");
var outline_f33_12_33993=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708854\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234194\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10518612\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050610\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16342255\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050602\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234173\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234158\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050614\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234250\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050605\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050613\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234253\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234249\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050617\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050601\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050600\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234239\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234167\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234169\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10517724\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050609\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050599\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050616\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050607\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2998179\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12882\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12882|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=related_link\">",
"      Vincristine (conventional): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/7/42100?source=related_link\">",
"      Vincristine (conventional): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_12_33994="Diagnosis of suspected deep vein thrombosis of the lower extremity";
var content_f33_12_33994=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of suspected deep vein thrombosis of the lower extremity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/12/33994/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/12/33994/contributors\">",
"     Brydon JB Grant, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/12/33994/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/12/33994/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/12/33994/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/12/33994/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/12/33994/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/12/33994/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deep vein thrombosis (DVT) and acute pulmonary embolism (PE) are two manifestations of the same disorder, venous thromboembolism (VTE). DVT of the lower extremity is subdivided into two categories (",
"    <a class=\"graphic graphic_figure graphicRef75219 \" href=\"mobipreview.htm?42/56/43906\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Distal (calf) vein thrombosis, in which thrombi remain confined to the deep calf veins or the muscular calf veins, and",
"     </li>",
"     <li>",
"      Proximal vein thrombosis, in which thrombosis involves the popliteal, femoral, or iliac veins.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This concept is supported by the fact that over 90 percent of cases of acute PE are due to emboli emanating from the proximal veins of the lower extremities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In addition, anticoagulation is highly effective therapy for both conditions. As a result, tests designed to diagnosis DVT are also of importance for the diagnosis of acute PE.",
"   </p>",
"   <p>",
"    The tests that may be used to confirm the presence of suspected lower extremity DVT and an overview of the usefulness of noninvasive testing in diagnosing acute PE in adults will be reviewed here [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/3\">",
"     3",
"    </a>",
"    ]. The evaluation of the patient with venous thrombosis, with emphasis on the indications for and methods of screening for a hypercoagulable state, the prevention of DVT, and issues related to DVT in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11930?source=see_link\">",
"     \"Evaluation of the patient with established venous thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/28/25033?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/57/14234?source=see_link\">",
"     \"Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When approaching the patient with suspected DVT of the lower extremity, it is important to appreciate that only a minority of patients (17 and 32 percent in two large series) actually have the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. This low proportion illustrates the importance of noninvasive testing to minimize the likelihood of inappropriate anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptomatic patients without DVT have a variety of other disorders, including popliteal (Baker's) cysts, muscle pulls and tears, and venous insufficiency. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=see_link&amp;anchor=H10#H10\">",
"     \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEEP VEIN THROMBOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deep vein thrombosis of the lower extremity is subdivided into either distal (calf vein) or proximal (thigh) vein thrombosis (",
"    <a class=\"graphic graphic_figure graphicRef75219 \" href=\"mobipreview.htm?42/56/43906\">",
"     figure 1",
"    </a>",
"    ). Proximal vein thrombosis is of greater importance clinically, since it is more commonly associated with serious, chronic disease (eg, active cancer, congestive failure, respiratory insufficiency, age &gt;75), whereas distal thrombosis is more often associated with transient risk factors (eg, recent surgery, immobilization, travel) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. As a further example, over 90 percent of cases of acute PE are due to emboli emanating from the proximal, rather than the distal, veins of the lower extremities, and the mortality rate of proximal DVT is higher than that of distal DVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A diagnosis of DVT raises other important clinical issues, such as the presence of an inherited or acquired hypercoagulable state as well as anatomic variations in venous return (eg, inferior vena caval anomalies, May-Thurner syndrome). An overview of these issues is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=see_link\">",
"     \"Overview of the causes of venous thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=see_link&amp;anchor=H3#H3\">",
"     \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\", section on 'Initial approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Proximal vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proximal deep vein thrombosis is considered to be of more importance clinically, since it is more commonly associated with serious disease and possibly fatal outcomes. Proximal deep venous thrombosis can be identified by noninvasive testing in 20 to 50 percent of patients with acute pulmonary embolism when only a single study is performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link&amp;anchor=H10#H10\">",
"     \"Diagnosis of acute pulmonary embolism\", section on 'Lower extremity ultrasound'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In many cases of proximal DVT, silent PE has already occurred by the time that the patient is seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In one study of 622 patients without symptoms of PE, for example, approximately 40 percent with proven DVT had a high probability lung scan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/12\">",
"     12",
"    </a>",
"    ]. Some high-risk patients (eg, after major surgery) develop DVT without local signs and symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/13\">",
"     13",
"    </a>",
"    ]. Such patients may present with sudden and often fatal pulmonary embolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Thoracic Society (ATS) statement on the diagnostic approach to acute venous thromboembolism, as well as other ATS guidelines, can be accessed through the ATS website at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements\">",
"     www.thoracic.org/statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Calf vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal calf vein thrombosis is felt to be of lesser clinical importance than proximal vein thrombosis and its optimal diagnosis and treatment have yet to be defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/7,8,15-17\">",
"     7,8,15-17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=see_link&amp;anchor=H15994263#H15994263\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Isolated calf vein (distal, below the knee) thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study, for example, evaluated 68 patients who were clinically suspected to have or were at high risk for DVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thrombosis was limited to the calf veins in 12; none had clinical or",
"      <span class=\"nowrap\">",
"       ventilation/perfusion",
"      </span>",
"      scan evidence of pulmonary embolism",
"     </li>",
"     <li>",
"      Thrombosis involved both the proximal (thigh) and calf veins in 15; eight had scan evidence of pulmonary embolism",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The accuracy of the Wells score and D-dimer test for the diagnosis of isolated distal DVT was assessed in a single center, cross-sectional study including 873 consecutive outpatients with suspected DVT, in whom pre-test clinical probability, D-dimer, and a complete compression ultrasonography of both lower limbs were performed. The prevalence of isolated distal DVT was 12.4 percent in this group. While the Wells test and D-dimer alone were of little diagnostic utility for isolated DVT, isolated distal DVT could be essentially ruled out by the combination of a low pre-test clinical probability and a normal D-dimer: the negative predictive value was 99 percent (95% CI 95-100) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If anticoagulation is not administered for isolated asymptomatic distal venous thrombosis, serial noninvasive studies of the lower extremity should be performed over the next 10 to 14 days to assess for proximal extension of the thrombus, which has a higher incidence of pulmonary embolism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the high risk associated with proximal lower extremity DVT that is not treated and the potential risk of anticoagulating a patient who does not have a DVT, accurate diagnosis is essential. Classic symptoms of DVT include swelling, pain, and discoloration in the involved extremity. In addition, risk factors for DVT should be sought (",
"    <a class=\"graphic graphic_table graphicRef78473 \" href=\"mobipreview.htm?2/14/2283\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Physical examination may reveal a palpable cord (reflecting a thrombosed vein), ipsilateral edema, warmth,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    superficial venous dilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. However, the clinical diagnosis of DVT is",
"    <strong>",
"     not",
"    </strong>",
"    sufficiently accurate since the symptoms and findings are often nonspecific. Thus, testing is generally indicated to confirm or exclude the diagnosis.",
"   </p>",
"   <p>",
"    The differential diagnosis in patients with suspected DVT includes a variety of disorders, such as musculoskeletal injury and venous insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=see_link&amp;anchor=H10#H10\">",
"     \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study of 160 consecutive patients with suspected DVT who had negative venograms, the following causes of leg pain were identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Muscle strain, tear, or twisting injury to the leg &mdash; 40 percent",
"     </li>",
"     <li>",
"      Leg swelling in a paralyzed limb &mdash; 9 percent",
"     </li>",
"     <li>",
"      Lymphangitis or lymph obstruction &mdash; 7 percent",
"     </li>",
"     <li>",
"      Venous insufficiency (reflux) &mdash; 7 percent",
"     </li>",
"     <li>",
"      Baker's cyst &mdash; 5 percent (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/46/13033?source=see_link\">",
"       \"Clinical features of rheumatoid arthritis\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Cellulitis &mdash; 3 percent",
"     </li>",
"     <li>",
"      Knee abnormality &mdash; 2 percent",
"     </li>",
"     <li>",
"      Unknown &mdash; 26 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CONTRAST VENOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contrast venography has long been considered the reference test for the diagnosis of DVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The validity of using contrast venography for this purpose was established in a study that evaluated the course of 160 patients suspected clinically of having DVT in whom contrast venography was negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/23\">",
"     23",
"    </a>",
"    ]. During a six-month follow-up, only 1.3 percent developed DVT (95% CI 0.4-5.4 percent).",
"   </p>",
"   <p>",
"    However, venography is",
"    <strong>",
"     not",
"    </strong>",
"    recommended as an initial screening due to patient discomfort and difficulty in obtaining an adequate study. The frequency of this problem was illustrated in a report comparing impedance plethysmography and ultrasound to venography in 127 hospitalized patients with clinically suspected DVT of the lower extremity; venography could not be performed in 20 percent of cases because of contraindications or technical factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Noninvasive tests with nearly equivalent diagnostic accuracy for DVT have drastically reduced the need for venography. Venography is currently reserved for situations in which ultrasound or impedance plethysmography is not feasible, when noninvasive studies are equivocal, or when noninvasive studies are discordant with a strong clinical impression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/26\">",
"     26",
"    </a>",
"    ]. As an example, compression ultrasonography does not detect isolated thrombi in the iliac vein. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Compression ultrasonography'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NONINVASIVE TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although noninvasive tests of the lower extremities are more readily available and are associated with lower morbidity and cost, they may be less accurate than invasive techniques. Thus, accurate assessment of the role of noninvasive testing in the diagnosis of lower extremity thrombosis requires a direct comparison with the diagnostic results obtained from invasive testing. In addition, clinical outcomes need to be determined in prospective studies on consecutive patients and the results compared with the outcomes of patients whose therapy was based upon the results of standard invasive techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     IMPEDANCE PLETHYSMOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impedance plethysmography requires the patient to lie still while a thigh cuff is inflated. The change in blood volume at the calf is measured from the impedance of the calf as determined by electrodes wrapped around it [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/27\">",
"     27",
"    </a>",
"    ]. After rapid deflation of the cuff, the proportional change of impedance over the subsequent three seconds is used to measure venous outflow obstruction in a manner similar to spirometry. At present, however, many facilities have neither the equipment nor skilled personnel to perform impedance plethysmography, while the availability of ultrasonography is more widespread.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impedance plethysmography is associated with several shortcomings. Although the equipment is simple and inexpensive, the patient must lie still for at least two minutes and must be positioned correctly to avoid obstruction of venous outflow. As a result, the procedure can be difficult to perform in a paraplegic with involuntary muscle spasms and cannot be performed at all in a patient whose leg is in a plaster cast. Furthermore, false positive tests may result from poor filling due to severe arterial disease, or from venous outflow obstruction in patients with prior venous disease, raised venous pressure associated with heart failure, or raised intrathoracic pressure due to mechanical ventilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Accuracy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite these limitations, impedance plethysmography is useful for the diagnosis and clinical management of patients suspected of having deep vein thrombosis. Proximal vein thrombosis can be detected by this technique with a sensitivity and a specificity of 91 and 96 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two prospective outcome studies of patients suspected of having DVT found that no serious adverse events occurred if serial examinations were performed over two weeks and anticoagulants were withheld from patients with negative results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a Canadian series, there were no fatal pulmonary emboli in 311 such patients, and only 1.9 percent developed DVT during a 12-month follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report from the Netherlands, no fatal pulmonary emboli were observed in 289 patients in whom treatment was withheld, and only 0.3 percent of patients developed DVT during a six-month follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since detection of calf vein thrombosis is poor by impedance plethysmography, the clinical utility of essentially ignoring calf vein thrombosis was substantiated by these studies. However, impedance plethysmography only detects venous obstruction; as a result, it is prone to false positive results if this obstruction is due to causes other than venous thrombosis.",
"   </p>",
"   <p>",
"    The possibility of increasing the accuracy of impedance plethysmography by adding D-dimer measurements is discussed below (see",
"    <a class=\"local\" href=\"#H24\">",
"     'Addition to impedance plethysmography'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Recurrent DVT",
"    </span>",
"    &nbsp;&mdash;&nbsp;If available, impedance plethysmography is the preferred test for the evaluation of suspected recurrent DVT. A distinct advantage of impedance plethysmography in this setting is that it normalizes at a rapid, predictable rate after a first DVT. In one series of 161 patients with proven DVT and an abnormal impedance plethysmography, a repeat test became normal in 67 percent by three months and 92 percent by nine months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Normalization is less common with compression ultrasonography, occurring at a rate of 60 to 70 percent at one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Magnetic resonance imaging may ultimately supersede impedance plethysmography in this setting because the concentration of methemoglobin within a thrombus increases over time; consequent alterations in signal characteristics permit an estimation of clot age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     COMPRESSION ULTRASONOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A more direct approach to the diagnosis of DVT involves use of compression ultrasonography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/34\">",
"     34",
"    </a>",
"    ]. The chronicity of the thrombus may be inferred from the echogenicity of the clot because older clots appear more echodense [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Nevertheless, there are no prospective clinical trials that validate this inference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of venous thrombosis using compression ultrasonography is made by the findings such as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abnormal compressibility of the vein",
"     </li>",
"     <li>",
"      Abnormal Doppler color flow",
"     </li>",
"     <li>",
"      The presence of an echogenic band",
"     </li>",
"     <li>",
"      Abnormal change in diameter during the Valsalva maneuver",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The American Thoracic Society (ATS) statement on the diagnostic approach to acute venous thromboembolism, as well as other ATS guidelines, can be accessed through the ATS website at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements\">",
"     www.thoracic.org/statements",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Prospective studies have demonstrated that lack of compressibility of a vein with the ultrasound probe is highly sensitive (&gt;95 percent) and specific (&gt;95 percent) for proximal vein thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Color flow imaging, in addition to duplex Doppler ultrasound, is a less demanding study and is also highly accurate for the diagnosis of above the knee DVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/38\">",
"     38",
"    </a>",
"    ]. In comparison, the presence of an echogenic band, although sensitive for DVT, has a specificity of only about 50 percent. The variation of venous size with the Valsalva maneuver has a low sensitivity and specificity for the presence of DVT and is not performed in many centers.",
"   </p>",
"   <p>",
"    Compression ultrasonography requires the patient to lie in both the supine and prone positions in order to permit examination of the popliteal veins. It is less demanding for the patient than impedance plethysmography in terms of the necessity of lying still.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11727192\">",
"    <span class=\"h3\">",
"     Portable devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of portable vascular ultrasonic machines for assessing the presence or absence of DVT in emergency departments (EDs) and critical care units (CCUs) has been the subject of a number of studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, ED physicians were given a 10-minute training session on the use of this apparatus at two specific points (common femoral and popliteal vessels). A total of 47 physicians performed 199 two-point compression ultrasonographic examinations in the ED. When compared with ultrasonographic reports from tests performed by the Department of Radiology, the sensitivity and specificity of the ED examinations were 100 and 99 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/44\">",
"       44",
"      </a>",
"      ]. Additional studies will be required in order to develop a standard protocol for use of this modality in general ED practice [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A multicenter, retrospective review compared 128 bedside intensivist-performed compression ultrasonographic studies (IP-CUS) with a formal vascular study (FVS) performed by ultrasound technicians and interpreted by radiologists [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/43\">",
"       43",
"      </a>",
"      ]. All fellows and attending physicians performing IP-CUS had received formal training at a three-day critical care ultrasonography training course. When compared with the companion FVS study ordered immediately after completion of the IP-CUS study, IP-CUS studies had a sensitivity and specificity of 86 and 96 percent, respectively, with a median time delay between the ordering of the FVS and the FVS result of 13.8 hours. It was concluded that, before adopting an IP-CUS strategy, intensivists must be sure to achieve similar competence as the attending physicians and fellows involved in this study.",
"     </li>",
"     <li>",
"      A meta-analysis of 16 studies involving 2379 patients assessed the accuracy of emergency physician-performed ultrasound (EPPU) for the bedside diagnosis of DVT compared with either color-flow duplex ultrasound performed by a radiology department or vascular laboratory, or to angiography [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/46\">",
"       46",
"      </a>",
"      ]. Sensitivity and specificity of EPPU compared with the reference imaging test were 96 and 97 percent, respectively. Prospective studies are warranted to confirm the usefulness of EPPU in the management of patients with suspected DVT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compression ultrasonography has several limitations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It does not detect isolated thrombi in the iliac vein or that portion of the femoral vein within the adductor canal (",
"      <a class=\"graphic graphic_figure graphicRef75219 \" href=\"mobipreview.htm?42/56/43906\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As with impedance plethysmography, the results are limited in patients with deformities or a plaster cast.",
"     </li>",
"     <li>",
"      Serial studies need to be performed when the initial test is negative; approximately 2 percent of patients with an initially negative ultrasound develop a positive study when retested seven days later [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/48\">",
"       48",
"      </a>",
"      ]. A single repeat study that is negative five to seven days after an initial negative study predicts a less than 1 percent likelihood of venous thromboembolism over months of follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with pelvic neoplasms or abscesses may demonstrate isolated noncompressibility of the femoral vein when thrombosis is absent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Recurrent DVT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compression ultrasonography is less useful than impedance plethysmography for recurrent DVT. As noted above, only 50 to 70 of studies return to normal at one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/31,32,50\">",
"     31,32,50",
"    </a>",
"    ] compared with over 90 percent with impedance plethysmography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in a series of 205 patients with suspected recurrent ipsilateral DVT, the incidence of confirmed VTE during a 6-month follow-up period was 1.3 percent in patients with stable or improved ultrasound findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/51\">",
"     51",
"    </a>",
"    ]. It has therefore been suggested that patients presenting with lack of compressibility of a previously fully compressible vein segment or those with an increased vein diameter &gt;4 mm (as compared with earlier vein assessments) be considered to have recurrent DVT, while all others need further testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/48,51,52\">",
"     48,51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The safety of these diagnostic strategies to exclude recurrent VTE was explored in two studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 284 subjects in whom recurrent VTE had been excluded by the above criteria and anticoagulation was not given, eight subjects (2.8 percent) developed confirmed, non-fatal VTE over the subsequent three months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/52\">",
"       52",
"      </a>",
"      ]. Of interest, six of these eight subjects had a superficial or distal vein thrombosis diagnosed at the time of the suspected recurrent VTE episode.",
"     </li>",
"     <li>",
"      A second report suggested that it may be safe to withhold anticoagulation from patients with suspected recurrent ipsilateral DVT who have stable or slightly increased (ie, up to 4 mm) vein diameter and negative D-dimer levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/53\">",
"       53",
"      </a>",
"      ]. Among 75 newly symptomatic patients who met these criteria and were not treated with anticoagulation, the incidence of recurrent VTE was zero at three months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More data with longer follow-up are required before these approaches can be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Accuracy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compression ultrasonography has been compared with ascending contrast venography for the detection of proximal vein thrombosis in clinically suspected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/37\">",
"     37",
"    </a>",
"    ] as well as asymptomatic DVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/54\">",
"     54",
"    </a>",
"    ]. In one study of consecutive outpatients with clinically suspected DVT, compression ultrasonography had a sensitivity and specificity of 100 and 99 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/37\">",
"     37",
"    </a>",
"    ]. The high sensitivity of compression ultrasonography was confirmed in a cohort of 1702 patients in whom DVT was suspected clinically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/55\">",
"     55",
"    </a>",
"    ]. The 1290 patients with negative studies on presentation and at one week had a cumulative rate of venous thromboembolic complications of 0.7 percent at six months, suggesting that very few DVTs were missed by compression ultrasonography.",
"   </p>",
"   <p>",
"    A prospective outcome study supported both the clinical utility of compression ultrasonography and the view that it is superior to impedance plethysmography for the diagnosis of DVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/56\">",
"     56",
"    </a>",
"    ]. In this trial, 985 consecutive outpatients with suspected DVT were randomly assigned to be tested with either impedance plethysmography or compression ultrasonography. Serial studies were performed on days one, two, and seven, and the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although there were no fatal PEs in either group, compression ultrasonography produced fewer false positive studies.",
"     </li>",
"     <li>",
"      The incidence of venous thromboembolism over a six-month follow-up period in patients who had a negative test and were not treated with anticoagulants was not significantly different between impedance plethysmography and compression ultrasonography (2.6 versus 1.5 percent).",
"     </li>",
"     <li>",
"      The positive predictive value was 94 percent for compression ultrasonography and 83 percent for impedance plethysmography. As a result, 11 percent more patients were anticoagulated unnecessarily in the impedance plethysmography group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The conclusion was that compression ultrasonography was superior to impedance plethysmography in guiding therapeutic strategy. Nevertheless, this study confirmed the utility of impedance plethysmography if compression ultrasonography is unavailable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Extended (complete) lower extremity ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, routine compression ultrasonography has certain limitations, two of which are the lack of detection of iliac vein disease and the need for serial studies, with which the patient may not comply, if the first is test is negative and clinical suspicion is high. One approach that may overcome these limitations of venous ultrasound involves imaging the entire venous system, including distal (ie, calf) veins, at the time of initial presentation (ie, whole leg ultrasonography) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Five similarly designed studies used complete lower extremity ultrasound as the sole diagnostic test in more than 3000 patients with suspected DVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/58-62\">",
"     58-62",
"    </a>",
"    ]. The incidence of DVT or symptomatic PE among patients with a negative initial study was between 0.24 and 1.9 percent during the first three months of follow-up. Two of the studies noted a 1 to 1.5 percent technical failure rate that prevented interpretation and necessitated additional testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial compared the three-month incidence of objectively confirmed symptomatic VTE in 2098 consecutive symptomatic outpatients with a first episode of suspected DVT of the lower extremities who had an initially negative workup after being randomly assigned to one of the two following diagnostic protocols [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/63\">",
"     63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Whole leg color-coded Doppler ultrasonography (US) performed once, or",
"     </li>",
"     <li>",
"      US of the common femoral vein at the groin and the popliteal vein down to its branching calf deep veins at the popliteal fossa plus D-dimer measurement. Subjects with an initially negative US study and a positive D-dimer underwent a second US study at one week, or earlier if clinically indicated (serial 2-point protocol) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subjects who tested negative were not anticoagulated. The three-month incidences of objectively confirmed symptomatic VTE for subjects testing negative via the whole leg and serial 2-point protocols were equivalent at 1.2 and 0.9 percent, respectively (observed difference 0.3%, 95% CI -1.4-0.8 percent).",
"   </p>",
"   <p>",
"    A subsequent meta-analysis reviewed seven studies in which there was a negative whole-leg compression ultrasound study, anticoagulation was withheld, and at least 90 days of follow-up were obtained. In the 4731 subjects included in this study, the combined VTE event rate at 3 months was 0.57 percent (95% CI 0.25-0.89) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the generalizability of these observations may be limited because the quality of complete lower extremity ultrasound studies is operator-dependent; thus, results may vary on the basis of operator experience",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other technical factors. In addition, the majority of patients enrolled in these trials were outpatients, many had low pre-test probability of DVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/64\">",
"     64",
"    </a>",
"    ], and the sensitivity of complete lower extremity ultrasound among inpatients is less clear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/65\">",
"     65",
"    </a>",
"    ]. At the present time, this approach should be reserved for patients enrolled in clinical trials at centers with significant experience in complete lower extremity ultrasound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Addition of pretest probability (Wells score)",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with all tests, ultrasonography for DVT is most useful when the results are combined with an assessment of pretest probability. While other pretest probability scoring systems are available, such as the Hamilton score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/66,67\">",
"     66,67",
"    </a>",
"    ], the Wells score for DVT (ie, Wells criteria for DVT) appears to be most commonly used.",
"   </p>",
"   <p>",
"    One report of 593 patients with suspected DVT validated a measure of pretest probability in conjunction with an algorithm designed to minimize the use of venography or repeat ultrasonography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/68\">",
"     68",
"    </a>",
"    ]. This measure of pretest probability is referred to as the Wells score or Wells criteria for DVT probability (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?1/30/1505?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef75871 \" href=\"mobipreview.htm?23/1/23580\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Paralysis, paresis, or recent orthopedic casting of a lower extremity (1 point)",
"     </li>",
"     <li>",
"      Recently bedridden for longer than three days or major surgery within the past four weeks (1 point)",
"     </li>",
"     <li>",
"      Localized tenderness in the deep vein system (1 point)",
"     </li>",
"     <li>",
"      Swelling of an entire leg (1 point)",
"     </li>",
"     <li>",
"      Calf swelling 3 cm greater that the other leg, measured 10 cm below the tibial tuberosity (1 point)",
"     </li>",
"     <li>",
"      Pitting edema greater in the symptomatic leg (1 point)",
"     </li>",
"     <li>",
"      Collateral non-varicose superficial veins (1 point)",
"     </li>",
"     <li>",
"      Active cancer or cancer treated within six months (1 point)",
"     </li>",
"     <li>",
"      Alternative diagnosis more likely than DVT (eg, Baker's cyst, cellulitis, muscle damage, post phlebitic syndrome, inguinal lymphadenopathy, external venous) compression (-2 points)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A total of three to eight points indicates that there is a high probability of DVT, one to two points indicates that there is a moderate probability of DVT, and zero or fewer points indicates that there is a low probability of DVT.",
"   </p>",
"   <p>",
"    The algorithm that was used in conjunction with the Wells criteria for DVT probability is shown in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef52720 \" href=\"mobipreview.htm?41/20/42318\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/68\">",
"     68",
"    </a>",
"    ]. DVT was documented in 3, 17, and 75 percent of patients with low, moderate, and high pretest probabilities, respectively. Serial ultrasonography was required in 28 percent and venography in 6 percent of patients; venous thromboembolism was diagnosed during a three month follow-up period in only 0.6 percent of patients thought not to have a DVT by this algorithm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Modified Wells score",
"    </span>",
"    &nbsp;&mdash;&nbsp;This measure has been modified (the modified Wells score or modified Wells criteria for DVT probability) to take one other clinical feature into account. Patients with a previously documented DVT are given an additional one point. According to the modified measure, DVT is likely among patients who have a score of two or greater and DVT is unlikely among patients who have a score of one or less (",
"    <a class=\"graphic graphic_table graphicRef75871 \" href=\"mobipreview.htm?23/1/23580\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     D-DIMER",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of measuring D-dimer, a degradation product of cross-linked fibrin, has been extensively studied for the diagnosis of both DVT and pulmonary embolus. D-dimers are detectable at levels greater than 500",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    of fibrinogen equivalent units in nearly all patients with venous thromboembolism.",
"   </p>",
"   <p>",
"    However, the finding of elevated D-dimer concentrations alone is insufficient to establish the diagnosis of venous thromboembolism, because elevated D-dimer levels are not specific for VTE and are commonly present in hospitalized patients, particularly the elderly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/70\">",
"     70",
"    </a>",
"    ], those with malignancy, recent surgery, and a myriad of other conditions, including the second and third trimester of a normal pregnancy (",
"    <a class=\"graphic graphic_table graphicRef60881 \" href=\"mobipreview.htm?6/49/6940\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/71-79\">",
"     71-79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17832?source=see_link&amp;anchor=H2#H2\">",
"     \"Abnormalities of coagulation and platelet function in preeclampsia\", section on 'Changes in hemostasis during normal pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A meta-analysis of 11 studies pooling 1337 patients revealed a negative predictive value of D-dimer assays of 94 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/80\">",
"     80",
"    </a>",
"    ]. When D-dimers were less than 500",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    the likelihood of venous thromboembolism remained less than 10 percent even when pretest probabilities were as high as 55 percent. This hypothesis was supported by a trial in 150 inpatients with suspected DVT in which a low pretest probability and a negative D-dimer by rapid RBC agglutination testing (SimpliRED) had a 96 percent negative predictive value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/81\">",
"     81",
"    </a>",
"    ], as well as by other similar studies in low risk populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/82,83\">",
"     82,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies have documented a reduced negative predictive value when the D-dimer assay was applied to a population with a high prevalence of DVT, such as those examined in an emergency department setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/84\">",
"     84",
"    </a>",
"    ]. While the negative predictive value of a normal D-dimer assay as a stand-alone test to rule out DVT may not be sufficiently high in cancer patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/85\">",
"     85",
"    </a>",
"    ], the combination of a negative D-dimer assay and a low clinical pre-test probability appears to be more effective in such patients. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Addition of Wells score'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A negative D-dimer assay may be insufficient as a stand-alone test in patient populations with a high prevalence of venous thromboembolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/84-88\">",
"     84-88",
"    </a>",
"    ]. The results of the above and other published studies concerning the usefulness of D-dimer measurement may be difficult to generalize, since available test methodologies and sensitivities vary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/74,78,86,87,89-91\">",
"     74,78,86,87,89-91",
"    </a>",
"    ]. A systematic meta-analysis on this subject has concluded the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/92\">",
"     92",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      D-dimer analysis using enzyme-linked immunosorbent assays (ELISA) yield the best sensitivities (approximately 95 percent) and negative likelihood ratios (approximately 10 percent) for excluding deep vein thrombosis and pulmonary embolism.",
"     </li>",
"     <li>",
"      A negative quantitative rapid ELISA result is as diagnostically useful as a normal lung scan or negative duplex ultrasonography finding for excluding VTE.",
"     </li>",
"     <li>",
"      The D-dimer test is unidirectional in that a negative test is useful in ruling out VTE but a positive test does not have a sufficiently high specificity or positive likelihood ratio to be helpful in increasing the certainty of a diagnosis of VTE. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Addition to impedance plethysmography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usefulness of impedance plethysmography or compression ultrasound may be improved when combined with an assay quantitating the amount of D-dimer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. One study evaluated the clinical utility of D-dimer measurements and impedance plethysmography alone and in combination in 214 consecutive patients suspected of having DVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/95\">",
"     95",
"    </a>",
"    ]. All patients underwent contrast venography (as the gold standard), impedance plethysmography, and measurement of D-dimer levels. The individual sensitivity and specificity of impedance plethysmography and elevated levels of D-dimer for the diagnosis of DVT were 67 and 96 percent, and 93 and 77 percent, respectively. The combination of D-dimer assay and impedance plethysmography was highly accurate when the results were concordant:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A negative D-dimer assay and normal impedance plethysmography had negative predictive values for all DVT and proximal DVT of 97 and 99 percent, respectively.",
"     </li>",
"     <li>",
"      A positive D-dimer assay and abnormal impedance plethysmography had positive predictive values for all DVT and proximal DVT of 93 and 90 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results of the two tests were discordant in 28 percent of patients; the tests could not be used reliably in combination in these patients.",
"   </p>",
"   <p>",
"    A second prospective study of 398 patients with a first episode of suspected DVT found similar positive and negative predictive values for the detection of DVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/96\">",
"     96",
"    </a>",
"    ]. It has therefore been suggested that the combination of D-dimer assay and impedance plethysmography, when concordant, may avoid the need for serial examinations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Addition to compression ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three studies of patients undergoing compression ultrasonography found that a negative ultrasound, in conjunction with a normal D-dimer measurement, safely obviated the need for a follow-up ultrasound at seven days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/97-99\">",
"     97-99",
"    </a>",
"    ], allowing treatment decisions to be made at the time of initial presentation in most patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Addition of Wells score",
"    </span>",
"    &nbsp;&mdash;&nbsp;A D-dimer level less than 200 to 500",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    by ELISA or a negative SimpliRED assay in conjunction with a low clinical probability of DVT appears to be useful and cost-effective in excluding DVT without the need for an ultrasound examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/6,69,71,74,86,89,100-105\">",
"     6,69,71,74,86,89,100-105",
"    </a>",
"    ]. This has been shown to hold in populations at high risk of having DVT, such as those with malignancy, as well as in populations in which the Wells score and the D-dimer may have reduced specificity, such as in the elderly.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two studies, one in 224 cancer patients and the other in 193 patients with colorectal cancer, the negative predictive values for a normal D-dimer test in conjunction with a low pre-test probability were 99 and 100 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/106,107\">",
"       106,107",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a combined analysis of three prospective studies, negative predictive values for a normal D-dimer test in conjunction with a",
"      <span class=\"nowrap\">",
"       low/unlikely",
"      </span>",
"      pre-test probability were &ge;99 percent for subgroups of patients &lt;60, &ge;60, &ge;70, and &ge;80 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/108\">",
"       108",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A trial of 1096 outpatients presenting with suspected DVT evaluated the patients as likely or unlikely to have DVT using a clinical model (Wells score for DVT probability) (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?1/30/1505?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) and then randomly assigned them to undergo ultrasound imaging alone (control group), or to undergo D-dimer testing (D-dimer group) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/69\">",
"     69",
"    </a>",
"    ]. All patients in the D-dimer group underwent ultrasound testing unless the D-dimer test (SimpliRED or IL-test) was negative and the patient was considered \"unlikely\" to have DVT. Results included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall prevalence of VTE during the three-month follow-up was 15.7 percent, and was 28 and 5.5 percent, respectively, in those categorized as \"likely\" or \"unlikely\" to have DVT in the pretest clinical model (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Addition of pretest probability (Wells score)'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      For patients assigned to the D-dimer group who were judged \"unlikely\" to have DVT and had a negative D-dimer test (and therefore did not have ultrasonography), the incidence of subsequent VTE in the next three months was 0.9 percent. In this group, the negative and positive predictive values for the D-dimer test were 99 and 14 percent, respectively.",
"     </li>",
"     <li>",
"      For patients assigned to the control group who were judged \"unlikely\" to have DVT and had negative ultrasonography, the incidence of subsequent VTE was 1.5 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on the above studies, a diagnostic strategy for investigation of suspected lower-extremity thrombosis combining pretest probability, D-dimer testing, and compression ultrasound imaging has been presented. The basics of this algorithm are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/109\">",
"     109",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pretest probability of DVT is determined from the Wells score (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?1/30/1505?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) and a D-dimer test is performed.",
"     </li>",
"     <li>",
"      For those with a \"low probability\" score and a negative D-dimer, DVT is effectively ruled out. If the D-dimer test is positive, ultrasound is performed to rule out DVT.",
"     </li>",
"     <li>",
"      For those in whom DVT is likely (ie, Wells score &ge;1) ultrasound is performed in all patients to rule out DVT. For the separate group in which the D-dimer test was positive and the initial ultrasound negative, a repeat ultrasound is performed one week later to rule out DVT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A retrospective analysis suggested that greater diagnostic utility might be obtained by altering the cutoff D-dimer level for those with decreased levels of pretest probability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/110\">",
"     110",
"    </a>",
"    ]. From that analysis, a strategy was developed to rule out first time DVT that did not require ultrasonography in every patient suspected of first time DVT when the D-dimer was &gt;500",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (uniform testing). In this prospective multicenter randomized trial, selective testing in 860 patients was used to rule out DVT without ultrasonography in those with a low pretest probability and D-dimer &lt;1000",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    or in those with a moderate pretest probability and D-dimer &lt;500",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    while ultrasonography without D-dimer measurement was employed in all inpatients and outpatients with a high pretest probability. The incidence of symptomatic venous thromboembolism during a three-month follow-up was not significantly different between the 860 subjects undergoing uniform testing or the 860 undergoing selective testing (0.5 percent in both groups) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/111\">",
"     111",
"    </a>",
"    ]. This selective testing approach may not apply to all assays of D-dimer or to patients with recurrent DVT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Limitations of the Wells score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Wells score (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?1/30/1505?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) was developed as an objective means for determining the pre-test probability of a patient having DVT, using patients from a secondary care outpatient setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/20,68,112\">",
"     20,68,112",
"    </a>",
"    ]. It may not perform as well in a primary care setting, due, in part, to differences in the population served, methodology, and interpretation of the individual criteria comprising the Wells score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/113\">",
"     113",
"    </a>",
"    ]. In their original study, patients with a Wells score of &le;1 and a normal D-dimer had an incidence of DVT of 0.9 percent, while in this latter study, the percent of cases with missed DVT (false negatives) was much higher (2.9 percent) when the Wells score was combined with a negative D-dimer using sensitive quantitative techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of 51 studies has shown that the overall assessment of clinical probability of DVT by use of the Wells score is more useful than any of the individual components comprising the score, with a negative likelihood ratio (0.25, 95% CI 0.21-0.29) similar to that of an empirical assessment. Nevertheless, when the population to be assessed contained a large percentage of elderly patients or those with a prior DVT or other comorbidities, as might occur in a primary care setting, the performance of the Wells criteria was reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/105,114\">",
"     105,114",
"    </a>",
"    ]. Therefore, it seems prudent that the Wells criteria are used to complement rather than displace the clinician's empirical assessment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Addition of Hamilton score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Hamilton score is calculated as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/67\">",
"     67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Plaster immobilization of lower limb: 2 points",
"     </li>",
"     <li>",
"      Active malignancy (within six months or current): 2 points",
"     </li>",
"     <li>",
"      Strong clinical suspicion of DVT without other diagnostic possibilities: 2 points",
"     </li>",
"     <li>",
"      Bed rest (&gt;3 days) or recent surgery (within four weeks): 1 point",
"     </li>",
"     <li>",
"      Male sex: 1 point",
"     </li>",
"     <li>",
"      Calf circumference &gt;3 cm on affected side (measured 10 cm below tibial tuberosity): 1 point",
"     </li>",
"     <li>",
"      Erythema: 1 point",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For this clinical probability score the unlikely versus likely cutoff is two or less points.",
"   </p>",
"   <p>",
"    In a study of 542 consecutive ambulatory patients presenting to an emergency department for assessment of lower limb DVT, the combination of an unlikely probability Hamilton score and a negative Simplify D-dimer assay had a negative predictive value of 99 percent (95% CI 94.7-100) for ruling our DVT and obviating the need for ultrasound evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/66,115\">",
"     66,115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Clinical decision rule for primary care providers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cost-effective clinical decision rule (AMUSE rule or primary care rule) has been developed specifically for the primary care setting, which uses seven objective clinical items and a rapid point-of-care D-dimer assay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/116-120\">",
"     116-120",
"    </a>",
"    ]. This scoring system was employed in 1002 evaluable primary care patients suspected of having DVT primarily because of leg pain (87 percent) or leg swelling (78 percent). Patients with a total score &le;3 did not receive a referral for ultrasonography and did not receive anticoagulation, while those with a total score &ge;4 were referred for ultrasonography. Results included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the 500 evaluable subjects with a total score &le;3, the incidence of symptomatic VTE at three months was 1.4 percent (95% CI 0.6-2.9).",
"     </li>",
"     <li>",
"      In the 502 subjects with a score &ge;4, the incidence of VTE on subsequent ultrasonography was 24 percent. The negative likelihood ratio is estimated to be 0.093 (95% CI 0.045-0.192).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results are consistent with other studies that have indicated a low incidence of clinically evident VTE in patients with a low pretest probability and a negative D-dimer. They are also consistent with the current recommendations that all patients with a high pretest probability of DVT should undergo ultrasonography irrespective of the D-dimer test result.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     MAGNETIC RESONANCE VENOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance venography is as accurate as contrast venography for the diagnosis of DVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/33,121-123\">",
"     33,121-123",
"    </a>",
"    ]. This was illustrated in one study that evaluated 85 patients suspected of having DVT, all of whom underwent both magnetic resonance and contrast venography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/121\">",
"     121",
"    </a>",
"    ]. Magnetic resonance venography had a sensitivity of 100 percent and a specificity of 96 percent. There were only three discrepancies out of 101 comparisons between magnetic resonance and contrast venography, and there was only one discrepancy out of 41 comparisons between magnetic resonance venography and compression ultrasonography.",
"   </p>",
"   <p>",
"    Some investigators have claimed that magnetic resonance venography is superior to contrast venography in special circumstances such as acetabular fractures. In this setting, one report found that magnetic resonance venography yielded a 22 percent greater detection of thrombi than did contrast venography (10 of 45 comparisons) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/124\">",
"     124",
"    </a>",
"    ]. However, the study design did not permit the determination of whether treatment of these additional cases altered outcome.",
"   </p>",
"   <p>",
"    Although the diagnostic accuracy of magnetic resonance venography is comparable to that of contrast venography, outcome data are lacking. In addition, the present high cost of magnetic resonance venography makes it unlikely that it will gain prominence as a noninvasive test for DVT. However, magnetic resonance venography is a useful approach when contrast venography is required but precluded because of allergy to contrast material.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Direct thrombus imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance direct thrombus imaging (MRDTI) may be more accurate than compression ultrasonography (CU) for the diagnosis of recurrent DVT. In one study of 43 consecutive patients with a first episode of VTE, MRDTI normalized over a period of 6 months in all patients, while CU remained abnormal in 31 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/125\">",
"     125",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Recurrent DVT'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     COMPUTED TOMOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience is increasing with the use of computed tomography (CT) for establishing the presence of DVT. The protocols under most active investigation image the pulmonary arteries and the subdiaphragmatic deep veins (including the legs) at the same sitting, ideally with no additional contrast medium or venipunctures beyond what is required for a CT pulmonary angiogram [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/74,126-129\">",
"     74,126-129",
"    </a>",
"    ]. In some reports, CT venography has performed in a manner comparable to ultrasonographic evaluation in the detection of femoropopliteal venous thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/128\">",
"     128",
"    </a>",
"    ]. At present, the use of CT in this setting remains experimental, although the technique holds potential for simplifying the diagnosis of venous thromboembolism in the future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     LOWER EXTREMITY STUDIES AND THE DIAGNOSIS OF ACUTE PULMONARY EMBOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section will provide a brief overview of how noninvasive lower extremity studies contribute to the diagnosis and management of patients suspected of having acute pulmonary embolism. An extensive review of the diagnostic strategies for acute pulmonary embolism, including the use of invasive and noninvasive testing, is provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ventilation-perfusion lung scanning remains the best validated noninvasive approach in the diagnostic evaluation of patients with suspected PE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/130\">",
"     130",
"    </a>",
"    ]. The scan is most useful when it is negative or when it indicates a high probability for pulmonary embolism, particularly when the clinical (pretest) probability is also high (",
"    <a class=\"graphic graphic_table graphicRef78592 \" href=\"mobipreview.htm?16/12/16587\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/131\">",
"     131",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 515 consecutive patients with a negative perfusion scan, withholding anticoagulants resulted in a 0.6 percent rate of non-fatal venous thromboembolic disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/132\">",
"       132",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The specificity of a high probability scan ranges between 90 and 92 percent, depending upon the criteria used [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/133\">",
"       133",
"      </a>",
"      ]. When present, a high probability scan is considered sufficient evidence to establish the diagnosis in a patient with a strong clinical likelihood of acute PE (",
"      <a class=\"graphic graphic_table graphicRef78592 \" href=\"mobipreview.htm?16/12/16587\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/131\">",
"       131",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unfortunately, the overall sensitivity of ventilation-perfusion scanning is low, ranging from 53 to 57 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/133\">",
"     133",
"    </a>",
"    ]. As a result, approximately 71 percent of ventilation-perfusion scans in patients suspected of acute PE are nondiagnostic.",
"   </p>",
"   <p>",
"    Since over 90 percent of PEs emanate from the proximal veins, some investigators have suggested that a reasonable approach is to withhold anticoagulants in patients in whom the ventilation-perfusion scans were nondiagnostic if serial impedance plethysmography revealed no evidence of proximal vein thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/134\">",
"     134",
"    </a>",
"    ]. Using this strategy, venous thromboembolism occurred in only 3 percent of 414 patients. It is important to realize, however, that only patients without severe cardiopulmonary disease were enrolled in this protocol, because even a small embolus in such patients may have serious consequences. Severe cardiopulmonary disease was defined by the presence of pulmonary edema, right ventricular failure, systemic hypotension with blood pressure less than 90 mmHg systolic, syncope, acute tachyarrhythmias, abnormal spirometry with FEV1 less than 1 liter or vital capacity less than 1.5 liters, or respiratory failure (PaO2 less than 50 mmHg",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PaCO2 greater than 45 mmHg while breathing room air).",
"   </p>",
"   <p>",
"    More recently, other investigators have shown that the need for pulmonary angiography to diagnose pulmonary embolism could be reduced from 71 to 29 percent if this algorithm were to be implemented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/135\">",
"     135",
"    </a>",
"    ]. Prospective confirmation of a similar algorithm was described in 1998 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/136\">",
"     136",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/3/1075?source=see_link\">",
"       \"Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/34/30242?source=see_link\">",
"       \"Patient information: Doppler ultrasound (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/44/12998?source=see_link\">",
"       \"Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the approach to a diagnosis of deep vein thrombosis (DVT) of the lower extremity, we and others recommend initial evaluation using a validated clinical prediction rule in conjunction with a high sensitivity assay for D-dimer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/69,137\">",
"     69,137",
"    </a>",
"    ]. Available prediction rules and D-dimer testing perform best when applied to a first episode of VTE, younger patients, those without significant comorbidities, and a short duration of symptoms (see",
"    <a class=\"local\" href=\"#H26\">",
"     'Addition of Wells score'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    A reasonable diagnostic approach is as follows, and is consistent with clinical practice guidelines from the American Academy of Family Physicians and the American College of Physicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/137\">",
"     137",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In selected patients with a low pretest probability of DVT according to the Wells score (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?1/30/1505?source=see_link\">",
"       calculator 1",
"      </a>",
"      ), the likelihood of DVT is low, and further testing (eg, ultrasonography) may not be needed unless the D-dimer is positive or unavailable. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Addition of pretest probability (Wells score)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ultrasound evaluation is recommended for patients with intermediate to high pretest probability of DVT according to the Wells score. Repeat ultrasound or venography may be required for those with suspected calf vein DVT and a negative initial ultrasound investigation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most circumstances, compression ultrasonography is the noninvasive approach of choice for the diagnosis of patients with suspected DVT. If unavailable, impedance plethysmography with serial studies is an acceptable alternative. One exception noted above is that impedance plethysmography is preferred for possible recurrent DVT since it normalizes more quickly after a previous episode [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/29\">",
"     29",
"    </a>",
"    ] than compression ultrasonography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A positive noninvasive study in patients with a first episode of DVT usually establishes the diagnosis, with positive predictive values for compression ultrasonography and impedance plethysmography of 94 percent (95% CI 87 to 98 percent) and 83 percent (95% CI 75 to 90 percent), respectively. If the initial study is negative and the clinical suspicion of DVT is high, a repeat study should be obtained on day 5 to 7 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/12/33994/abstract/4,55\">",
"     4,55",
"    </a>",
"    ]. Venography is currently used only when noninvasive testing is not clinically feasible or the results are equivocal.",
"   </p>",
"   <p>",
"    Noninvasive testing of the lower extremities also has utility for the management of patients suspected of acute pulmonary embolism when the ventilation-perfusion scans are nondiagnostic and when the patients do not have a high cardiopulmonary risk. Because the morbidity of noninvasive studies is almost nonexistent, it may be reasonable to consider performing ultrasonography prior to exposing a patient to the risks of pulmonary angiography. Such applications must be undertaken tentatively until a diagnostic approach to suspected pulmonary embolism which incorporates noninvasive testing for DVT has been clinically validated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/1\">",
"      Browse NL, Thomas ML. Source of non-lethal pulmonary emboli. Lancet 1974; 1:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/2\">",
"      Havig O. Deep vein thrombosis and pulmonary embolism. An autopsy study with multiple regression analysis of possible risk factors. Acta Chir Scand Suppl 1977; 478:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/3\">",
"      Tan M, van Rooden CJ, Westerbeek RE, Huisman MV. Diagnostic management of clinically suspected acute deep vein thrombosis. Br J Haematol 2009; 146:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/4\">",
"      Birdwell BG, Raskob GE, Whitsett TL, et al. The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Intern Med 1998; 128:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/5\">",
"      Huisman MV, B&uuml;ller HR, ten Cate JW, Vreeken J. Serial impedance plethysmography for suspected deep venous thrombosis in outpatients. The Amsterdam General Practitioner Study. N Engl J Med 1986; 314:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/6\">",
"      Hirsh J, Lee AY. How we diagnose and treat deep vein thrombosis. Blood 2002; 99:3102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/7\">",
"      Galanaud JP, Sevestre-Pietri MA, Bosson JL, et al. Comparative study on risk factors and early outcome of symptomatic distal versus proximal deep vein thrombosis: results from the OPTIMEV study. Thromb Haemost 2009; 102:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/8\">",
"      Galanaud JP, Quenet S, Rivron-Guillot K, et al. Comparison of the clinical history of symptomatic isolated distal deep-vein thrombosis vs. proximal deep vein thrombosis in 11 086 patients. J Thromb Haemost 2009; 7:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/9\">",
"      Moser KM, LeMoine JR. Is embolic risk conditioned by location of deep venous thrombosis? Ann Intern Med 1981; 94:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/10\">",
"      Turkstra F, Kuijer PM, van Beek EJ, et al. Diagnostic utility of ultrasonography of leg veins in patients suspected of having pulmonary embolism. Ann Intern Med 1997; 126:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/11\">",
"      Huisman MV, B&uuml;ller HR, ten Cate JW, et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest 1989; 95:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/12\">",
"      Meignan M, Rosso J, Gauthier H, et al. Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis. Arch Intern Med 2000; 160:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/13\">",
"      Dermody M, Alessi-Chinetti J, Iafrati MD, Estes JM. The utility of screening for deep venous thrombosis in asymptomatic, non-ambulatory neurosurgical patients. J Vasc Surg 2011; 53:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/14\">",
"      Pineda LA, Hathwar VS, Grant BJ. Clinical suspicion of fatal pulmonary embolism. Chest 2001; 120:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/15\">",
"      Gibson NS, Schellong SM, Kheir DY, et al. Safety and sensitivity of two ultrasound strategies in patients with clinically suspected deep venous thrombosis: a prospective management study. J Thromb Haemost 2009; 7:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/16\">",
"      Galanaud JP, Sevestre MA, Genty C, et al. Comparison of the clinical history of symptomatic isolated muscular calf vein thrombosis versus deep calf vein thrombosis. J Vasc Surg 2010; 52:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/17\">",
"      Palareti G, Schellong S. Isolated distal deep vein thrombosis: what we know and what we are doing. J Thromb Haemost 2012; 10:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/18\">",
"      Sartori M, Cosmi B, Legnani C, et al. Wells rule and d-dimer for the diagnosis of isolated distal deep vein thrombosis. J Thromb Haemost 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/19\">",
"      Hirsh J, Hull RD, Raskob GE. Clinical features and diagnosis of venous thrombosis. J Am Coll Cardiol 1986; 8:114B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/20\">",
"      Wells PS, Hirsh J, Anderson DR, et al. Accuracy of clinical assessment of deep-vein thrombosis. Lancet 1995; 345:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/21\">",
"      Kahn SR, Joseph L, Abenhaim L, Leclerc JR. Clinical prediction of deep vein thrombosis in patients with leg symptoms. Thromb Haemost 1999; 81:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/22\">",
"      Hyers TM. Venous thromboembolism. Am J Respir Crit Care Med 1999; 159:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/23\">",
"      Hull R, Hirsh J, Sackett DL, et al. Clinical validity of a negative venogram in patients with clinically suspected venous thrombosis. Circulation 1981; 64:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/24\">",
"      Lensing AW, B&uuml;ller HR, Prandoni P, et al. Contrast venography, the gold standard for the diagnosis of deep-vein thrombosis: improvement in observer agreement. Thromb Haemost 1992; 67:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/25\">",
"      Heijboer H, Cogo A, B&uuml;ller HR, et al. Detection of deep vein thrombosis with impedance plethysmography and real-time compression ultrasonography in hospitalized patients. Arch Intern Med 1992; 152:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/26\">",
"      Kearon C, Julian JA, Newman TE, Ginsberg JS. Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. Ann Intern Med 1998; 128:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/27\">",
"      Hull R, Taylor DW, Hirsh J, et al. Impedance plethysmography: the relationship between venous filling and sensitivity and specificity for proximal vein thrombosis. Circulation 1978; 58:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/28\">",
"      Hull RD, Hirsh J, Carter CJ, et al. Diagnostic efficacy of impedance plethysmography for clinically suspected deep-vein thrombosis. A randomized trial. Ann Intern Med 1985; 102:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/29\">",
"      Huisman MV, B&uuml;ller HR, ten Cate JW. Utility of impedance plethysmography in the diagnosis of recurrent deep-vein thrombosis. Arch Intern Med 1988; 148:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/30\">",
"      Koopman MM, van Beek EJ, ten Cate JW. Diagnosis of deep vein thrombosis. Prog Cardiovasc Dis 1994; 37:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/31\">",
"      Prandoni P, Cogo A, Bernardi E, et al. A simple ultrasound approach for detection of recurrent proximal-vein thrombosis. Circulation 1993; 88:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/32\">",
"      Heijboer H, Jongbloets LM, B&uuml;ller HR, et al. Clinical utility of real-time compression ultrasonography for diagnostic management of patients with recurrent venous thrombosis. Acta Radiol 1992; 33:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/33\">",
"      Moody AR, Pollock JG, O'Connor AR, Bagnall M. Lower-limb deep venous thrombosis: direct MR imaging of the thrombus. Radiology 1998; 209:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/34\">",
"      Donnelly R, Hinwood D, London NJ. ABC of arterial and venous disease. Non-invasive methods of arterial and venous assessment. BMJ 2000; 320:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/35\">",
"      Peter DJ, Flanagan LD, Cranley JJ. Analysis of blood clot echogenicity. J Clin Ultrasound 1986; 14:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/36\">",
"      O'Shaughnessy AM, FitzGerald DE. Organization patterns of venous thrombus over time as demonstrated by duplex ultrasound. J Vasc Invest 1996; 2:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/37\">",
"      Lensing AW, Prandoni P, Brandjes D, et al. Detection of deep-vein thrombosis by real-time B-mode ultrasonography. N Engl J Med 1989; 320:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/38\">",
"      Mattos MA, Londrey GL, Leutz DW, et al. Color-flow duplex scanning for the surveillance and diagnosis of acute deep venous thrombosis. J Vasc Surg 1992; 15:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/39\">",
"      Monreal M, Montserrat E, Salvador R, et al. Real-time ultrasound for diagnosis of symptomatic venous thrombosis and for screening of patients at risk: correlation with ascending conventional venography. Angiology 1989; 40:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/40\">",
"      American College of Emergency Physicians. Emergency ultrasound imaging criteria compendium. American College of Emergency Physicians. Ann Emerg Med 2006; 48:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/41\">",
"      Burnside PR, Brown MD, Kline JA. Systematic review of emergency physician-performed ultrasonography for lower-extremity deep vein thrombosis. Acad Emerg Med 2008; 15:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/42\">",
"      Kline JA, O'Malley PM, Tayal VS, et al. Emergency clinician-performed compression ultrasonography for deep venous thrombosis of the lower extremity. Ann Emerg Med 2008; 52:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/43\">",
"      Kory PD, Pellecchia CM, Shiloh AL, et al. Accuracy of ultrasonography performed by critical care physicians for the diagnosis of DVT. Chest 2011; 139:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/44\">",
"      Crisp JG, Lovato LM, Jang TB. Compression ultrasonography of the lower extremity with portable vascular ultrasonography can accurately detect deep venous thrombosis in the emergency department. Ann Emerg Med 2010; 56:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/45\">",
"      Blaivas M. Point-of-care ultrasonographic deep venous thrombosis evaluation after just ten minutes' training: is this offer too good to be true? Ann Emerg Med 2010; 56:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/46\">",
"      Pomero F, Dentali F, Borretta V, et al. Accuracy of emergency physician-performed ultrasonography in the diagnosis of deep-vein thrombosis: a systematic review and meta-analysis. Thromb Haemost 2013; 109:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/47\">",
"      Bundens WP, Bergan JJ, Halasz NA, et al. The superficial femoral vein. A potentially lethal misnomer. JAMA 1995; 274:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/48\">",
"      Kearon C, Ginsberg JS, Hirsh J. The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Ann Intern Med 1998; 129:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/49\">",
"      Birdwell BG, Raskob GE, Whitsett TL, et al. Predictive value of compression ultrasonography for deep vein thrombosis in symptomatic outpatients: clinical implications of the site of vein noncompressibility. Arch Intern Med 2000; 160:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/50\">",
"      Piovella F, Crippa L, Barone M, et al. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis. Haematologica 2002; 87:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/51\">",
"      Prandoni P, Lensing AW, Bernardi E, et al. The diagnostic value of compression ultrasonography in patients with suspected recurrent deep vein thrombosis. Thromb Haemost 2002; 88:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/52\">",
"      Le Gal G, Kovacs MJ, Carrier M, et al. Validation of a diagnostic approach to exclude recurrent venous thromboembolism. J Thromb Haemost 2009; 7:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/53\">",
"      Prandoni P, Tormene D, Dalla Valle F, et al. D-dimer as an adjunct to compression ultrasonography in patients with suspected recurrent deep vein thrombosis. J Thromb Haemost 2007; 5:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/54\">",
"      Kassa&iuml; B, Boissel JP, Cucherat M, et al. A systematic review of the accuracy of ultrasound in the diagnosis of deep venous thrombosis in asymptomatic patients. Thromb Haemost 2004; 91:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/55\">",
"      Cogo A, Lensing AW, Koopman MM, et al. Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. BMJ 1998; 316:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/56\">",
"      Heijboer H, B&uuml;ller HR, Lensing AW, et al. A comparison of real-time compression ultrasonography with impedance plethysmography for the diagnosis of deep-vein thrombosis in symptomatic outpatients. N Engl J Med 1993; 329:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/57\">",
"      Elias A, Colombier D, Victor G, et al. Diagnostic performance of complete lower limb venous ultrasound in patients with clinically suspected acute pulmonary embolism. Thromb Haemost 2004; 91:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/58\">",
"      Elias A, Mallard L, Elias M, et al. A single complete ultrasound investigation of the venous network for the diagnostic management of patients with a clinically suspected first episode of deep venous thrombosis of the lower limbs. Thromb Haemost 2003; 89:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/59\">",
"      Schellong SM, Schwarz T, Halbritter K, et al. Complete compression ultrasonography of the leg veins as a single test for the diagnosis of deep vein thrombosis. Thromb Haemost 2003; 89:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/60\">",
"      Stevens SM, Elliott CG, Chan KJ, et al. Withholding anticoagulation after a negative result on duplex ultrasonography for suspected symptomatic deep venous thrombosis. Ann Intern Med 2004; 140:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/61\">",
"      Subramaniam RM, Heath R, Chou T, et al. Deep venous thrombosis: withholding anticoagulation therapy after negative complete lower limb US findings. Radiology 2005; 237:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/62\">",
"      Sevestre MA, Labar&egrave;re J, Casez P, et al. Outcomes for inpatients with normal findings on whole-leg ultrasonography: a prospective study. Am J Med 2010; 123:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/63\">",
"      Bernardi E, Camporese G, B&uuml;ller HR, et al. Serial 2-point ultrasonography plus D-dimer vs whole-leg color-coded Doppler ultrasonography for diagnosing suspected symptomatic deep vein thrombosis: a randomized controlled trial. JAMA 2008; 300:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/64\">",
"      Johnson SA, Stevens SM, Woller SC, et al. Risk of deep vein thrombosis following a single negative whole-leg compression ultrasound: a systematic review and meta-analysis. JAMA 2010; 303:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/65\">",
"      Fraser JD, Anderson DR. Deep venous thrombosis: recent advances and optimal investigation with US. Radiology 1999; 211:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/66\">",
"      Subramaniam RM, Chou T, Heath R, Allen R. Importance of pretest probability score and D-dimer assay before sonography for lower limb deep venous thrombosis. AJR Am J Roentgenol 2006; 186:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/67\">",
"      Subramaniam RM, Snyder B, Heath R, et al. Diagnosis of lower limb deep venous thrombosis in emergency department patients: performance of Hamilton and modified Wells scores. Ann Emerg Med 2006; 48:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/68\">",
"      Wells PS, Anderson DR, Bormanis J, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 1997; 350:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/69\">",
"      Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003; 349:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/70\">",
"      Douma RA, Tan M, Schutgens RE, et al. Using an age-dependent D-dimer cut-off value increases the number of older patients in whom deep vein thrombosis can be safely excluded. Haematologica 2012; 97:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/71\">",
"      Schutgens RE, Haas FJ, Biesma DH. Reduced efficacy of clinical probability score and D-dimer assay in elderly subjects suspected of having deep vein thrombosis. Br J Haematol 2005; 129:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/72\">",
"      Aguilar C, del Villar V. Diagnostic performance of D-dimer is lower in elderly outpatients with suspected deep venous thrombosis. Br J Haematol 2005; 130:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/73\">",
"      Goldhaber SZ, Simons GR, Elliott CG, et al. Quantitative plasma D-dimer levels among patients undergoing pulmonary angiography for suspected pulmonary embolism. JAMA 1993; 270:2819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/74\">",
"      Yankelevitz DF, Gamsu G, Shah A, et al. Optimization of combined CT pulmonary angiography with lower extremity CT venography. AJR Am J Roentgenol 2000; 174:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/75\">",
"      Goodacre S, Sampson FC, Sutton AJ, et al. Variation in the diagnostic performance of D-dimer for suspected deep vein thrombosis. QJM 2005; 98:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/76\">",
"      Paneesha S, Cheyne E, French K, et al. High D-dimer levels at presentation in patients with venous thromboembolism is a marker of adverse clinical outcomes. Br J Haematol 2006; 135:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/77\">",
"      Righini M, Perrier A, De Moerloose P, Bounameaux H. D-Dimer for venous thromboembolism diagnosis: 20 years later. J Thromb Haemost 2008; 6:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/78\">",
"      Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood 2009; 113:2878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/79\">",
"      Thachil J, Fitzmaurice DA, Toh CH. Appropriate use of D-dimer in hospital patients. Am J Med 2010; 123:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/80\">",
"      Bounameaux H, de Moerloose P, Perrier A, Reber G. Plasma measurement of D-dimer as diagnostic aid in suspected venous thromboembolism: an overview. Thromb Haemost 1994; 71:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/81\">",
"      Wells PS, Anderson DR, Bormanis J, et al. Application of a diagnostic clinical model for the management of hospitalized patients with suspected deep-vein thrombosis. Thromb Haemost 1999; 81:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/82\">",
"      Aschwanden M, Labs KH, Jeanneret C, et al. The value of rapid D-dimer testing combined with structured clinical evaluation for the diagnosis of deep vein thrombosis. J Vasc Surg 1999; 30:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/83\">",
"      Lennox AF, Delis KT, Serunkuma S, et al. Combination of a clinical risk assessment score and rapid whole blood D-dimer testing in the diagnosis of deep vein thrombosis in symptomatic patients. J Vasc Surg 1999; 30:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/84\">",
"      Farrell S, Hayes T, Shaw M. A negative SimpliRED D-dimer assay result does not exclude the diagnosis of deep vein thrombosis or pulmonary embolus in emergency department patients. Ann Emerg Med 2000; 35:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/85\">",
"      Lee AY, Julian JA, Levine MN, et al. Clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis. Ann Intern Med 1999; 131:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/86\">",
"      Frost SD, Brotman DJ, Michota FA. Rational use of D-dimer measurement to exclude acute venous thromboembolic disease. Mayo Clin Proc 2003; 78:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/87\">",
"      Brotman DJ, Segal JB, Jani JT, et al. Limitations of D-dimer testing in unselected inpatients with suspected venous thromboembolism. Am J Med 2003; 114:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/88\">",
"      Righini M, Aujesky D, Roy PM, et al. Clinical usefulness of D-dimer depending on clinical probability and cutoff value in outpatients with suspected pulmonary embolism. Arch Intern Med 2004; 164:2483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/89\">",
"      Keeling DM, Mackie IJ, Moody A, et al. The diagnosis of deep vein thrombosis in symptomatic outpatients and the potential for clinical assessment and D-dimer assays to reduce the need for diagnostic imaging. Br J Haematol 2004; 124:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/90\">",
"      Kelly J, Rudd A, Lewis RR, Hunt BJ. Plasma D-dimers in the diagnosis of venous thromboembolism. Arch Intern Med 2002; 162:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/91\">",
"      Di Nisio M, Squizzato A, Rutjes AW, et al. Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. J Thromb Haemost 2007; 5:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/92\">",
"      Stein PD, Hull RD, Patel KC, et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. Ann Intern Med 2004; 140:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/93\">",
"      Lensing AW, Prandoni P, Prins MH, B&uuml;ller HR. Deep-vein thrombosis. Lancet 1999; 353:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/94\">",
"      Perrier A, Desmarais S, Miron MJ, et al. Non-invasive diagnosis of venous thromboembolism in outpatients. Lancet 1999; 353:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/95\">",
"      Wells PS, Brill-Edwards P, Stevens P, et al. A novel and rapid whole-blood assay for D-dimer in patients with clinically suspected deep vein thrombosis. Circulation 1995; 91:2184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/96\">",
"      Ginsberg JS, Kearon C, Douketis J, et al. The use of D-dimer testing and impedance plethysmographic examination in patients with clinical indications of deep vein thrombosis. Arch Intern Med 1997; 157:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/97\">",
"      Bernardi E, Prandoni P, Lensing AW, et al. D-dimer testing as an adjunct to ultrasonography in patients with clinically suspected deep vein thrombosis: prospective cohort study. The Multicentre Italian D-dimer Ultrasound Study Investigators Group. BMJ 1998; 317:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/98\">",
"      Tick LW, Ton E, van Voorthuizen T, et al. Practical diagnostic management of patients with clinically suspected deep vein thrombosis by clinical probability test, compression ultrasonography, and D-dimer test. Am J Med 2002; 113:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/99\">",
"      Kearon C, Ginsberg JS, Douketis J, et al. A randomized trial of diagnostic strategies after normal proximal vein ultrasonography for suspected deep venous thrombosis: D-dimer testing compared with repeated ultrasonography. Ann Intern Med 2005; 142:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/100\">",
"      ten Wolde M, Kraaijenhagen RA, Prins MH, B&uuml;ller HR. The clinical usefulness of D-dimer testing in cancer patients with suspected deep venous thrombosis. Arch Intern Med 2002; 162:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/101\">",
"      Fancher TL, White RH, Kravitz RL. Combined use of rapid D-dimer testing and estimation of clinical probability in the diagnosis of deep vein thrombosis: systematic review. BMJ 2004; 329:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/102\">",
"      Siragusa S, Anastasio R, Porta C, et al. Deferment of objective assessment of deep vein thrombosis and pulmonary embolism without increased risk of thrombosis: a practical approach based on the pretest clinical model, D-dimer testing, and the use of low-molecular-weight heparins. Arch Intern Med 2004; 164:2477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/103\">",
"      Wells PS, Owen C, Doucette S, et al. Does this patient have deep vein thrombosis? JAMA 2006; 295:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/104\">",
"      Goodacre S, Stevenson M, Wailoo A, et al. How should we diagnose suspected deep-vein thrombosis? QJM 2006; 99:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/105\">",
"      Qaseem A, Snow V, Barry P, et al. Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Fam Med 2007; 5:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/106\">",
"      Di Nisio M, Rutjes AW, B&uuml;ller HR. Combined use of clinical pretest probability and D-dimer test in cancer patients with clinically suspected deep venous thrombosis. J Thromb Haemost 2006; 4:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/107\">",
"      Stender MT, Fr&oslash;kjaer JB, Hagedorn Nielsen TS, et al. Combined use of clinical pre-test probability and D-dimer test in the diagnosis of preoperative deep venous thrombosis in colorectal cancer patients. Thromb Haemost 2008; 99:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/108\">",
"      Carrier M, Le Gal G, Bates SM, et al. D-dimer testing is useful to exclude deep vein thrombosis in elderly outpatients. J Thromb Haemost 2008; 6:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/109\">",
"      Scarvelis D, Wells PS. Diagnosis and treatment of deep-vein thrombosis. CMAJ 2006; 175:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/110\">",
"      Linkins LA, Bates SM, Ginsberg JS, Kearon C. Use of different D-dimer levels to exclude venous thromboembolism depending on clinical pretest probability. J Thromb Haemost 2004; 2:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/111\">",
"      Linkins LA, Bates SM, Lang E, et al. Selective D-dimer testing for diagnosis of a first suspected episode of deep venous thrombosis: a randomized trial. Ann Intern Med 2013; 158:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/112\">",
"      Wells PS, Hirsh J, Anderson DR, et al. A simple clinical model for the diagnosis of deep-vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnostic process. J Intern Med 1998; 243:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/113\">",
"      Oudega R, Hoes AW, Moons KG. The Wells rule does not adequately rule out deep venous thrombosis in primary care patients. Ann Intern Med 2005; 143:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/114\">",
"      Goodacre S, Sutton AJ, Sampson FC. Meta-analysis: The value of clinical assessment in the diagnosis of deep venous thrombosis. Ann Intern Med 2005; 143:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/115\">",
"      Subramaniam RM, Heath R, Cox K, et al. Does an immunochromatographic D-dimer exclude acute lower limb deep venous thrombosis? Emerg Med Australas 2006; 18:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/116\">",
"      Oudega R, Moons KG, Hoes AW. Ruling out deep venous thrombosis in primary care. A simple diagnostic algorithm including D-dimer testing. Thromb Haemost 2005; 94:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/117\">",
"      B&uuml;ller HR, Ten Cate-Hoek AJ, Hoes AW, et al. Safely ruling out deep venous thrombosis in primary care. Ann Intern Med 2009; 150:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/118\">",
"      Ten Cate-Hoek AJ, Toll DB, B&uuml;ller HR, et al. Cost-effectiveness of ruling out deep venous thrombosis in primary care versus care as usual. J Thromb Haemost 2009; 7:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/119\">",
"      van der Velde EF, Toll DB, Ten Cate-Hoek AJ, et al. Comparing the diagnostic performance of 2 clinical decision rules to rule out deep vein thrombosis in primary care patients. Ann Fam Med 2011; 9:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/120\">",
"      Janssen KJ, van der Velde EF, Ten Cate AJ, et al. Optimisation of the diagnostic strategy for suspected deep-vein thrombosis in primary care. Thromb Haemost 2011; 105:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/121\">",
"      Carpenter JP, Holland GA, Baum RA, et al. Magnetic resonance venography for the detection of deep venous thrombosis: comparison with contrast venography and duplex Doppler ultrasonography. J Vasc Surg 1993; 18:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/122\">",
"      Fraser DG, Moody AR, Morgan PS, et al. Diagnosis of lower-limb deep venous thrombosis: a prospective blinded study of magnetic resonance direct thrombus imaging. Ann Intern Med 2002; 136:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/123\">",
"      Fraser DG, Moody AR, Davidson IR, et al. Deep venous thrombosis: diagnosis by using venous enhanced subtracted peak arterial MR venography versus conventional venography. Radiology 2003; 226:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/124\">",
"      Montgomery KD, Potter HG, Helfet DL. Magnetic resonance venography to evaluate the deep venous system of the pelvis in patients who have an acetabular fracture. J Bone Joint Surg Am 1995; 77:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/125\">",
"      Westerbeek RE, Van Rooden CJ, Tan M, et al. Magnetic resonance direct thrombus imaging of the evolution of acute deep vein thrombosis of the leg. J Thromb Haemost 2008; 6:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/126\">",
"      Loud PA, Katz DS, Klippenstein DL, et al. Combined CT venography and pulmonary angiography in suspected thromboembolic disease: diagnostic accuracy for deep venous evaluation. AJR Am J Roentgenol 2000; 174:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/127\">",
"      Duwe KM, Shiau M, Budorick NE, et al. Evaluation of the lower extremity veins in patients with suspected pulmonary embolism: a retrospective comparison of helical CT venography and sonography. 2000 ARRS Executive Council Award I. American Roentgen Ray Society. AJR Am J Roentgenol 2000; 175:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/128\">",
"      Garg K, Kemp JL, Wojcik D, et al. Thromboembolic disease: comparison of combined CT pulmonary angiography and venography with bilateral leg sonography in 70 patients. AJR Am J Roentgenol 2000; 175:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/129\">",
"      Garg K, Mao J. Deep venous thrombosis: spectrum of findings and pitfalls in interpretation on CT venography. AJR Am J Roentgenol 2001; 177:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/130\">",
"      Rathbun SW, Raskob GE, Whitsett TL. Sensitivity and specificity of helical computed tomography in the diagnosis of pulmonary embolism: a systematic review. Ann Intern Med 2000; 132:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/131\">",
"      Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). The PIOPED Investigators. JAMA 1990; 263:2753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/132\">",
"      Hull RD, Raskob GE, Coates G, Panju AA. Clinical validity of a normal perfusion lung scan in patients with suspected pulmonary embolism. Chest 1990; 97:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/133\">",
"      Hull RD, Raskob GE. Low-probability lung scan findings: a need for change. Ann Intern Med 1991; 114:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/134\">",
"      Hull RD, Raskob GE, Coates G, et al. A new noninvasive management strategy for patients with suspected pulmonary embolism. Arch Intern Med 1989; 149:2549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/135\">",
"      Stein PD, Hull RD, Pineo G. Strategy that includes serial noninvasive leg tests for diagnosis of thromboembolic disease in patients with suspected acute pulmonary embolism based on data from PIOPED. Prospective Investigation of Pulmonary Embolism Diagnosis. Arch Intern Med 1995; 155:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/136\">",
"      Wells PS, Ginsberg JS, Anderson DR, et al. Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med 1998; 129:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/12/33994/abstract/137\">",
"      Qaseem A, Snow V, Barry P, et al. Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med 2007; 146:454.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1351 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-D8E5382BBA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_12_33994=[""].join("\n");
var outline_f33_12_33994=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEEP VEIN THROMBOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Proximal vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Calf vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CONTRAST VENOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NONINVASIVE TESTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      IMPEDANCE PLETHYSMOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Accuracy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Recurrent DVT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      COMPRESSION ULTRASONOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11727192\">",
"      - Portable devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Recurrent DVT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Accuracy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Extended (complete) lower extremity ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Addition of pretest probability (Wells score)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Modified Wells score",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      D-DIMER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Addition to impedance plethysmography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Addition to compression ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Addition of Wells score",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Limitations of the Wells score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Addition of Hamilton score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Clinical decision rule for primary care providers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      MAGNETIC RESONANCE VENOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Direct thrombus imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      COMPUTED TOMOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      LOWER EXTREMITY STUDIES AND THE DIAGNOSIS OF ACUTE PULMONARY EMBOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1351\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1351|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?41/20/42318\" title=\"algorithm 1\">",
"      Diagnostic algorithm for DVT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1351|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/56/43906\" title=\"figure 1\">",
"      Deep veins of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1351|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/14/2283\" title=\"table 1\">",
"      Risk factors for DVT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/1/23580\" title=\"table 2\">",
"      Pretest probability of DVT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/49/6940\" title=\"table 3\">",
"      Causes elevated D-dimer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/12/16587\" title=\"table 4\">",
"      PIOPED diagnosis of PE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?1/30/1505?source=related_link\" title=\"calculator 1\">",
"      Calculator: DVT probability: Wells score system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17832?source=related_link\">",
"      Abnormalities of coagulation and platelet function in preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/57/14234?source=related_link\">",
"      Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/28/25033?source=related_link\">",
"      Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/44/12998?source=related_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/3/1075?source=related_link\">",
"      Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/34/30242?source=related_link\">",
"      Patient information: Doppler ultrasound (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_12_33995="Validated criteria for stenosis in visceral vessels";
var content_f33_12_33995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Validated criteria for stenosis in visceral vessels",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Artery",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent of stenosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Superior mesenteric",
"       </td>",
"       <td>",
"        &ge;70 percent",
"       </td>",
"       <td>",
"        Peak systolic velocity &gt;275 cm/s",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Celiac artery",
"       </td>",
"       <td>",
"        &ge;70 percent",
"       </td>",
"       <td>",
"        Peak systolic velocity &gt;200 cm/s",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal artery",
"       </td>",
"       <td>",
"        &ge;60 percent",
"       </td>",
"       <td>",
"        Renal aortic ratio &gt;3.5 (PSV in renal artery/PSV in adjacent aorta)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal artery",
"       </td>",
"       <td>",
"        &ge;80 percent",
"       </td>",
"       <td>",
"        Renal aortic ratio &gt;3.5 and renal artery end diastolic velocity &ge;150 cm/s",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Moneta GL, Lee RW, Yeager RA, et al. Mesenteric duplex scanning: a blinded prospective study. J Vasc Surg 1993; 17:79.",
"       </li>",
"       <li>",
"        Gentile AT, Moneta GL, Lee RW, et al. Usefulness of fasting and postprandial duplex ultrasound examinations for predicting high-grade superior mesenteric artery stenosis. Am J Surg 1995; 169:476.",
"       </li>",
"       <li>",
"        Moneta GL. Screening for mesenteric vascular insufficiency and follow-up of mesenteric artery bypass procedures. Semin Vasc Surg 2001; 14:186.",
"       </li>",
"      </ol>",
"      <br>",
"       Courtesy of Dr. Erica Mitchell.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_12_33995=[""].join("\n");
var outline_f33_12_33995=null;
var title_f33_12_33996="Breast ca survival pregnancy";
var content_f33_12_33996=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F58572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F58572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Five-year survival rates by nodal status in pregnancy-associated breast cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Year",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Author",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        N",
"       </td>",
"       <td class=\"subtitle1\">",
"        Five-year survival, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Five-year survival, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        LN (-)",
"       </td>",
"       <td class=\"subtitle2\">",
"        LN (+)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1955",
"       </td>",
"       <td>",
"        White TT",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1962",
"       </td>",
"       <td>",
"        Holleb AI",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1962",
"       </td>",
"       <td>",
"        Byrd BJ",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1963",
"       </td>",
"       <td>",
"        Bunker M",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1963",
"       </td>",
"       <td>",
"        Rosemond G",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1973",
"       </td>",
"       <td>",
"        Applewhite RR",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1985",
"       </td>",
"       <td>",
"        Krig R",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1991",
"       </td>",
"       <td>",
"        Pebrek J",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        47",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1992",
"       </td>",
"       <td>",
"        Ishida T",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1997",
"       </td>",
"       <td>",
"        Kuerer HM",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1997",
"       </td>",
"       <td>",
"        Bonnier P",
"       </td>",
"       <td>",
"        154",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        31",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2003",
"       </td>",
"       <td>",
"        Reed W",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        60 to 62",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LN (-): lymph node negative; LN (+): lymph node positive.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_12_33996=[""].join("\n");
var outline_f33_12_33996=null;
var title_f33_12_33997="Pneu vaccine antibody testing";
var content_f33_12_33997=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F77758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F77758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pneumococcal vaccines and antibody testing for conjugate and pure pneumococcal polysaccharides",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Serotypes",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Vaccines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        23-PPV",
"       </td>",
"       <td class=\"subtitle2\">",
"        7-PCV",
"       </td>",
"       <td class=\"subtitle2\">",
"        13-PCV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        6A",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        6B",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        7F",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        9N",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        9V",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        10A",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        11A",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        12F",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        14",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        15B",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        17F",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        18C",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        19A",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        19F",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        20",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        22F",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        23F",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        33F",
"       </td>",
"       <td class=\"centered\">",
"        X",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     23-PPV: 23-valent polysaccharide vaccine; 7-PCV: heptavalent conjugate vaccine; 13-PCV: 13-valent conjugate vaccine.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of RU Sorensen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_12_33997=[""].join("\n");
var outline_f33_12_33997=null;
var title_f33_12_33998="Long and short stimulat cycles";
var content_f33_12_33998=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Examples of different approaches to ovarian stimulation used in IVF programs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 504px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     gnRHa: gonadotropin releasing hormone agonist analogues; hMG: human menopausal gonadotropin; FSH: follicle stimulating hormone; hCG: human chorionic gonadotropin.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Barbieri, RL. Assisted Reproduction. In Reproductive Endocrinology, 4th edition, Yen, SSC, Jaffe, RB, Barbieri, RL (eds), Saunders, Philadelphia, 1999, p 603.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_12_33998=[""].join("\n");
var outline_f33_12_33998=null;
var title_f33_12_33999="Helical scanning modes";
var content_f33_12_33999=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Single- and variable-mode CT scanning",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 221px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of single-mode helical scanning and variable-mode scanning.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_12_33999=[""].join("\n");
var outline_f33_12_33999=null;
